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1CHAPTER I
INTRODUCTION
Objective
The risk for atherosclerosis is influenced greatly by genetic or pharmacologic
disruptions of cellular cholesterol homeostasis. For example, the expression of
apolipoprotein (apo) E protects macrophages from accumulating cholesterol and lowers
atherosclerosis risk. Another example is the statin drugs, which reduce intracellular
cholesterol synthesis and have become the most common intervention for risk reduction.
Cholesterol homeostasis in macrophages is of critical importance because these cells
have a pivotal function in the vessel wall and in the development of atherosclerotic
lesions. Macrophages scavenge modified lipoproteins in the arterial wall and transform
into foam cells as cholesterol accumulates intracellularly. Processes that influence
cellular cholesterol balance and foam cell transformation include cholesterol synthesis,
lipoprotein uptake, cholesterol ester storage, and cholesterol efflux. Research on apoE,
apoAI, and on the ATP-Binding Cassette (ABC) A1 transporter suggests that cholesterol
efflux has a role in macrophage cholesterol homeostasis that directly affects
atherosclerosis risk. Decreases in cholesterol efflux can be a causative mechanism for
foam cell formation, while increases in cholesterol efflux may represent compensation for
dysregulation of cholesterol synthesis, uptake, or storage. Few studies have been done to
characterize the interactions between efflux and the other processes of cholesterol
balance in macrophages of atherosclerosis models. We hypothesize that macrophages
with genotypes that are known to affect the progression of atherosclerosis, will have
changes in cholesterol efflux and cellular cholesterol homeostasis. Our studies emphasize
the ability for cholesterol efflux to change in response to cholesterol imbalances. We
studied the cholesterol imbalance created by the cholesterol storage deficit that results
from the deletion of the cholesterol esterifying enzyme, acyl-coenzyme A: cholesterol
acyltransferase (ACAT). Our studies also emphasize the capacity for cholesterol
acceptors to stimulate cholesterol efflux from macrophages that endogenously synthesize
apoE or transgenic apoAI.
2Specific Aims
We hypothesize that cholesterol efflux is an important mechanism of cholesterol
homeostasis that is affected by deficits in cholesterol storage and the synthesis of
cholesterol acceptors. This hypothesis was addressed by the following aims:
Aim 1. To develop experimental protocols and data analysis software for assaying
cholesterol efflux in vitro (Chapter III).
Aim 2. To characterize the effects of cholesterol ester storage deficits on cholesterol
efflux and cholesterol homeostasis (Chapter IV and V).
Aim 3. To examine the effects of endogenously synthesized cholesterol acceptors on
cholesterol efflux (Chapter VI, VII, and VIII).
3CHAPTER II
BACKGROUND AND SIGNIFICANCE
Pathogenesis of Atherosclerosis
Atherosclerosis is a complex disease resulting from a coordinated series of events
including endothelial dysfunction, lipid accumulation, inflammation, oxidative stress, cell
proliferation, and cell death. These events are the consequence of risk factors and genetic
predisposition and are a part of the development of fatty streaks, complex lesions, and
clinically relevant complications.
Risk Factors.  Atherosclerosis is the major cause of morbidity and mortality in the
United States, with coronary heart disease and stroke being its two most common
expressions (Gordon and Rifkind, 1989; Gordon et al., 1977). The progression of this
disease involves multiple steps that span decades of human life. Numerous risk factors
for atherosclerosis have been identified: age, male sex, family history, high levels of "bad
cholesterol" (LDL), low levels of "good cholesterol" (HDL), high plasma triglycerides,
hypertension, sedentary lifestyle, tobacco smoking, obesity, and diabetes mellitus
(ATPIII, 2002; Fruchart et al., 2004; Grundy et al., 1999; Pearson et al., 2002). These
factors modify the progression of the disease from normal vessels, to fatty streaks, to
complicated plaques, and finally to clinical manifestations. Processes that characterize
atherogenesis within the vessel wall are inflammation, immune response, and lipid
homeostasis. Within the vessel wall, macrophages are a central player in all of these
processes.
Systemic Cholesterol Homeostasis.  Cholesterol in the body comes from two
sources, dietary uptake and peripheral synthesis. Cholesterol is incorporated into particles
called lipoproteins, which contain apolipoproteins and lipids. Apolipoproteins help to
make lipoproteins soluble in aqueous solution, act as ligands for receptor-mediated
uptake, and activate enzymes involved in lipoprotein processing. Lipoprotein assembly
occurs primarily in the liver and intestine. Each type of lipoprotein has distinct profiles of
4apolipoproteins and lipids. Lipoproteins like LDL, that lead to the deposition of
cholesterol in peripheral tissues, are considered pro-atherogenic. Lipoproteins like HDL,
that promote the return of cholesterol from peripheral tissue, are considered anti-
atherogenic. This is the reason that LDL is referred to as "bad cholesterol" and HDL is
referred to as "good cholesterol". There is an anti-atherogenic cascade of events that
removes cholesterol from peripheral tissues, transports it through blood plasma and
lymphatics back to the liver, and then excretes the cholesterol as bile. This system is
called the reverse cholesterol transport (RCT) system. The deposition of cholesterol in
the walls of vessels and the reverse transport of cholesterol significantly modify the
progression of atherosclerosis.
Foam cells and Fatty Streaks.  The earliest events of atherosclerosis involve
endothelial damage, subendothelial lipoprotein retention, and oxidative stress (Kovanen
and Tabas, 2001). Lipoproteins deposited in the subendothelial space result in the
recruitment of macrophages. As macrophages accumulate cholesteryl esters, they
transform into foam cells, which have a characteristic foamy appearance upon
microscopic analysis. Foam cells become constituents of fatty streaks in the walls of
medium and large arteries. In humans, fatty streak formation begins in the first decade of
life (Burke et al., 1986; Restrepo and Tracy, 1975). Lipid accumulation, inflammation,
oxidative stress, cell proliferation, and cell death influence the formation and progression
of fatty streaks. Foam cell lesions mature into plaques that are more complex in structure
and can cause clinically significant complications.
Complicated Plaques.  The maturation of fatty streaks into complex plaques
involves multiple cell types and many pathological processes (Forrester, 2002; Libby et
al., 1996). Early lesions mature as more macrophages are recruited and transform into
foam cells. Concurrently, smooth muscle cells migrate into the intima of the vessel wall
and proliferate (Fazio et al., 2005). More cholesterol accumulates in the extracellular
space and an acellular lipid core forms that is surrounded by cells undergoing apoptosis
and necrosis. In very complex lesions, a fibrous cap forms on the luminal side of the
5plaque. The plaque can undergo calcification, rupture, and promote thrombosis. Rupture
and thrombosis lead to lumen occlusion and tissue infarction.
The Multiple Roles of Macrophages in Atherosclerosis
Atherosclerosis involves many cell types, but macrophages are arguably the most
important and play a central role during every stage of disease progression. Lipid-laden
foam cell macrophages are the defining characteristic of the atheroma. Gene deletion and
transgene expression have been used to dissect the contributions of single genes to foam
cell formation and atherosclerosis. Focusing specifically on the physiology of
macrophages within the vessel wall has proven to be difficult because of the systemic
effects of the genetic manipulation (e.g. decreased animal viability or changes in plasma
lipid profile). While in vivo experiments with genetically engineered animals are good for
studying systemic effects on atherosclerosis, in vitro experiments are better at isolating
specific effects on macrophage physiology. Bone marrow transplantation has been used
to study the specific effects of macrophage physiology on the progression of
atherosclerosis, in vivo (Fazio and Linton, 2001; Linton et al., 1995; Linton and Fazio,
1999). In bone marrow transplantation studies, recipient mice are lethally irradiated to
kill their bone marrow cells. The irradiated recipient mice are reconstituted with bone
marrow from healthy donor mice of a different genotype. Macrophages and other types of
blood cells are derived from bone marrow progenitor cells. A transplanted recipient
mouse is chimeric and will produce new macrophages of the donor's genotype. The
advantage of this type of study over systemic deletion of genes is the focus on
macrophage physiology and the expression of genes by macrophage locally in the vessel
wall. These studies isolate the contributions of macrophages to atherosclerosis. Bone
marrow transplantation studies have been a powerful tool for understanding the roles of
macrophages in the progression of atherosclerosis. Bone marrow transplantation and
other types of studies have elucidated many roles for macrophages in the vessel wall: an
inflammatory cell, an immune cell, a scavenger cell, and a cell that affects vascular lipid
metabolism (Figure 1).
6Figure 1. The Multiple Roles of Macrophages in Atherosclerosis.
Macrophages in the vessel wall have many roles that affect the development of
atherosclerosis. Macrophages act as inflammatory cells, an immune cells,
scavenger cells, and cells that affects vascular lipid metabolism. Each of these
roles influence macrophage cholesterol homeostasis and foam cell formation.
Role as an Inflammatory Cell
Atherosclerosis is not just a disease of lipid imbalance, it also has the
characteristics of an inflammatory disease (Ross, 1999). Like other inflammatory
diseases, atherosclerosis involves the initial injury, leukocyte attraction, release of
chemical mediators, proteolytic degradation, and tissue repair.
Injury, Activation, Adhesion, and Chemoattraction.  The initial injury in
atherosclerosis is in many instances perpetuated by lipoproteins from the plasma. This
injury triggers the activation of endothelial cells which up-regulate adhesion molecules.
Leukocytes that are circulating in the plasma, including monocytes, interact with the
endothelial adhesion molecules. Activated vascular endothelial cells express vascular cell
adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, P-selectin,
and E-selectin. Monocyte/macrophages express cell adhesion molecules including very
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7late antigen (VLA)-1 integrin, b2 integrins, P-selectin glycoprotein ligand (PSGL)-1, and
sialyl Lewisx (Osterud and Bjorklid, 2003). Adhesion molecules in the monocyte are up-
regulated, leading to firm attachment and migration into the vascular wall.
Chemoattraction is mediated by chemokines and other molecules including monocyte
chemoattractant protein (MCP)-1 and interleukin (IL)-8 (Boisvert, 2004; Nelken et al.,
1991). Maturation of monocytes into macrophages also occurs by stimulation with
macrophage-colony stimulating factor (M-CSF) (Clinton et al., 1992; Rosenfeld et al.,
1992).
Macrophage Activity.  Macrophages orchestrate inflammation within the vessel
wall. They do so by secreting cytokines, prostaglandins, oxygen radicals, proteases, and
complement factors (Linton and Fazio, 2003). Macrophages also secrete matrix
metalloproteinases (MMP) that digest structural proteins in the extracellular matrix, such
as collagen (Galis et al., 1995; Galis et al., 1994). These MMPs can be grouped into
gelatinases (MMP-2 and 9), interstitial collagenase (MMP-1), and stromelysin (MMP-3)
(Galis et al., 1994). MMP activity leads to tissue remodeling, which is a characteristic of
acute and chronic inflammation. Together, these activities put macrophages at the center
of the changes that occur during vascular inflammation.
Inflammation and Macrophage-Induced Atherosclerosis.  As an inflammatory
cell, the macrophage has direct effects on atherogenesis. Studies designed to isolate the
contributions of macrophages to atherosclerosis have focused on many mediators of
inflammation (Table 1). These mediators, which are expressed by macrophages, have a
wide range of inflammatory functions. For example, phospholipase A2 (PLA2) liberates
fatty acids for the production of bioactive lipids like prostaglandins and leukotrienes
(Webb et al., 2003). Cyclooxygenase 2 (COX-2) is an inducible enzyme that is rate
limiting in the production of prostaglandins from arachidonic acid (Burleigh et al., 2002).
5-Lipoxygenase (5-LO) is the rate limiting enzyme in the production of leukotrienes
(Mehrabian et al., 2002). Uncoupling protein 2 (UCP2) produces reactive oxygen species
in cells (Blanc et al., 2003). CC-chemokine receptor 2 (CCR2) mediates signal
transduction in response to the chemotactic cytokine, MCP-1 (Guo et al., 2003).
8Plasminogen activator inhibitor-1 (PAI-1) inhibits fibrinolysis and may promote cell
migration, cell proliferation, and matrix remodeling (Luttun et al., 2002). The growth
suppressor p27 inhibits cell proliferation and migration (Diez-Juan et al., 2004). The
tumor suppressor p53 inhibits cell proliferation and promotes cell death (Merched et al.,
2003; van Vlijmen et al., 2001). Bax is a pro-apoptotic member of the Bcl-2 family of
cell death regulators (Liu et al., 2004). Expression of each of these genes by macrophages
affects the cellular processes involved in inflammation and changes the course of
atherosclerosis.
Role as an Immune Cell
There is overlap between the role of macrophages as immune cells and their role
as inflammatory cells. Macrophages participate in innate immunity by recognizing and
phagocytizing pathogens (Gough and Gordon, 2000; Li and Glass, 2002). Macrophages
also participate in acquired immunity by functioning as antigen-presenting cells (Gordon
et al., 1995). In atherosclerosis, it is hypothesized that modified lipoproteins can be an
immunologic stimulus (Boyd et al., 1989; Major et al., 2002). The role of the
macrophages as an immune cell also involves the orchestration of responses from T-cells,
endothelial cells, and smooth muscle cells.
T-lymphocyte Activation.  Macrophages express major histocompatibility
complex (MHC) class II, which is involved in antigen presentation and activation of T-
lymphocytes via the T-cell antigen receptor (Libby et al., 1996). Activated T-
lymphocytes secrete lymphokines that stimulate macrophages to release the cytokines IL-
1 and tumor necrosis factor (TNF)-a.
Endothelial Cell Activation.  Cytokines released by macrophages can activate
endothelial cells (Libby et al., 1996). The endothelial cells secrete tissue factor when they
are activated, which promotes coagulation. Activated endothelial cells also secrete
plasminogen activator inhibitor, which blocks the fibrinolysis of clots. Cell adhesion
molecules are at increased levels on activated endothelial cells (O'Brien et al., 1993).
9Smooth Muscle Cell Activation.  Cytokines released by macrophages can activate
smooth muscle cells (Libby et al., 1996). This activation increases the secretion of
enzymes that degrade the extracellular matrix and decreases the secretion of collagen
from smooth muscle cells. Together, these changes contribute to tissue remodeling and
make plaques less stable.
Table 1. Macrophage-Induced Atherosclerosis as Studied by Bone Marrow Transplantation
Experiments
Bone Marrow Genotype Aortic Plaques Serum
Cholesterol
(Ref.)
INFLAMMATORY FUNCTIONS
Secretory PLA2 (tng) ­ 75% « (Webb et al., 2003)
COX2(-/-) ¯ 35% « (Burleigh et al., 2002) *
5-LO(+/-) ¯ 95% « (Mehrabian et al., 2002)
UCP2(-/-) ­ 95% « (Blanc et al., 2003)
CCR2(-/-) ¯ 85% « (Guo et al., 2003)
PAI-1(-/-) ­ 20% « (Luttun et al., 2002)
p27(-/-) ­ 85% « (Diez-Juan et al., 2004)
p53(-/-) ­125% « (van Vlijmen et al., 2001)
    '' ­ 80% « (Merched et al., 2003)
Bax(-/-) ­ 50% « (Liu et al., 2004)
IMMUNE FUNCTIONS
IL-5(-/-) ­ 20% « (Binder et al., 2004)
CD11b(-/-) « « (Kubo et al., 2000)
CXCR2(-/-) ¯ 60% ¯ 30% (Boisvert et al., 1998)
IKK2(-/-) ­ 60% « (Kanters et al., 2003)
SCAVENGER FUNCTIONS
SR-A (overexpression) ¯ 20% (n.s.) ¯ 20% (Van Eck et al., 2000a)
    '' ¯ 20% (n.s.) ­ 20% (Herijgers et al., 2000a)
SR-BI(-/-) ­ 85% « (Zhang et al., 2003a)
    '' ­ 70% « (Covey et al., 2003)
LIPID METABOLISM
apoE(-/-) ­ 900% « (Fazio et al., 1997)
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Bone Marrow Genotype Aortic Plaques Serum
Cholesterol
(Ref.)
    '' ­ 270% « (Van Eck et al., 2000b)
apoE(+/+) ¯ 98% ¯ 70% (Linton et al., 1995)
    '' ¯ (qual.) ¯ 80% (Boisvert et al., 1995)
    '' ¯ (qual.) ¯ 80% (Van Eck et al., 1997)
    '' ¯ 95% ¯ 90 (Van Eck et al., 2000b)
apoE(+/+) LDLR(-/-) ¯ 60% « (Fazio et al., 2002)
apoAI(tng) apoE(-/-) ¯ 95% « (Major et al., 2001)
    '' ¯ 95% « (Ishiguro et al., 2001) #
    '' ¯ 30% « (Su et al., 2003)
apoE3-(tng) apoE(-/-) ¯ 40% « (Yoshida et al., 2001) #
apoE3-Leiden(tng) apoE(-/-) ¯ 30% (n.s.) ¯ 50% (tr.) (Van Eck et al., 2000b)
apoE2(tng) apoE(-/-) ¯ 30% (n.s.) ¯ 50% (tr.) (Van Eck et al., 2000b)
    '' « « (Yoshida et al., 2001) #
apoEcys142(tng) apoE(-/-) ­ 60% « (Yoshida et al., 2001) #
LDLR(-/-) ¯ 65%
¯ 65%
«
«
(Herijgers et al., 2000b)
(Linton et al., 1999)
LDLR(+/+) « « (Boisvert et al., 1997)
    '' « « (Linton et al., 1999)
    '' « « (Herijgers et al., 1997)
ACAT1(-/-) ­ 120% « (Fazio et al., 2001)
ABCA1(-/-) ­ 50% « (Aiello et al., 2002)
    '' X « (Haghpassand et al., 2001)
PPARg(-/-) ­ 35% « (Chawla et al., 2001)
aP2(-/-) ¯ 65% « (Makowski et al., 2001)
LPL(-/-) ¯ 35% « (Babaev et al., 2000)
    '' ¯ 55% « (Babaev et al., 1999)
    '' ¯ 50% ¯ 50% (Van Eck et al., 2000c)
HL(-/-) ¯ 65% « (Nong et al., 2003)
Bone marrow transplantation and the genes that have been studied by this method are briefly
described in the text. Bone marrow genotypes are compared to appropriate controls. For example,
recipients of (-/-) marrow were compared with recipients of (+/+) marrow, while recipients of
(+/+) marrow were compared with recipients of (-/-) marrow. Data is reported as percentage
change relative to the appropriate control group: increase (­), decrease (¯), no difference («),
not reported (X), not significant (n.s.), transient change (tr.), and qualitative assessment (qual.).
Changes were statistically significant unless otherwise noted. Genes can also be introduced by
viral transduction (#) of bone marrow cells before transplantation. Fetal liver cell transplant (*) is
another type of hematopoietic cell transplant.
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Immunity and Macrophage-Induced Atherosclerosis.  The role of the macrophage
as an immune cell affects atherogenesis. Studies designed to isolate the contributions of
macrophages to atherosclerosis have focused on many mediators of immunity (Table 1).
These mediators, which are expressed by macrophages, function as ligands, receptors,
and transcription factors in the signaling pathways for immunity. For example, IkB
kinase 2 (IKK2) is an activator of NF-kB, an important pathway in innate and adaptive
immune responses (Kanters et al., 2003). IL-5 stimulates B-cells to secrete
immunoglobulin (Ig) M (Binder et al., 2004). CD11b is a subunit of the b2-integrin, Mac-
1, which mediates adherence and extravasation of leukocytes (Kubo et al., 2000). CXCR2
is the receptor for IL-8, which is a chemokine that is a mediator of acute inflammation
(Boisvert et al., 1998). Expression of each of these genes by macrophages affects
immunity and inflammation in the vascular wall.
Role as a Scavenger Cell
Macrophages are commonly referred to as scavenger cells because of their role in
the clearance of lipoproteins, cells, bacteria, and tissue debris. Endocytosis is the process
by which macrophages engulf and then degrade material. The different types of
endocytosis include pinocytosis, phagocytosis, and patocytosis. Clearance of LDL and
modified LDL is considered the major factor that contributes to the accumulation of
intracellular cholesterol and foam cell transformation (Kruth, 2001; Kruth, 2002).
Pinocytosis of LDL and modified LDL occurs by the receptor-mediated entry of
monomeric lipoproteins into vesicles. Phagocytosis occurs with larger LDL aggregates
and cellular debris. Patocytosis is a very distinctive type of endocytosis where very large
aggregates of LDL are taken into an intracellular membrane labyrinth that remains
connected to the surface. Receptors such as SR-A, SR-BI, and CD36 are important in the
recognition of modified lipoproteins and many other ligands that macrophages scavenge.
In addition to being scavengers of lipoproteins, macrophages have a role in the clearance
of apoptotic and necrotic cells (Fadok et al., 2001). Apoptotic cells present specific
phospholipids like phosphatidyl serine, oxidized phospholipids, and certain vitronectins,
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that lead to receptor-mediated recognition and clearance by macrophages. Not only can
scavenger receptors bind these apoptotic ligands, but they can also interact with receptors
that have higher specificity for apoptotic ligands (Savill and Fadok, 2000).
Scavenger Functions and Macrophage-Induced Atherosclerosis.  Studies designed
to isolate the contributions of macrophages to atherosclerosis have focused on some
macrophage scavenger receptors that are involved in binding and endocytosis of modified
lipoproteins and cellular debris (Table 1). Each scavenger receptor is expressed by
macrophages and has a wide ligand specificity. For example, SR-A is an oxLDL receptor
but it also binds many other ligands (Herijgers et al., 2000a; Horiuchi et al., 2003; Van
Eck et al., 2000a). SR-BI is an HDL receptor, but it also binds LDL, oxLDL and a wide
range of other ligands, as well (Covey et al., 2003; Horiuchi et al., 2003; Zhang et al.,
2003a).
Role in Vascular Lipid Metabolism
In the vascular wall, macrophages maintain cholesterol homeostasis by balancing
lipoprotein uptake, cholesterol storage, cholesterol synthesis, and cholesterol efflux.
Pathways of macrophage cholesterol homeostasis are discussed in detail in subsequent
sections.
Vascular Cholesterol Metabolism and Macrophage-Induced Atherosclerosis.
Studies designed to isolate the contributions of macrophages to atherosclerosis have
focused on many mediators of cholesterol and lipoprotein metabolism (Table 1). Most of
these mediators have a role in cholesterol transport. For example, both apoE and apoAI
play important roles in lipoprotein metabolism with structural functions, ligand functions,
and cholesterol acceptor functions (Fazio et al., 1997; Ishiguro et al., 2001; Major et al.,
2001; Van Eck et al., 2000b). LDLR binds and mediates the uptake of LDL, IDL, and
VLDL (Boisvert et al., 1997; Herijgers et al., 1997; Herijgers et al., 2000b; Linton et al.,
1999). ACAT1 is the enzyme that esterifies cellular cholesterol so that it can be stored in
lipid droplets (Buhman et al., 2000a; Fazio et al., 2001). ATP-Binding Cassette (ABC)-
A1 is responsible for phospholipid and cholesterol efflux to apoAI (Aiello et al., 2002;
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Haghpassand et al., 2001). Peroxisome proliferator-activated receptors (PPAR) are
nuclear hormone receptors that are involved in cholesterol metabolism and inflammation
(Chawla et al., 2001; Moore et al., 2001). The fatty acid binding protein aP2 is involved
in the cellular metabolism of fatty acids (Makowski et al., 2001). Lipoprotein lipase
(LPL) is involved in the de-esterification of triglycerides and cholesterol esters from
lipoproteins (Babaev et al., 1999; Babaev et al., 2000; Van Eck et al., 2000c). Hepatic
lipase (HL) hydrolyzes triglycerides and phospholipids in chylomicron remnants, IDL,
and HDL (Nong et al., 2003). Each of these genes directly or indirectly affects cellular
cholesterol homeostasis in macrophages.
The Pathways of Macrophage Cholesterol Homeostasis
The studies of cholesterol homeostasis presented here focus mainly on cholesterol
efflux because this process is both a marker and a mediator of cholesterol balance
(Rothblat et al., 1999). Three other processes that influence cellular cholesterol balance
are cholesterol ester storage, cholesterol synthesis, and lipoprotein uptake. Cholesterol
homeostasis in macrophages is of critical importance because these cells have a pivotal
function in the vessel wall and in the development of atherosclerotic lesions. Disruption
of one process of cholesterol balance results in compensation by others to maintain
homeostasis (Figure 2). As the initial step of the reverse cholesterol transport (RCT)
system, cholesterol efflux is a homeostatic process with great potential to affect
atherosclerosis risk. Overburdening the compensatory processes leads to total disruption
of homeostasis, foam cell formation, and apoptosis (Mitchinson et al., 1996).
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Figure 2. Cellular Cholesterol Homeostasis and the Reverse Cholesterol
Transport System.
Cholesterol Storage
Free Cholesterol.  Most cellular free cholesterol is incorporated into membranes
but crystallization can occur when concentrations are too high (Kellner-Weibel et al.,
1998; Kellner-Weibel et al., 1999). Regulation of the amount of cellular free cholesterol
is accomplished by mediators such as sterol regulatory element binding protein (SREBP)
and HMG-CoA reductase. Because free cholesterol is the substrate for ACAT, this
enzyme lowers the concentration of free cholesterol in the cell. Free cholesterol is
available for efflux, which also lowers cellular cholesterol concentrations.
Cholesterol Esterification and ACAT.  Cholesterol is stored by ACAT enzymes in
neutral lipid droplets (Buhman et al., 2000a; Buhman et al., 2001). By the enzymatic
action of ACAT, free cholesterol is esterified with fatty acids. The sterol specificity of
ACAT includes cholesterol and oxysterols (Zhang et al., 2003b). The specificity of
ACAT for bile acid derivatives is relatively low (Cho et al., 2003). ACAT is allosterically
activated by cholesterol and some oxysterols (Cases et al., 1998a; Cho et al., 2003).
ACAT has broad specificity for long-chain fatty acids but the highest specificity is for
oleic acid (Cases et al., 1998a).
ACAT has two isozymes, ACAT1 and ACAT2. In mice, the ACAT1 isozyme is
found at high levels in macrophages and steroidogenic tissues, where it is involved in
intracellular storage of cholesterol. ACAT2 is expressed in the liver and the small
EFFLUX
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intestines, where it is involved in absorption of dietary cholesterol and in lipoprotein
assembly. The distribution is similar in humans, except that hepatocytes express both
ACAT1 and ACAT2 (Buhman et al., 2000b; Chang et al., 2000; Lee et al., 2000).
The regulation of ACAT expression differs from other genes that are involved in
cholesterol homeostasis. ACAT1, unlike many other mediators of sterol metabolism,
does not have a promoter element for regulation by sterol regulatory element binding
protein (SREBP) (Li et al., 1999). However, expression is increased by monocyte-
macrophage differentiation, 1,25-dihydroxyvitamin D3, and 9-cis-retinoic acid (Buhman
et al., 2001; Maung et al., 2001).
ACAT Inhibition and ACAT Deletion.  The identification of cholesterol storage
within macrophages as one of the initial steps in atherosclerosis has prompted studies on
pharmacologic inhibition of the enzymes involved in this process. Many studies have
reported increased cellular cholesterol efflux with pharmacologic inhibition of ACAT
activity (Kellner-Weibel et al., 1998; Mazzone and Reardon, 1994; Rodriguez et al.,
1999; Warner et al., 1995; Zhang et al., 1996). However, there are many conflicting
reports of both increased and decreased atherosclerosis in animal models following the
administration of ACAT inhibitors (Buhman et al., 2000a). A study from our laboratory
showed that hyperlipidemic mice reconstituted with ACAT1(-/-) macrophages have
increased atherosclerosis (Fazio et al., 2001). The mechanisms behind this increase are
currently under investigation, both in the studies presented here and in other studies
within our laboratory. The effects of decreased cholesterol storage on macrophage
cholesterol efflux and cholesterol homeostasis have only been studied with
pharmacologic inhibitors of ACAT. Understanding the cellular consequences of the total
absence of cholesterol storage by ACAT1 gene deletion has great significance because it
may provide explanations for discrepancies between the effects of ACAT1 gene deletion
and the effects of ACAT inhibition on atherogenesis.
Cholesterol Synthesis
Cholesterol synthesis occurs in many tissues and is tightly regulated (Hampton et
al., 1996). HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis. This
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enzyme is regulated by feedback inhibition by cholesterol and other mevalonate
metabolites, by hormonal sensitivity to insulin and glucagon, by sterol-mediated
transcriptional regulation, and by competitive inhibitors of HMG-CoA reductase.
Although most cholesterol in foam cells is likely to be derived from lipoprotein uptake,
de novo cholesterol synthesis may contribute to internal cholesterol pools that lead to
foam cell formation (Johnson et al., 1995; Mendez et al., 1991). Newly synthesized
cholesterol is available for efflux to cholesterol acceptors (Johnson et al., 1995).
Cholesterol Uptake
Uptake of cholesterol occurs via the binding and uptake of native or modified
lipoproteins by lipoprotein receptors including LDLR, SR-BI, cluster of differentiation
antigen (CD)36, SR-A, heparan sulfate proteoglycans, and LRP (Herz and Strickland,
2001; Krieger, 2001; Linton and Fazio, 2001; Nicholson et al., 2001). The constitutive
nature of SR-A expression and the feed-forward regulation of CD36 in macrophages lead
to unregulated uptake of modified LDL and foam cell formation (Kita et al., 2001). The
delivery of modified LDL to lysosomes following receptor-mediated uptake results in the
hydrolysis of cholesterol esters and the processing of the free cholesterol. Accumulation
of free cholesterol results in dysfunction of hydrolysis, which leads to lysosomal
accumulation of both cholesterol esters and free cholesterol. Cholesterol in loaded
lysosomes is resistant to efflux (Yancey and Jerome, 2001).
Scavenger Receptors.  Macrophages are scavenger cells that take up and degrade
lipoproteins and cellular debris in the walls of vessels. Research into scavenger receptors
began with the study of a putative receptor for modified lipoproteins, later identified as
SR-A (Goldstein et al., 1979). One characteristic of scavenger receptors is that they bind
multiple ligands. Lipoprotein uptake is just one of the physiological functions of
scavenger receptors (Krieger, 1997). This class of receptors includes SR-A, CD36, and
SR-BI (Herz and Hui, 2004; Horiuchi et al., 2003).
LDL Receptor Family.  LDLR is an essential mediator in cholesterol metabolism
because it takes up apoB containing lipoproteins, like LDL, from plasma (Brown and
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Goldstein, 1986; Goldstein and Brown, 1974; Wilkinson, 1950). LDLR binds apoE and
apoB on LDL, IDL, and VLDL. Mutations in LDLR have been shown to be the cause of
familial hypercholesterolemia (Goldstein and Brown, 1974). LDLR is down-regulated by
cellular cholesterol via SREBP (Wang et al., 1993). The LDLR family is a group of
receptors that share homology with LDLR. The receptor family has a broad range of
functions and many members: LDLR, LRP, VLDLR, megalin, and apoE receptor 2
(apoER2) (Takahashi et al., 2003).
Proteoglycans.  Heparan sulfate proteoglycans (HSPG) are high capacity, low
affinity receptors on hepatocytes, macrophages, and other peripheral cells (Libeu et al.,
2001; Saito et al., 2003; Wilsie and Orlando, 2003). HSPG binds apoE-containing
lipoproteins including VLDL, IDL, and LDL as well as enzymes like lipoprotein lipase
(Mahley, 1988). The uptake of lipoproteins is often a multi-step process. These steps
include transfers of lipoproteins between HSPG and receptors like LDLR and LRP,
followed by uptake and degradation.
Lipoprotein Internalization and Degradation.  Lipoproteins are internalized by
endocytosis after binding to receptors associated with clathrin-coated pits on microvilli or
uncoated regions on the membrane ruffles (Kruth, 2001). Lipoproteins are taken into
endosomes and then trafficked to lysosomes where degradation occurs. Lysosomal acid
lipase hydrolyzes the cholesteryl esters on lipoproteins (Du and Grabowski, 2004; Werb
and Cohn, 1972). In contrast to endocytosis, selective uptake of cholesteryl esters can
occur by docking to receptors or uptake into surface-connected tubules (Rinninger et al.,
1995; Rinninger and Greten, 1990).
Cholesterol Trafficking.  Once free cholesterol dissociates from lipoproteins and
cholesteryl esters have been hydrolyzed, lipoprotein-derived cholesterol is trafficked by
Neiman-Pick protein to the plasma membrane (Reid et al., 2003; Soccio and Breslow,
2004). From the plasma membrane, cholesterol is trafficked to the endoplasmic reticulum
where it can be esterified by ACAT. Cholesteryl esters are stored within neutral lipid
droplets and are subsequently hydrolyzed by neutral cholesteryl ester hydrolase (NCEH).
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In addition to these pathways, cellular cholesterol trafficking involves many sterol carrier
proteins (Ioannou, 2001; Schroeder et al., 2001).
Cholesterol Efflux and Reverse Cholesterol Transport
Cholesterol homeostasis in macrophages is of critical importance in
atherosclerosis research because these cells perform crucial functions in the vessel wall.
One process by which macrophages maintain cholesterol balance is cholesterol efflux. As
the initial step of the reverse cholesterol transport (RCT) system, cholesterol efflux is a
homeostatic process with great potential to affect atherosclerosis risk. The importance of
RCT in preventing atherosclerosis and the high degree of connectivity between the four
processes of cholesterol homeostasis make cholesterol efflux the sentinel measurement of
cholesterol balance in macrophages (Figure 2). Besides the notable exceptions of apoE
deficiency and ABCA1 deficiency, very few studies have been performed to test the
correlation of lesion development with cholesterol efflux from macrophages of
genetically engineered atherosclerosis models. Bone marrow and fetal liver cell
transplantation studies have led to the identification of many macrophage-specific factors
that contribute to atherogenesis (Table 1). While much attention is given to the plasma
components of the RCT system, most characterizations of these models fall short of
characterizing cholesterol efflux from macrophages.
Cholesterol Efflux: Mechanisms and Mediators
Cholesterol efflux can occur by many mechanisms including diffusion, membrane
microsolubilization, ABCA1-mediated efflux, receptor-mediated efflux, and lipoprotein
assembly (Figure 3). Early investigations of cellular cholesterol metabolism by Rothblat
and of the low density lipoprotein receptor (LDLR) by Brown and Goldstein have driven
the study of cholesterol efflux (Ho et al., 1980; Rothblat and Phillips, 1986).
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Figure 3. Mechanisms of Macrophage Cholesterol Efflux.
(1) Diffusion of Free Cholesterol, (2) Cholesterol Acceptors, (3) ApoE and
Proteoglycans, (4) ApoAI and ABCA1 and (5) HDL and SR-BI.
Diffusion
Membrane cholesterol spontaneously enters the aqueous phase by a process
known as desorption or diffusion (Rothblat and Phillips, 1982). Diffusion of membrane
cholesterol into the aqueous extracellular space follows first-order kinetics and is
reversible. Diffusion is thought to be the first step of efflux to most cholesterol acceptors.
Cholesterol Acceptors
Cholesterol efflux is stimulated by cholesterol acceptors, which provide a
hydrophobic environment for cholesterol while remaining aqueous. The common
structural organization of cholesterol acceptors is a hydrophobic core or pocket
surrounded by a hydrophilic shell. This is the structural organization of phospholipid
vesicles, apolipoproteins, lipoproteins, cyclodextrins, and albumin. Receptor binding,
microsolubilization of membranes, and diffusion are mechanisms of interaction between
acceptors and the cholesterol in cellular membranes (Rothblat et al., 1999). Important
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work with apolipoproteins, phospholipid vesicles, and cyclodextrins determined that the
relationship between acceptor concentration and cholesterol efflux is linear but saturable
(Rothblat and Phillips, 1986; Yancey et al., 1996).
Apolipoproteins
Research in the field of cholesterol efflux has focused on two cholesterol
acceptors that are important in the prevention of atherosclerosis, apoE and apoAI.
Previous studies to investigate the protective roles of macrophage-derived
apolipoproteins have not characterized the effects on macrophage cholesterol efflux or
macrophage cholesterol homeostasis. The association of certain lipoproteins with either
increased or decreased atherosclerosis risk has led to research on the functions, structure,
and metabolism of apolipoproteins. One important class of apolipoproteins, known as
exchangeable apolipoproteins, has important anti-atherogenic properties. These
exchangeable apolipoproteins, including apoE and apoAI, have common secondary
structural elements that facilitate common functional characteristics (Hara and
Yokoyama, 1991; Segrest et al., 1992). Targeted mutagenesis and other types of studies
have shown that amphipathic alpha helices are necessary for the cholesterol acceptor
functionality of these apolipoproteins (Hara et al., 1992). Understanding the nature of the
protective functions of apolipoproteins as locally synthesized cholesterol acceptors has
great significance because it will provide validation for therapeutic efforts to deliver
apolipoproteins to lesions through drug therapy, viral gene therapy, and bone marrow
transplantation.
Apolipoprotein E.  Apolipoprotein E is a cholesterol acceptor that is a protein
constituent of very low density lipoproteins (VLDL), intermediate density lipoproteins
(IDL), and high density lipoproteins (HDL) (Mahley, 1988; Mahley and Rall, 2000).
Receptors with specificity for apoE-containing particles include LDLR, proteoglycans,
and LDLR related protein (LRP). Hepatocytes, adipocytes, and macrophages synthesize
apoE (Basu et al., 1981; Jeejeebhoy et al., 1975). Macrophage apoE has been shown to
protect against atherosclerosis (Fazio et al., 1997; Linton et al., 1995). Endogenous
synthesis of apoE in J774 cells, a macrophage-like cell line, results in increased
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cholesterol efflux (Lin et al., 1999). These studies also determined that endogenous apoE
resulted in more efflux from the cells than similar concentrations of exogenous apoE.
Furthermore, endogenous apoE synthesis increases cholesterol efflux to exogenous
acceptors such as phospholipid vesicles, cyclodextrins, and albumin. Other studies show
that interactions with proteoglycans are necessary for the endogenous apoE-mediated
efflux (Lin et al., 2001).
Apolipoprotein AI.  Apolipoprotein AI is a cholesterol acceptor that is the main
protein constituent of HDL (Atmeh et al., 1983). ApoAI is synthesized by hepatocytes,
but in contrast to apoE, it is not synthesized by macrophages (Basu et al., 1981). Plasma
apoAI and HDL have been shown to protect against atherosclerosis (Gordon and Rifkind,
1989). There is an inverse relationship between plasma HDL and risk for coronary artery
disease (Wilson et al., 1988). Like macrophage apoE, macrophage expression of
transgenic apoAI has been shown to be protective (Ishiguro et al., 2001; Major et al.,
2001; Su et al., 2003).
Exchangeable Apolipoproteins.  Although apoE and apoAI are the main
mediators of cholesterol efflux from macrophages in the vessel wall, many other
apolipoproteins act as cholesterol acceptors. The exchangeable apolipoproteins have
similar structural and functional characteristics (Saito et al., 2004). This group includes
apoE, apoAI, apoAII, apoAIV, apoAV, apoCI, apoCII, and apoCIII. These
apolipoproteins have amphipathic helices that are able to solubilize phospholipids and
cholesterol. All of these apolipoproteins are substrates for ABCA1-mediated cholesterol
efflux, and some accept cholesterol independently of the ABCA1 pathway (Bortnick et
al., 2000; Remaley et al., 2001). Efflux to apoE, for example has been reported to occur
by mechanisms that are independent of ABCA1 (Huang et al., 2001).
HDL, ATP Binding Cassette-A1, and Tangier Disease
Studies of ABCA1 suggest that it adds phospholipids to apoAI (Fielding et al.,
2000; Wang et al., 2001). ApoAI binding studies suggest that ABCA1 is a phospholipid
flippase that changes the local phospholipid content of the outer membrane leaflet in a
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manner that favors the association of apoAI with the membrane (Chambenoit et al.,
2001). Although apoAI is thought to be the physiological acceptor for ABCA1, other
apolipoproteins and amphipathic peptides can accept cholesterol from ABCA1 (Bortnick
et al., 2000). The local importance of ABCA1 in the vessel wall is not fully understood,
but systemically, ABCA1 is a critical part of the RCT system (Aiello et al., 2002;
McNeish et al., 2000). Tangier disease is a classic example of how decreased HDL and
apoAI can dramatically increase atherosclerosis in humans (Assmann et al., 1977;
Henderson et al., 1978; Mautner et al., 1992; Schmitz et al., 2000). Mutations in the
ABCA1 gene cause this inherited disease. Tangier patients lack the ability to add
phospholipids to apoAI. Lipid-free apoAI is quickly cleared from plasma by the kidneys.
Low plasma apoAI concentrations are associated with increased atherosclerosis (Gordon
and Rifkind, 1989; Gordon et al., 1977). Not only is phospholipid-associated apoAI
resistant to clearance, it is a very efficient acceptor of cellular cholesterol.
With increased association of cholesterol and phospholipids, apoAI progresses to
nascent HDL, to pre-beta HDL, and then to alpha HDL. Nascent HDL has two apoAI
proteins surrounding a small unilamellar phospholipid bilayer and has a discoidal shape
(Segrest et al., 1999). Spherical alpha HDL has two to four apoAI proteins and a more
complex lipid composition. The maturation of HDL structure and composition is
mediated by ABCA1 which adds more cellular lipids and SR-BI which docks HDL to
cells for cholesterol and cholesteryl ester exchange. HDL is also modified by lecithin:
cholesterol acyltransferase (LCAT) which esterifies HDL cholesterol and phospholipid
transfer protein (PLTP) which transfers lipids between HDL and other lipoproteins
(Segrest et al., 2000).
Receptor-Mediated Docking
Receptor-mediated docking allows for the transfer of lipids between cells and
lipoproteins without uptake and degradation. Scavenger receptor (SR)-BI and
proteoglycans mediate this type of interaction. SR-BI allows HDL to dock at the plasma
membrane and exchange cholesterol along a concentration gradient. Docking facilitates
bi-directional exchange of cholesterol between the cell and HDL particles (Yancey et al.,
2000). Selective uptake of cholesteryl esters also occurs via interactions between SR-BI
23
and HDL (Connelly et al., 2001). Docking of apoE to proteoglycans facilitates
cholesterol efflux by preventing escape from the cell surface (Lin et al., 2001).
Proteoglycans are low-affinity receptors for apoE but have a high capacity on the cell
surface.
Oxysterols and Liver X Receptor
Liver X receptor (LXR) is a transcription factor that up-regulates many
cholesterol homeostasis genes including apoE and ABCA1 (Millatt et al., 2003).
Oxysterols are the endogenous ligands for LXR. LXR is a transcription factor that binds
oxysterols and forms heterodimers with retinoid X receptor (RXR) to regulate genes with
LXR response elements. Genes under the control of LXR perform functions that include
cholesterol efflux (e.g. ABCA1 and apoE), cholesterol ester metabolism (e.g. cholesterol
ester transfer protein), cholesterol synthesis (e.g. SREBP-2 and HMG-CoA synthase),
fatty acid synthesis (e.g. SREBP-1c), and inflammation (e.g. TNFa). Together,
oxysterols from modified lipoproteins and LXR control a coordinated response that
includes apoE-mediated and ABCA1-mediated cholesterol efflux.
Summary
Atherosclerosis is characterized by the failure of cholesterol homeostasis in
macrophages within vessel wall lesions (Figure 4). Cholesterol-filled macrophage foam
cells are the hallmark of this disease. Cholesterol efflux is an important marker and
mediator of macrophage cholesterol homeostasis because it is the first step of the reverse
cholesterol transport system. We hypothesize that macrophages with genotypes that are
known to affect the progression of atherosclerosis, will have changes in cholesterol efflux
and cellular cholesterol homeostasis. The studies presented here investigate whether
cholesterol storage deficits cause changes in cholesterol efflux. We also investigate the
mechanisms by which endogenously synthesized cholesterol acceptors produce increases
in macrophage cholesterol efflux.
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Figure 4. Overview of Macrophage Cholesterol Homeostasis: Cholesterol
Uptake, Storage, Synthesis, and Efflux.
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CHAPTER III
DEVELOPMENT OF EXPERIMENTAL PROTOCOLS AND DATA ANALYSIS
SOFTWARE FOR ASSAYING CHOLESTEROL EFFLUX
Abstract
Objective.  The study of cholesterol efflux began in the 1960’s and 1970’s with
studies of cellular cholesterol metabolism and macrophage foam cell formation. The
efflux of cholesterol to cholesterol acceptors is the first step in the reverse cholesterol
transport system and is considered to be anti-atherogenic. The central role of
macrophages in the pathophysiology of atherosclerosis has made this cell type the
primary focus of most studies of cholesterol efflux. The objective of the current study
was to develop experimental protocols for assaying cholesterol efflux from macrophages.
The aim was to apply these cholesterol efflux protocols to the study of cholesterol storage
deficits and the study of endogenously synthesized cholesterol acceptors.
Developments.  Through reviews of the literature and further development, we
have designed original protocols for assaying cholesterol efflux with 3H-cholesterol as a
tracer. Cultured macrophages are loaded with modified lipoproteins and labeled with 3H-
cholesterol. After extensive washes, cholesterol efflux is initiated by the addition of
various cholesterol acceptors. Derivations of this type of protocol were made in order to
facilitate larger experiments, to study the autocrine and paracrine actions of cholesterol
acceptors, and to study the effects of extracellular fluid mixing and kinetic energy on
cholesterol efflux.
Conclusions.  These protocols are efficient tools with which to probe the role of
cholesterol efflux in macrophage cholesterol homeostasis. Progress and future
developments are discussed.
Introduction
The central role of macrophages in the pathophysiology of atherosclerosis has
made macrophages the primary focus of most studies of cholesterol efflux. As
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macrophages take up modified lipoproteins, they transform into lipid-filled foam cells
(Brown et al., 1979). Following efflux, cholesterol from peripheral cells is carried
through the plasma on apolipoproteins (e.g. apoE and apoAI) and on lipoproteins (e.g.
HDL) (Ho et al., 1980). Cholesterol is taken up by the liver and secreted as bile
(Schwartz et al., 1978). This pathway is referred to as the reverse cholesterol transport
(RCT) system. The efflux of cholesterol to cholesterol acceptors is the first step in the
reverse cholesterol transport system and is, therefore, considered to be an anti-
atherogenic event.
Literature on cholesterol efflux reveals that assaying cholesterol efflux with 3H-
cholesterol as a tracer has been the historical standard (Rothblat et al., 2002). A
reproducible assay for cholesterol efflux and efficient data analysis techniques are
necessary for accurate measurements of macrophage cholesterol efflux. The objective of
the current study was to develop experimental protocols for assaying cholesterol efflux
from macrophages. Through reviews of the literature on cholesterol efflux, we have
designed original protocols for assaying cholesterol efflux with 3H-cholesterol as a tracer.
Derivations of this type of protocol were developed to facilitate larger experiments, to
study the autocrine and paracrine actions of cholesterol acceptors, and to study the effects
of extracellular fluid mixing and kinetic energy on cholesterol efflux. These protocols are
efficient tools with which to probe the role of cholesterol efflux in macrophage
cholesterol homeostasis.
Protocol Development: Results and Discussion
General 3H-Cholesterol Efflux Protocols
Cholesterol efflux protocols from murine peritoneal macrophages are based on
modifications to a general protocol from the laboratory of T. Mazzone (Table 2) (Lin et
al., 1999). These modifications are based on published methodologies designed to test
cholesterol efflux mediated by the ATP-Binding Cassette (ABC)-A1 transporter,
diffusional efflux, efflux mediated by endogenously synthesized cholesterol acceptors,
receptor-mediated efflux to acceptors, and pharmacologically induced changes in
cholesterol efflux. The validity of these protocols has been tested by comparing results to
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previously published results from other laboratories (Figure 5) (Bortnick et al., 2000; Lin
et al., 1999). The protocols and techniques have been utilized and refined in our
laboratory. Experiments with six samples (n=6) per group result in statistically
interpretable data. Group means have relative standard deviations of 5-10%. These
experiments are able to show that efflux changes of less than 1% of cellular 3H-
cholesterol counts are statistically significant by Student’s t-test or ANOVA. This sample
size (n=6) was calculated to detect a relative effect of 10-20% with an alpha value of 0.05
and a power of 0.8. Trends that are present in experimental data are reproducible in
subsequent replicate experiments.
Table 2. Summary of a General Cholesterol Efflux Protocol
1. Labeling/Loading 2. Rinses & Equilibration 3. Cholesterol Efflux
3H-Cholesterol
acLDL
Serum
Rinse (3x)
Equilibration (24 h)
Rinse (1x)
Initiation of Efflux to Acceptors
Sampling (0,3, or 6 h)
Analysis
Figure 5. Macrophage Cholesterol Efflux Mediated by Endogenous ApoE
and ABCA1.
Macrophages were treated for 36 hours with 1.5 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol. Cells were then cultured
in efflux media. Bars and error bars represent the mean (n=6) and standard
deviation of samples. (A) Effects of endogenous apoE synthesis on macrophage
cholesterol efflux to bovine serum albumin (0.1%). (B) Effects of ABCA1
expression on macrophage cholesterol efflux to apoAI (10 mg/ml).
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Protocol Summary.  Elicited murine peritoneal macrophages are harvested and
cultured on 24-well plates. To cholesterol-load cultured macrophages, culture media is
replaced with loading media consisting of Dulbecco’s Modified Eagle Medium
(DMEM)/2% fetal bovine serum (FBS) containing 1.5-2.0 mCi/ml of 3H-cholesterol and
70 mg/ml acLDL for 36 hours. After washing, monolayers are equilibrated for 4 hours
and rinsed once. The efflux period is initiated by the addition of efflux media. A)
Diffusional Efflux. To measure diffusional efflux, serum-free DMEM with 0.1% BSA is
added to designated wells. B) ABCA1-Mediated Efflux. To measure efflux mediated by
ABCA1, serum-free DMEM with 10 mg/ml human apoAI is added to designated wells.
C) Endogenous Acceptor-Mediated Efflux. To measure efflux mediated by endogenously
synthesized cholesterol acceptors, serum-free DMEM with no acceptors is added to
designated wells.
During efflux experiments, samples are removed from each well at appropriate
time intervals depending on the macrophage genotype, acceptor type, and acceptor
concentration. 3H-cholesterol counts are detected with a Beckman LS 6000IC
scintillation counter after the removal of cell debris by centrifugation. Total cellular 3H-
cholesterol counts and total cellular protein masses are determined by rinsing and lysing
labeled monolayers. Cholesterol efflux is calculated from the total supernatant counts
(media) and is expressed as a percentage of the total cell counts (media and lysate).
Experiments are performed with six samples for each unique experimental condition.
Efflux data is analyzed with Efflux 4.4 software.
96-Well Microtiter Plate Efflux Protocol
Basic modifications to the general efflux protocols (Table 2) were made in order
to use 96-well culture plates for efflux assays. 96-well plates have 8 rows and 12 columns
and wells are 6.4 mm in diameter with 0.32 cm2 area per well. These plates support
culture volumes from 50 to 250 ml per well. Plates can accommodate between 5x104 and
1.5x105 cells per well. The advantages of a 96-well efflux assay are that a greater number
of conditions can be tested using fewer cells, less 3H-cholesterol, and less modified LDL.
Also, the use of multi-channel pipetors can increase manual efficiency. The
disadvantages include greater variability among samples in each group, higher
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concentrations of 3H-cholesterol during labeling, and insufficient lipid mass for thin layer
chromatography or gas chromatography analyses. Since the 96-well efflux assay allows
for experiments with a larger number of groups, analysis software was expanded to
process, compare, and summarize data from up to 48 experimental groups. This system
has proven to be efficient and applicable to many studies (Chapter VI).
A typical experiment in a 96-well system compared unloaded macrophages to
macrophages treated with 100 mg/ml acLDL. The 96-well system used approximately
70% fewer cells, 70% less acLDL, and 30% less 3H-cholesterol compared to the same
experiment performed in a 24-well system (Figure 6). 96-well efflux assays using eight
samples per unique condition have relative standard deviations of 10-15% and yield
reproducible results. This sample size (n=8) was calculated to detect a relative effect of
15-25% with an alpha value of 0.05 and a power of 0.8.
Figure 6. Macrophage Cholesterol Efflux in a 96-well Culture System.
Experiments with 96-well system studying the effects of cholesterol loading used
approximately 70% fewer cells, 70% less acLDL, and 30% less 3H-cholesterol
compared to the same experiment performed in a 24-well system. Macrophages
(7x104 cells/well) were treated for 36 hours with 3.0 mCi/ml of 3H-FC and 0
("Unloaded") or 100 mg/ml acLDL ("acLDL") in DMEM/1% FBS to label
cellular cholesterol. Cells were then cultured in efflux media with 0.1 % BSA for
6 hours. Bars and error bars represent the mean (n=8) and standard deviation of
samples. Asterisk (*) denotes a statistically significant difference (p<0.05)
compared to the unloaded group as determined by Student’s t-test.
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Efflux 4.4 Data Analysis Spreadsheet
Software, in the form of a Microsoft ExcelÔ spreadsheet, was designed in our
laboratory to analyze, summarize, and present efflux data. The software includes data
processing selections and sheets for computation, results and statistical summaries,
graphs, and conclusions (Appendix, Figure 29). All results and graphs update
automatically upon the entry of new data or with changes in data processing
methodology. Efflux 4.4 is augmented by macros, which are automated routines written
using the Visual Basic for Applications language (Simon, 2002). This software is flexible
enough to process data from most cholesterol efflux protocols and other types of kinetic
experiments.
Volume-Dependence Efflux Protocol
A novel technique was developed with the aim of separating the autocrine and
paracrine effects of cholesterol acceptors. For example, a single apoE protein can accept
cholesterol from the macrophage that originally secreted it (i.e. autocrine effect) and then
accept cholesterol from surrounding macrophages (i.e. paracrine effect). The terms
"autocrine" and "paracrine" are traditionally applied to signaling peptides and hormones,
but they have also been used to describe the actions of mediators with a broad range of
functions besides signal transduction, including apoE (Kockx et al., 2004; Lafarga et al.,
1994; Shimano et al., 1991). Understanding which of these mechanisms is more
important for macrophages will give insight into the physiological importance of
macrophage apoE. The fact that the phrase “autocrine and/or paracrine” can be found in
so many papers emphasizes the point that traditional methodologies have not been very
successful at separating these effects. The objective of the novel methodology presented
here was to separate the autocrine and paracrine effects of macrophage apoE (Chapter
VII).
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Figure 7. Theoretical Separation of the Autocrine and Paracrine Effects of
Cholesterol Acceptors.
(A) Effects of an endogenous cholesterol acceptor that occur solely in the
intracellular/juxtacellular space (i.e. autocrine effect) are independent of the
extracellular distribution volume. Once an acceptor enters the extracellular space
it is diluted in the distribution volume before it can affect another cell (i.e.
paracrine effect). (B) The effect of an endogenous acceptor depends on the
distribution volume. (C) The effect of an endogenous acceptor depends on its
relative concentration (reciprocal volume).
Protocol Summary.  We used the following strategy to create a dose-response
curve for endogenously synthesized apoE. Increasing the distribution volume of an
endogenously synthesized acceptor decreases the concentration and decreases acceptor-
mediated efflux. The trend of this volume-dependent effect on efflux can be extrapolated
to an infinitely large distribution volume where the acceptor is so dilute that the
concentration is negligible. When the extracellular concentration of an acceptor is
extremely low or when the distribution volume for the acceptor is extremely large, the
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acceptor-mediated efflux is due only to intracellular or juxtacellular interactions of the
acceptor with cellular cholesterol. Theoretically, the extracellular acceptor mechanisms
of an endogenously synthesized cholesterol acceptor can be mathematically separated
from the intracellular/juxtacellular mechanisms (Figure 7). Efflux experiments to
measure volume-dependence have varying extracellular volumes of media with no
exogenous acceptors (e.g. 0.3, 0.5, 0.75, 1.0, 1.5, or 2.0 ml for 4x105 macrophages/well
in a 24-well plate). The acceptor-specific effects are calculated as the difference between
efflux from macrophages synthesizing the acceptor and efflux from acceptor deficient
macrophages. Acceptor-specific efflux is plotted versus the reciprocal of the distribution
volume. Since reciprocal volume is proportional to concentration, this plot is a relative
concentration curve. Linear regression through the linear portion of the plot produces a
line with a y-intercept that represents the intracellular/juxtacellular contribution of the
acceptor. This methodology is described in more detail in Chapter VII.
Flow-Dependence Efflux Protocol
Mixing cultured cells causes the culture media to flow and creates kinetic energy
that can stimulate cholesterol efflux (Yancey et al., 1996). The term 'mixing' as it is used
here takes into account multiple processes including diffusion of acceptors through
extracellular fluid, the flow of extracellular fluid, and turbulence within flowing
extracellular fluid. Together diffusion, flow rate, and turbulence affect the efficiency of
extracellular acceptors. A sigmoidal mixing trend created by increasing volumes of fluid
in a cell culture dish (Figure 8A) was also present as a sigmoidal anomaly in cholesterol
efflux data (Figure 8B). These data are indirect evidence of a correlation between mixing
within the extracellular space and cholesterol efflux.
Protocol Summary.  Colorimetric mixing assays were used to demonstrate the
mixing parameters of the culture plates used for cholesterol efflux assays. These cell-free
mixing assays consisted of 1 ml of glycerol-based loading dye (bromophenol blue and
xylene cyanole) placed at the bottom of increasing volumes of fluid in 24-well culture
plates (duplicates of 0.3, 0.5, 1.0, 1.5, and 2.0 ml of distilled water). Plates were
oscillated on a ThermolyneÔ Roto Mix orbital mixer at a constant speed for 2 minutes.
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Mixing of the dye with the fluid was measured spectrophotometrically from samples of
the fluid (540 nm absorption). Mixing was expressed as the percentage of the absorbance
after 2 minutes oscillation compared to the absorbance after equilibrium is reached.
Although the speed of the oscillating plates were the same for all of the fluid volumes, a
sigmoidal trend in mixing was produced by differences in the fluid dynamics and the
fluid velocities of columns of fluid with increasing heights.
Cholesterol efflux from macrophages was measured in experiments that are
analogous to the cell-free mixing assays. Cholesterol efflux was measured from unloaded
peritoneal macrophages in increasing volumes of serum-free media with 0.1% BSA
(quadruplets of 0.3, 0.5, 1.0, 1.5, and 2.0 ml). Plates were mixed on an oscillator at a
constant speed for 1 minute every 10 minutes over a total period of 6 hours. Efflux was
measured according to the general cholesterol efflux protocol.
Figure 8. Mixing in the Extracellular Space and Macrophage Cholesterol
Efflux.
(A) Effects of culture volume on mixing in a colorimetric cell-free mixing assay.
Loading dye (1 ml) was place in the bottom of culture plates with orbital mixing.
The mixing of the fluid were measured spectrophotometrically. Bars and error
bars represent the mean (n=2) and standard deviation of samples. (B) Effects of
culture volume on cholesterol efflux from macrophages with mixing.
Macrophages were treated for 36 hours with 1.5 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol. Cells were then cultured
in efflux media (0.1% BSA) with orbital mixing. Bars and error bars represent
the mean (n=4) and standard deviation of samples.
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Summary
In summary, we describe protocols for assays for macrophage cholesterol efflux.
These protocols were further modified to focus on larger experimental capacity and
greater experimental efficiency. Other developments include software for data analysis,
protocols to study the autocrine and paracrine effects of cholesterol acceptors, and
protocols to study the effects of extracellular fluid mixing on cholesterol efflux.
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CHAPTER IV
THE EFFECTS OF CHOLESTEROL STORAGE DEFICITS ON CHOLESTEROL
EFFLUX
Abstract
Objective.  Acyl-coenzyme A: cholesterol acyltransferase (ACAT) converts
intracellular free cholesterol (FC) into cholesteryl esters (CE) for storage in lipid droplets.
Recent studies in our laboratory have shown that the deletion of the macrophage ACAT1
gene results in apoptosis and increased atherosclerotic lesion area in the aortas of
hyperlipidemic mice. The objective of the current study was to elucidate the mechanism
of the increased atherosclerosis.
Methods and Results.  CE storage and FC efflux were studied in ACAT1(-/-)
peritoneal macrophages that were treated with acetylated low density lipoprotein
(acLDL). Our results show that efflux of cellular cholesterol was reduced by 25% in
ACAT1(-/-) cells compared to wildtype controls. This decrease occurred despite the up-
regulated expression of ABCA1, an important mediator of cholesterol efflux. In contrast,
ACAT1 deficiency increased efflux of the cholesterol derived from acLDL by 32%.
ACAT1(-/-) macrophages also showed a 26% increase in the accumulation of FC derived
from acLDL, which was associated with a 75% increase in the number of intracellular
vesicles.
Conclusions.  Together, these data show that macrophage ACAT1 influences the
efflux of both cellular and lipoprotein-derived cholesterol and propose a pathway for the
pro-atherogenic transformation of ACAT1(-/-) macrophages (Dove et al., 2005b).
Introduction
The development of atherosclerosis is influenced by abnormalities in cellular
cholesterol homeostasis. Acyl-coenzyme A: cholesterol acyltransferase (ACAT) is
responsible for the storage of cholesteryl ester (CE) within neutral lipid droplets in
macrophage foam cells (Buhman et al., 2000a). The ACAT1 isoform is found at high
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levels in macrophages and steroidogenic tissues. The ACAT2 isoform is expressed only
in the liver and the small intestine and is involved both in the absorption of dietary
cholesterol and in the assembly of lipoproteins. Inhibition of cholesterol esterification in
macrophages is expected to slow down foam cell formation and decrease lesion size by
blocking the storage of cholesterol and facilitating cholesterol efflux. However, recent
studies in our laboratory have shown that the deletion of the ACAT1 gene in macrophages
results in an increase in atherosclerotic lesion area in the aortas of hyperlipidemic mice
(Fazio et al., 2001).
Apolipoproteins (apo) E and AI, and the ATP-Binding Cassette (ABC) A1 are the
main modulators of cholesterol efflux in macrophages (Aiello et al., 2002; Linton et al.,
1995; Major et al., 2001). ABCA1 is responsible for the movement of phospholipids and
cholesterol to apoAI, which results in the formation of nascent HDL particles (Fielding et
al., 2000; Wang et al., 2001). Although the local importance of ABCA1 specifically
within the vessel wall is not completely understood, systemically ABCA1 is a critical part
of the reverse cholesterol transport (RCT) system (Aiello et al., 2002; McNeish et al.,
2000). Tangier disease, caused by mutations in the ABCA1 gene, results in severely
decreased HDL and apoAI levels, and accelerates atherosclerosis (Schmitz et al., 2000).
Both CE storage and FC efflux are important physiologic markers of cholesterol
balance in macrophages. Pharmacologic inhibition of ACAT has been shown to increase
cholesterol efflux in many studies (Kellner-Weibel et al., 1998; Mazzone and Reardon,
1994; Rodriguez et al., 1999; Warner et al., 1995; Zhang et al., 1996). However, there are
conflicting reports of both increased and decreased atherosclerosis in animal models
following the administration of ACAT inhibitors (Buhman et al., 2000a). In our previous
study, the worsening effect of ACAT1 gene deletion in hyperlipidemic mice may have
been related to increased macrophage apoptosis induced by FC accumulation (Fazio et
al., 2001; Kellner-Weibel et al., 1999; Warner et al., 1995). In the current studies, we
labeled cellular cholesterol to measure the effects of ACAT1 deficiency on CE formation
and FC efflux from macrophages. The mild cholesterol loading conditions used in these
studies are capable of perturbing cholesterol homeostasis without inducing toxicity. The
goal of this investigation was to determine whether ACAT1 deficiency in macrophages
was associated with changes in cholesterol efflux, cholesterol storage, or cellular
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morphology that would be consistent with increased susceptibility to atherosclerosis. Our
results suggest that ACAT1 deficiency disrupts the efflux of cholesterol and affects
cholesterol homeostasis prior to any toxic cellular effects (Dove et al., 2005b).
Methods
Primary Culture of Peritoneal Macrophages.  Murine peritoneal macrophages
were elicited by intraperitoneal injection of 3% thioglycollate. Macrophages were
harvested 3-4 days after injection by peritoneal lavage with ice-cold Dulbecco’s Modified
Eagle Medium (DMEM). Macrophages were washed, counted, and plated in DMEM with
10% fetal bovine serum (FBS) at 37°C.  After 2-6 hours of culture to allow adherence to
culture plates, non-adherent cells were aspirated and macrophage monolayers were
culture in DMEM with 4% FBS at 37°C.
Lipoprotein Preparation, 3H-Cholesteryl Oleate Association, and Chemical
Modification.  Low density lipoproteins (LDL, density = 1.019 g/ml to 1.063 g/ml) were
isolated from human plasma by sequential centrifugation. Briefly, human plasma from
normolipemic adults were adjusted to a density of 1.019 g/ml with sodium chloride. The
solution was centrifuged at 100,000 RPM for 3-4.5 hours in a Beckman TLN 100 rotor
with a Beckman-Coulter OptimaÔ TLX ultracentrifuge. Lipoproteins with density
greater than 1.019 g/ml were isolated and this solution was adjusted to 1.063 g/ml with
sodium chloride for another round of centrifugation. The LDL between the density of
1.019 and 1.063 g/ml was dialyzed in "lipoprotein buffer" (0.1 M sodium chloride and
0.3 mM EDTA). Incorporation of 3H-cholesteryl oleate into LDL was performed by
incubating LDL with 3H-cholesteryl oleate in a dimethylsulfoxide solution (Brown et al.,
1975; Johnson et al., 1990). Acetyl-LDL (acLDL) was prepared by repeated addition of
acetic anhydride to LDL in a sodium acetate solution (Basu et al., 1976). All lipoproteins
were dialyzed in lipoprotein buffer prior to use in cell culture experiments. Lipoprotein
species were confirmed by electrophoretic mobility. Protein concentrations were
determined by a modified Lowry assay (Lowry et al., 1951).
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14C-Adenine Release Assay for Cellular Toxicity.  Cholesterol-induced toxicity in
macrophages was assayed by measuring the leakage of 14C-adenine into media (Warner
et al., 1995). Murine peritoneal macrophages were elicited with thioglycollate and were
harvested. Cells were labeled in DMEM with 0.4 mCi/ml 14C-adenine (Amersham) for 3
hours. Cells were rinsed three times with DMEM. The release period was initiated by the
addition of loading media with DMEM/1% FBS and 70 mg/ml acLDL. Loading media
was removed following release periods of 24 or 48 hours and cell debris was removed by
centrifugation. Remaining cellular 14C-adenine was harvested by rinsing cells with PBS
and then lysing cells with 1.0 ml of 0.1N sodium hydroxide. Sample aliquots were loaded
into EcoliteÔ scintillation fluid (ICN, Costa Mesa, CA) and 14C-Adenine counts were
detected with a Beckman LS 6000IC scintillation counter. Adenine release was calculated
from the media 14C-adenine counts and expressed as a percentage of the total counts
(lysate plus media).
Quantitation of Sterol Mass in Cultured Macrophages.  Cellular lipids were
extracted by the Bligh-Dyer method and dried under nitrogen (Bligh and Dyer, 1959).
Cholesterol mass was determined by gas chromatography (Fazio et al., 2001).
Efflux of Cholesterol Mass.  Macrophages were cultured for 36 hours in
DMEM/1% serum with 70 mg/ml acLDL. Cells were rinsed and efflux was initiated by
the addition of 10 mg/ml lipid-free human apoAI in DMEM. After 18 hours of efflux,
cellular lipids were extracted with isopropanol overnight and the total cholesterol mass
was determined by gas chromatography with cholesterol methyl ester as an internal
standard (Yancey and Jerome, 2001). This procedure was performed as described by
Ishikawa et al. (Ishikawa et al., 1974) and as modified by Klansek et al. (Klansek et al.,
1995). The cholesterol mass remaining after the efflux period was expressed as a
percentage of the mass of parallel samples harvested before the efflux period.
Efflux of Radiolabeled Cellular or Lipoprotein-Derived Cholesterol.
Macrophages were labeled by two different methods of sterol delivery, either to
preferentially label cellular (membrane) cholesterol or to label lipoprotein-derived
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cholesterol (Chen et al., 2001). [1,2-3H(N)]cholesterol (3H-FC) and [1,2,6,7-
3H(N)]cholesteryl oleate (3H-CE) were obtained from Perkin Elmer Life Sciences.
Cellular cholesterol pools, including the plasma membrane and recycling
endosomes, were targeted by incubation with 1.5 mCi/ml of 3H-FC in DMEM/2% FBS
for 36 hours (Lin et al., 1999; Mukherjee et al., 1998). The addition of 70 mg/ml
unlabeled acLDL during the labeling period promotes cholesterol loading.
Lipoprotein-derived cholesterol contributed to lysosomes and late endosomes
were targeted by labeling/loading with 70 mg/ml 3H-CE/acLDL in DMEM/2% FBS for
36 hours (Yancey and Jerome, 2001). The uptake of 3H-CE/acLDL by macrophages was
calculated from 3H-sterol counts and the specific activity of 3H-CE/acLDL (cpm/mg
acLDL). The turnover of 3H-CE/acLDL by macrophages was measured by the
appearance of 3H-FC in loading media. Cholesterol storage as 3H-FC and 3H-CE was
measured in lysate.
Labeled macrophages were rinsed and the efflux period was initiated by the
addition of efflux media with 10 mg/ml lipid-free human apoAI in DMEM. Efflux media
was removed following the efflux period and cell debris was removed by centrifugation.
Remaining 3H-sterol and cellular protein were harvested by rinsing and lysing cells with
0.1N sodium hydroxide. 3H-Sterol counts in media samples and lysate samples were
detected by scintillation. Cholesterol efflux in media was expressed as a percentage of the
total counts (lysate plus media).
Separation of Cholesterol by Thin Layer Chromatography.  The samples were
extracted by the Bligh-Dyer method (Bligh and Dyer, 1959), dried, and spotted on silica
G thin layer chromatography plates (Alltech Associates). Plates were developed in
90:10:1 petroleum ether/ ethyl ether/ acetic acid and visualized with iodine vapor (Sigma
Chemical Co.). FC and CE bands were scraped and counted by liquid scintillation.
Quantitation of ABCA1 mRNA and ABCA1 Protein.  Cells were cultured for 36
hours in DMEM/1% FBS media with 70 mg/ml acLDL. Total RNA was isolated using
Trizol reagent (Invitrogen). Relative quantification of ABCA1 mRNA was performed
using a FAM-labeled TaqManÔ probe with the TaqManÔ One-Step RT-PCR Master
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Mix reagent kit (Applied Biosystems) on an ABI Prism 7700 sequence detection system
(Applied Biosystems) according to the method developed by Su et al. (Su et al., 2002).
Relative quantification of ABCA1 was normalized with 18S ribosomal RNA as an
internal control. The data were analyzed using the comparative CT method.
For Western blot analysis of ABCA1 protein, cell extracts were separated by 3-
8% NuPAGEÔ Tris-Acetate gels (Novex) and transferred to nitrocellulose membranes.
Murine ABCA1 was detected with a primary antibody (Novus Biological), visualized by
a chemiluminescent ECL PlusÔ (Amersham Pharmacia Biotech) according to Bortnick
et al. (Bortnick et al., 2000), and quantified by densitometric analysis.
Transmission Electron Microscopy and Image Analysis.  Macrophages were
treated with DMEM/1% FBS for 48 hours with 0 or 70 mg/ml acLDL. Cellular
morphology was characterized by transmission electron microscopy as described
(Yancey and Jerome, 1998). Sections (80 nm) of Spurr-embedded macrophages where
stained with uranyl acetate and lead citrate and visualized by a Philips CM12
transmission electron microscope operated at 80 keV. Twenty macrophages per group
were randomly selected. The percentages of total cellular volume occupied by vesicles
were determined by using point counting sterologic techniques (Weibel et al., 1966).
Volume percentages were calculated from the number of points on vesicles as a
percentage of total points on macrophages.
Immunofluorescence and Cytochemistry for Endosomes and Lysosomes.
Macrophages were treated with 0 or 70 mg/ml acLDL in DMEM/1% FBS for 36 hours
and then used for immunofluorescence or cytochemistry experiments. For
immunofluorescence, macrophages were fixed, permeabilized, and treated with primary
antibodies against the endosomal marker, EEA1 (Affinity BioReagents), or the lysosomal
marker, LAMP1 (BioDesign Pharmingen). Cells were labeled with TRITC-conjugated
secondary antibody (BioDesign Pharmingen). Fluorescence was visualized with a Zeiss
Axioplan ImagingÔ fluorescence microscope with digital camera and analyzed with
MetaMorphÔ 5.0 imaging software (Universal Imaging Corp.). The threshold was set to
display the brightest 30% of positive pixels for EEA1 fluorescence and brightest 45% of
41
positive pixels for LAMP1 fluorescence. The area of fluorescence from five random
fields was expressed as pixels per cell.
Cytochemistry for acid phosphatase in lysosomes was performed using Naphthol
ASBI phosphate (Vaughan et al., 1971). Cells were fixed, washed with cacodylate buffer.
Cells were stained with naphthol ASBI phosphate (0.2 mg/ml) and fast red violet LB salt
(0.6 mg/ml) in sodium acetate buffer (0.1 M). The reaction precipitate from acid
phosphatase activity was visualized by light microscopy with a Zeiss Axioplan
ImagingÔ microscope.
Results
Cholesterol Mass
To confirm that ACAT1 deficiency resulted in a functional deficit in the
esterification of cholesterol, sterol mass in macrophages was measured by gas
chromatography. Macrophages were treated for 28 hours with 50 mg/ml acLDL in
DMEM/10% FBS. ACAT1(-/-) macrophages treated with acLDL showed an 88%
decrease in CE mass compared to wildtype macrophages (3.6 ± 2.0 vs. 29.5 ± 0.7 mg
CE/mg cell protein, p<0.001, n=3). Under these mild cholesterol-loading conditions, the
mass of FC was not significantly different between genotypes (24.4 ± 1.7 vs. 25.1 ± 1.6
mg FC/mg cell protein, p=0.68, n=3).
Cholesterol-Induced Cytotoxicity
Mild cholesterol loading conditions were necessary because the goal of the study
was to examine changes in cholesterol homeostasis that may precede cholesterol-induced
toxicity. To determine whether the loading conditions could stress cholesterol
homeostasis in ACAT1(-/-) macrophages without inducing toxicity, the release of 14C-
adenine was measured during treatment with modified lipoproteins. As shown in Table 3,
there was no significant difference in toxicity between ACAT1(-/-) macrophages and
wildtype macrophages treated with acLDL.
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Table 3. Cholesterol-Induced Cytotoxicity in Macrophages Treated with acLDL
Wildtype ACAT1(-/-) p-value
24 Hours of  14C-Adenine Release (%) 32.70 ± 0.46 32.23 ± 0.62 0.16
48 Hours of  14C-Adenine Release (%) 41.62 ± 1.33 41.81 ± 0.55 0.76
Macrophages were treated with 70 mg/ml acLDL in DMEM/1% FBS for 24 and 48 hours.
Cytotoxicity was measured by the release of 14C-adenine into the media. Data are means (n=6)
and standard deviations of samples from ACAT1(+/+) (Wildtype) or ACAT1(-/-) macrophages as
compared by Student’s t-test.
Efflux of Cellular Cholesterol versus Lipoprotein-Derived Cholesterol
Because the efflux of both cellular and lipoprotein-derived sterols directly affect
foam cell formation, efflux was measured from macrophages labeled by two different
methods of sterol delivery, either to preferentially label cellular (membrane) cholesterol
or lipoprotein-derived cholesterol pools. Time-course experiments were performed for
these isotopic experiments.
The method to label cellular cholesterol pools resulted in decreased 3H-cholesterol
efflux from ACAT1(-/-) macrophages compared to wildtype macrophages (Figure 9A).
The method to label lipoprotein-derived cholesterol pools resulted in increased 3H-
cholesterol efflux from ACAT1(-/-) macrophages compared to wildtype macrophages
(Figure 9B).
3H-cholesterol efflux was compared to changes in total cholesterol mass during
the efflux period. Regardless of the labeling method, the cholesterol mass remaining after
the efflux period showed that ACAT1(-/-) macrophages retain more cholesterol mass
compared to wildtype macrophages (Figure 9A and Figure 9B). Cholesterol esters were
less than 1% of the cholesterol mass in either cell type, indicating very mild loading
conditions.
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Figure 9. ACAT1 Deficient Macrophages Have Decreased Cellular
Cholesterol Efflux and Increased Lipoprotein-Derived Cholesterol Efflux.
Macrophages were treated for 36 hours with 1.5 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol or 70 mg/ml 3H-
CE/acLDL in DMEM/2% FBS to label lipoprotein-derived cholesterol pools.
Cells were then cultured in efflux media with 10 mg/ml human apoAI for 18
hours. Bars and error bars represent the mean (n=4) and standard deviation of
samples from ACAT1(+/+) (WT) or ACAT1(-/-) (KO) macrophages. Asterisks
(*) denote a statistically significant difference (p<0.05) compared to the
appropriate ACAT1(+/+) group as determined by Student’s t-test. (A) Efflux of
cellular cholesterol to apoAI for 18 hours. The wildtype macrophages in this
experiment contained 37.9 ± 1.8 mg cholesterol/mg cell protein and 14701.14 ±
1373.92 cpm/mg cholesterol. The ACAT1(-/-) macrophages in this experiment
contained 36.0 ± 4.5 mg cholesterol/mg cell protein and 13868.64 ± 1288.55
cpm/mg cholesterol. (B) Efflux of lipoprotein-derived cholesterol to apoAI for 18
hours. The wildtype macrophages in this experiment contained 51.9 ± 2.8 mg
cholesterol/mg cell protein and 44146.84 ± 3213.66 cpm/mg cholesterol. The
ACAT1(-/-) macrophages in this experiment contained 44.5 ± 5.3 mg
cholesterol/mg cell protein and 40448.52 ± 6638.60 cpm/mg cholesterol.
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Cholesterol Efflux and ABCA1 Expression
The efflux of cellular and lipoprotein-derived cholesterol were measured in
experiments where ABCA1 was also measured. Cellular cholesterol was labeled with 3H-
FC while macrophages were treated with acLDL. Efflux of cellular 3H-FC to apoAI was
decreased by 25% in ACAT1(-/-) macrophages compared to wildtype macrophages
(p<0.005, n=4) (Figure 10A). Lipoprotein-derived cholesterol was labeled by the delivery
of 3H-CE to lysosomes via acLDL. Efflux of lipoprotein-derived 3H-FC to apoAI was
increased by 32% in ACAT1(-/-) macrophages compared to wildtype macrophages
(p<0.05, n=4) (Figure 10A).
In light of the decreased efflux of cellular cholesterol in ACAT1(-/-) macrophages,
we measured the expression of ABCA1, which is responsible for most of the cholesterol
efflux to apoAI. Unexpectedly, ACAT1(-/-) macrophages had a 236% increase in ABCA1
mRNA compared to wildtype macrophages (Figure 10B). The large increase in
expression was associated with a minor increase of ABCA1 protein compared to wildtype
macrophages (Figure 10C).
Uptake, Turnover, and Storage of Lipoprotein-Derived Cholesterol
In addition to changes in cholesterol efflux, other aspects of cholesterol
homeostasis can be affected by a defective cholesterol esterification process. Because the
uptake, turnover, and storage of lipoprotein-derived sterols directly affect foam cell
formation, these processes were measured following the delivery of 3H-CE to lysosomes
via acLDL.
Uptake of 3H-CE/acLDL was increased by 38% in ACAT1(-/-) macrophages
compared to wildtype macrophages (p<0.005, n=4) (Figure 10D).
Turnover of lipoprotein-derived cholesterol, which is the cumulative function of
many processes, is indicated by the appearance of 3H-FC in the growth media of
macrophages during incubation with lipoprotein associated 3H-CE. The turnover of
lipoprotein-associated CE by macrophages is the combination of lipoprotein uptake,
trafficking of endosomes, CE hydrolysis within lysosomes, trafficking of FC, FC
esterification, CE de-esterification, and finally, efflux of FC to extracellular cholesterol
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acceptors. ACAT1(-/-) macrophages treated with 3H-CE/acLDL released increased
amounts of 3H-FC into the loading media compared to wildtype macrophages (Figure
10E). Media 3H-FC was increased by 78% in ACAT1(-/-) macrophages (p<0.005, n=4).
Storage of intracellular 3H-CE in ACAT1(-/-) macrophages was decreased by 81%
in ACAT1(-/-) macrophages (p<0.005, n=4) (Figure 10F). However, storage of
intracellular 3H-FC was increased by 26% in ACAT1(-/-) macrophages (p<0.005, n=4)
(Figure 10F).
Macrophage Morphology
Electron microscopy analyses were performed to determine whether changes in
cholesterol homeostasis caused by ACAT1 deficiency were associated with
morphological changes. ACAT1(-/-) macrophages appeared to have increased surface
activity as characterized by cytoplasmic extensions and intracellular vesicles (Figure
11B). In untreated macrophages, total vesicle volume was 74% larger in ACAT1(-/-)
macrophages compared to wildtype macrophages (p<0.01, n=20). A similar trend was
measured in macrophages treated with acLDL, where total vesicle volume was 28%
larger in ACAT1(-/-) macrophages compared to wildtype macrophages but this difference
did not reach statistical significance. In these measurements, all membrane-limited
vesicles were counted, including endosomes, lysosomes, and secretory vesicles.
 Immunofluorescence of EEA1 revealed that ACAT1(-/-) macrophages have
significantly more endosomes than wildtype macrophages (Figure 12A). Treatment with
acLDL significantly increased EEA1 fluorescence in both cell types.
Immunofluorescence of LAMP1 revealed that ACAT1(-/-) macrophages have
significantly more lysosomes than wildtype macrophages (Figure 12B). Treatment with
acLDL increased LAMP1 fluorescence in wildtype cells but that levels in ACAT1(-/-)
macrophages stayed at the same high level. Naphthol staining for lysosomal acid
phosphatase revealed that wildtype macrophages (Figure 12C) had less activity than
ACAT1(-/-) macrophages (Figure 12D).
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Figure 10. ACAT1 Deficient Macrophages Have Increased Efflux, Uptake,
Turnover, and Storage of Lipoprotein-Derived Cholesterol.
Macrophages were treated for 36 hours with 1.5 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol (Cellular) or 70 mg/ml 3H-
CE/acLDL in DMEM/2% FBS to label lipoprotein-derived cholesterol pools
(Lipoprotein Derived). (A) Cholesterol efflux was measured from macrophages
to media with 10 mg/ml human apoAI for 6 hours. Bars and error bars represent
the mean (n=4) and standard deviation of samples from ACAT1(+/+) (WT) or
ACAT1(-/-) (KO) macrophages. Asterisks (*) denote a statistically significant
difference (p<0.05) compared to the appropriate ACAT1(+/+) group as
determined by Student’s t-test. (B and C) The relative quantity of ABCA1
mRNA was determined by real time quantitative RT-PCR. The relative quantity
of ABCA1 protein was measured by Western blot analysis. Values are expressed
relative to ACAT1(+/+) (WT) macrophages. Bars represent the value of pooled
samples (n=3, 2x106 cells/sample) and are representative of results from similar
experiments. (D, E, and F) The uptake, turnover, and storage of 3H-CE/acLDL
by macrophages was calculated after 36 hours. The turnover of 3H-CE by
macrophages was measured by the appearance of 3H-FC in the culture media
during the treatment period. After treatment with 3H-CE/acLDL, cholesterol
storage as 3H-FC (solid bars) and 3H-CE (empty bars) was measured in cellular
lysate. Bars and error bars represent the mean (n=4) and standard deviation of
samples from ACAT1(+/+) (WT) or ACAT1(-/-) (KO) macrophages. Asterisks
(*) denote a statistically significant difference (p<0.05) compared to the
appropriate ACAT1(+/+) group as determined by Student’s t-test.
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Figure 11. ACAT1 Deficient Macrophages have Altered Morphology and
Increased Cellular Vesicle Volume.
Macrophages were treated with 0 or 70 mg/ml acLDL in DMEM/1% FBS for 48
hours. Macrophages were fixed and visualized by transmission electron
microscopy (5600X magnification). Electron micrographs of (A) an ACAT1(+/+)
macrophage and (B) an ACAT1(-/-) macrophage treated with acLDL with a
magnified insert in the upper right to show smaller vesicles. The black scale bars
represent 2 mm. (C) Intracellular vesicle volumes were determined from electron
micrographs by point counting and is expressed as a percentage of total cellular
volume. Bars and error bars represent the mean (n=20) and standard error of
ACAT1(+/+) (WT) or ACAT1(-/-) (KO) macrophages treated with control or
acLDL media. Asterisk (*) denotes a statistically significant difference (p<0.05)
compared to the appropriate ACAT1(+/+) group as determined by two-way
ANOVA with Bonferroni post-test.
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Figure 12. ACAT1 Deficient Macrophages have More Endosomes and
Lysosomes.
Macrophages were treated with 0 or 70 mg/ml acLDL in DMEM/1% FBS for 48
hours. (A and B) Immunofluorescence microscopy was performed on
macrophages treated with primary antibodies against the endosomal marker,
EEA1, or the lysosomal marker, LAMP1 with TRITC-conjugated secondary
antibody. The area of fluorescence is expressed as pixels per cell. Bars and error
bars represent the mean (n=5 random fields) and standard deviation of
ACAT1(+/+) (WT) or ACAT1(-/-) (KO) macrophages. Asterisks (*) denote a
statistically significant difference (p<0.05) compared to the appropriate
ACAT1(+/+) group and pound signs (#) denote a statistically significant
difference (p<0.05) compared to untreated groups as determined by two-way
ANOVA with Bonferroni post-test. Light micrographs with naphthol staining for
acid phosphatase activity in (C) an ACAT1(+/+) macrophage and (D) an
ACAT1(-/-) macrophage treated with acLDL.
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Discussion
To address the question of whether the absence of ACAT1 results in altered
cholesterol homeostasis, we studied cholesteryl ester formation and free cholesterol
efflux in ACAT1(-/-) macrophages. We found that ACAT1(-/-) macrophages have
decreased efflux of the cellular cholesterol and increased efflux of the lipoprotein-derived
cholesterol. These changes were associated with an accumulation of lipoprotein-derived
free cholesterol and with an expanded pool of intracellular vesicles, but were not a
consequence of the toxic effects of free cholesterol.
ACAT1 Deficiency and Cholesterol Efflux.  For lipoprotein-derived cholesterol,
ACAT deficiency increased efflux to apoAI, which is the main cholesterol acceptor for
ABCA1-mediated efflux (Figure 10A). This is in agreement with the increased ABCA1
expression (Figure 10B and Figure 10C), since ABCA1 preferentially mediates
cholesterol mobilization and efflux from late endosomes/lysosomes (Chen et al., 2001).
In contrast to lipoprotein-derived cholesterol, absence of ACAT1 was associated
with decreased efflux of cellular cholesterol to apoAI (Figure 10A). Warner et al.
reported decreased cholesterol efflux with ACAT inhibition under heavy loading
conditions, where FC accumulation induces cytotoxicity (Warner et al., 1995). In our
study, we deliberately used mild cholesterol loading conditions that did not induce
cytotoxicity. However, efflux was decreased in ACAT1(-/-) macrophages, indicating that
cellular toxicity is not the reason why cholesterol efflux is affected. Another possibility is
that under our mild loading conditions, cholesterol was sequestered in a non-cytotoxic
pool (Kellner-Weibel et al., 2001).
The primary reason for using mild cholesterol loading conditions was to avoid the
changes that are secondary to cholesterol toxicity (Tabas, 2002). Shiratori et al. have
described the appearance of phospholipid whorls within the cytoplasm of heavily FC-
loaded macrophages (Shiratori et al., 1994). Under the mild cholesterol loading
conditions used in the current study, however, there was no morphological evidence of
phospholipid whorls in ACAT1(-/-) macrophages (Figure 11B). Another characteristic of
heavily FC-loaded macrophages, as reported by Feng et al., is decreased ABCA1 levels
due to increased degradation of the protein (Feng and Tabas, 2002). In contrast, the
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increased expression of ABCA1 mRNA and protein in ACAT1(-/-) macrophages in our
studies supports our contention that we were indeed successful in inducing only mild
cholesterol loading (Figure 10B and Figure 10C). However, the minor increase in protein
relative to the large increase in mRNA may indicate reduced stability of ABCA1 protein.
It is interesting to note that macrophages treated with the ACAT inhibitor, MCC-147,
have increases in ABCA1 expression that are similar to what we report for ACAT1(-/-)
macrophages (Sugimoto et al., 2004).
ACAT Inhibitors and Cholesterol Efflux.  Atherosclerosis studies with
hyperlipidemic mice show that macrophage ACAT1 deficiency increases necrosis and
apoptosis in lesions (Fazio et al., 2001). The rationale for treating atherosclerosis with
inhibitors of ACAT1 is to stop intracellular CE formation and prevent foam-cell
formation. The current studies confirm that the deficiency of ACAT1 increases the
turnover of lipoprotein-derived cholesterol in macrophages by blocking cholesterol
storage. This is viewed as an anti-atherogenic mechanism. However, the decrease in the
efflux of cellular cholesterol may represent a critical change in cholesterol homeostasis in
macrophages.
The current studies add to previous reports in which ACAT activity was reduced
by means of pharmacologic inhibitors. Rodriguez et al. reported increased efflux of
lipoprotein-derived cholesterol during treatment with the ACAT inhibitor 58-035 in
human monocyte-derived macrophages (Rodriguez et al., 1999). ACAT inhibition has
been reported to increase the efflux of cholesterol to various cholesterol acceptors
(Kellner-Weibel et al., 1998; Mazzone and Reardon, 1994; Warner et al., 1995; Zhang et
al., 1996). In our studies, ACAT1(-/-) macrophages had increased turnover of lipoprotein-
derived CE as measured by the reappearance of processed CE in the media as FC (Figure
10E). However, ACAT1 deficiency reduced the efflux of cellular cholesterol from
macrophages (Figure 10A). Although ACAT1 deficiency resulted in increased
cholesterol turnover during acLDL treatment (Figure 10E), this increase was not
sufficient to prevent the accumulation of FC (Figure 10F). The increase in FC may be
related to the increase in membrane-bound vesicles in ACAT1(-/-) macrophages (Figure
11), as these membranes represent a potential pool for FC.
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ACAT Inhibition and ACAT1 Deficient Macrophages.  In additional experiments
not presented here, ACAT inhibition was compared with the effects ACAT1 deficiency
on lipoprotein uptake, cholesterol turnover to acceptors in media, and cholesterol
esterification. Both ACAT1 deficiency and ACAT inhibition increased the turnover of
lipoprotein-derived cholesterol and decreased the esterification of labeled cholesterol
(Appendix, Figure 30C). One notable difference was that ACAT1 deficiency increased
FC accumulation while ACAT inhibition did not change intracellular FC when compared
to untreated wildtype macrophages. This may be due to residual ACAT activity or to the
acuteness of pharmacologic inhibition. ACAT1 deficiency may result in structurally and
functionally abnormal macrophages due either to chronic compensatory mechanisms or
to direct effects of the absence of ACAT1. For example, the accumulation of membrane-
bound vesicles with ACAT1 deficiency (Figure 11) may represent compensatory changes
in vesicular transport and cholesterol trafficking in macrophages. A second notable
difference was that ACAT1 deficiency increased the efflux of lipoprotein-derived
cholesterol while ACAT inhibition reduced efflux compared to untreated wildtype
macrophages. This may be due to the differences in FC accumulation between ACAT
inhibition and ACAT1 deficiency.
Cholesterol Trafficking and Vesicles in ACAT1 Deficient Macrophages.  What is
clear from our studies is that cholesterol efflux is not the simple consequence of free
cholesterol availability. Complex interconnected processes like the trafficking and
sequestration of intracellular cholesterol are intimately associated with cholesterol efflux.
Mechanistic insight into the disruptions in cholesterol efflux and morphological changes
can be gained by comparing ACAT1(-/-) macrophages with NPC1(-/-) cells. Niemann-
Pick type C1 (NPC1) traffics cholesterol from lysosomes to the plasma membrane and
endoplasmic reticulum. The phenotype of NPC1(-/-) cells includes the accumulation of
cholesterol in lysosomes, decreased cholesterol efflux, decreased cholesterol
esterification, increased cholesterol synthesis, and decreased lipoprotein uptake (Ory,
2004). Like the NPC1(-/-) cells, ACAT1(-/-) macrophages have accumulation of
lipoprotein derived cholesterol (Figure 10F), disrupted cholesterol efflux (Figure 9A),
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decreased cholesterol esterification, increased cholesterol synthesis (Chapter V), and
increased lipoprotein uptake (Figure 10D). The phenotype of disrupted cholesterol efflux
in ACAT1(-/-) macrophages and the increased number of intracellular vesicles suggests
that these macrophages have a disruption in cholesterol trafficking that goes beyond
decreased esterification. Decreased efflux of cellular cholesterol (Figure 9A) may
indicate sequestration of cholesterol. Based on these data, one could speculate that the
cholesterol esterification cycle is an essential loop in the cholesterol trafficking route,
even under conditions where cholesterol esters do not accumulate.
The intracellular vesicles that accumulate in ACAT1(-/-) macrophages are an
interesting finding. Previous studies with ACAT inhibitors have described similar
accumulations of vesicles (Robenek and Schmitz, 1988). In these studies, Robenek and
Schmitz described foamy organelles and lamellar bodies that form in macrophages
treated with acLDL and an ACAT inhibitor. These vesicles were stored in a cytoplasmic
compartment and interacted with HDL to promote cholesterol efflux. In other studies,
similar vesicles were observed in macrophages that were treated with acLDL (Sakashita
et al., 2000). These vesicles resulted from vesiculation of the endoplasmic reticulum and
co-localized with a significant portion of the total cellular ACAT1. Accumulation of
these types of vesicles, in both intracellular and extracellular spaces, is associated with
the progression of fatty streaks into more complicated plaques (Guyton and Klemp, 1989;
Guyton and Klemp, 1994). These vesicles may be analogous to those seen in the
ACAT1(-/-) macrophages in our studies. The proliferation of intracellular vesicles in
ACAT1(-/-) macrophages provides a potential source for the extracellular cholesterol in
atherosclerotic lesions and thus a potential mechanism for increased atherosclerosis. In
addition to the vesicular changes associated with ACAT inhibition, Robenek and Schmitz
described vesicular changes that were associated with disrupted calcium homeostasis
(Robenek and Schmitz, 1988). Free cholesterol loading has been shown to deplete
endoplasmic reticulum calcium stores and lead to apoptosis (Feng et al., 2003). The
proliferation of intracellular vesicles in ACAT1(-/-) macrophages may be the first sign of
a cholesterol-mediated disruption of calcium homeostasis and apoptosis.
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Summary.  In summary, these data show that the deficiency in macrophage
ACAT1 disrupts the efflux of cellular cholesterol despite increased expression of
ABCA1. The increased efflux of lipoprotein-derived cholesterol cannot counter-balance
the accumulation rate of FC. These alterations in cholesterol homeostasis are associated
with changes in cellular morphology, precede cholesterol-induced cytotoxicity, and may
represent the basis for accelerated macrophage apoptosis in the growing plaque.
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CHAPTER V
THE EFFECTS OF CHOLESTEROL STORAGE DEFICITS ON CHOLESTEROL
SYNTHESIS AND ESTERIFICATION
Abstract
Objective.  Acyl-coenzyme A: cholesterol acyltransferase (ACAT) esterifies free
cholesterol and stores cholesteryl esters in lipid droplets. Our laboratory has shown that
macrophage ACAT1 deficiency results in increased atherosclerotic lesion area in
hyperlipidemic mice. These atherogenic macrophages have disrupted cholesterol efflux,
increased lipoprotein uptake, and accumulation of intracellular vesicles. The objective of
the current study was to determine whether lipid synthesis in macrophages is affected by
ACAT1.
Methods and Results.  The synthesis, esterification, and efflux of new cholesterol
and new phospholipids were measured in peritoneal macrophages from ACAT1(-/-) mice.
Cholesterol synthesis was increased by 134% (p<0.001) in ACAT1(-/-) macrophages
compared to wildtype macrophages. Increased synthesis resulted in a proportional
increase in the efflux of the newly synthesized cholesterol. Although the esterification of
new cholesterol was reduced by 93% (p<0.001), ACAT1(-/-) macrophages still contained
trace amounts of newly synthesized cholesteryl esters. In contrast to cholesterol
synthesis, there were no differences in the synthesis or efflux of phospholipids in
ACAT1(-/-) macrophages. Because fatty acids are substrates of ACAT1 and regulators of
cholesterol synthesis, the fatty acid content of membrane phospholipids was also studied.
Saturated/monounsaturated fatty acids were not altered in ACAT1(-/-) macrophages and
were not affected by treatment with modified LDL. However, for macrophages treated
with modified LDL, polyunsaturated fatty acids were increased 26% (p=0.036) in
ACAT1(-/-) macrophages compared to wildtype macrophages.
Conclusions.  Together, these data show that macrophage ACAT1 influences the
synthesis of cholesterol but not phospholipids. Increased cholesterol synthesis in
ACAT1(-/-) macrophages suggests that ACAT1 contributes to a regulatory pool of
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cholesterol in macrophages. This change in cholesterol homeostasis may contribute to the
atherogenic potential of ACAT1(-/-) macrophages.
Introduction
 Atherosclerosis is characterized by the accumulation of cholesteryl esters in lipid
droplets in arterial macrophages. The enzyme responsible for cholesterol esterification in
macrophages is acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT1) (Tabas et al.,
1986). Recent studies in our laboratory have shown that ACAT1(-/-) macrophages
promote the formation of atherosclerosis in hyperlipidemic mice (Fazio et al., 2001).
ACAT1 deficiency has a variety of effects on cholesterol homeostasis that may contribute
to the paradoxical formation of foam cell lesions in the absence of cholesterol
esterification. These changes include decreased efflux of cellular cholesterol, increased
uptake of modified lipoproteins, the accumulation of intracellular membrane bound
vesicles, and the accumulation of free cholesterol despite higher turnover of lipoprotein-
derived cholesterol (Chapter IV). However, little is known about the relationship between
cholesterol synthesis and the cholesterol esterification cycle. The contribution of de novo
cholesterol synthesis to foam cell formation may be physiologically relevant, especially if
synthesis is not down-regulated when the cholesterol esterification cycle is not functional.
Previous studies have reported that cholesterol efflux results in increased cholesterol
synthesis because a regulatory pool of cholesterol is being depleted (Johnson et al., 1995;
Mendez et al., 1991). This regulatory pool of cholesterol is also diminished by the
esterification activity of ACAT1 (Tabas et al., 1988; Tabas et al., 1986). It is unknown if
ACAT1 can modulate cholesterol synthesis by contributing cholesterol to a regulatory
cholesterol pool. It is also unknown if ACAT1 can affect cholesterol synthesis indirectly
by affecting the fatty acid substrates. Studies suggest that polyunsaturated fatty acids,
which are substrates for ACAT1, affect cholesterol homeostasis by altering the amount of
cholesterol in a regulatory cholesterol pool (Worgall et al., 1998).
In the current study, we measured 3H-acetate incorporation into free cholesterol,
cholesteryl esters, and phospholipids in peritoneal macrophages from ACAT1(-/-) mice.
We show that cholesterol synthesis is increased in ACAT1(-/-) macrophages compared to
wildtype macrophages. Despite unchanged phospholipid synthesis, polyunsaturated fatty
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acids accumulate in ACAT1(-/-) macrophages. These data suggest that increased
cholesterol synthesis and changes in membrane phospholipids contribute to the
atherogenic potential of ACAT1(-/-) macrophages.
Methods
Lipoprotein Preparation and Modification.  Low density lipoproteins (LDL)
(density = 1.019 to 1.063 g/ml) and lipoprotein deficient serum (LPDS) (density > 1.210
g/ml) were isolated from human blood by sequential centrifugation as described in
Chapter IV. Acetyl-LDL (acLDL) was prepared by repeated addition of acetic anhydride
to LDL (Basu et al., 1976). Oxidized LDL (oxLDL) was prepared by copper oxidation
(Yancey and Jerome, 2001). Lipoprotein species and modifications were confirmed by
electrophoretic mobility on agarose gels. Lipoprotein oxidation was also confirmed
spectrophotometrically by measuring absorbance at 234 nm (Lopes-Virella et al., 2000).
3H-Acetate Incorporation.  Cholesterol synthesis was measured by the
incorporation of 3H-acetate into cholesterol (Lin et al., 2001). Peritoneal macrophages
were thioglycollate-elicited as described in Chapter IV. Macrophages were cultured for
36 hours in DMEM/5% LPDS. The incorporation period (24 h) was initiated by the
addition of 40 mCi/ml 3H-acetate in DMEM/2% FCS. During this incorporation period
macrophages where stimulated with 0 or 50 mg/ml oxLDL. Cells were rinsed and lysed in
0.1 N sodium hydroxide. Protein concentration in cell lysates was determined by a
modified Lowry assay (Lowry et al., 1951). Lipids were extracted, separated by TLC, and
counted as described in Chapter IV. Lipid synthesis was expressed as counts per unit cell
protein. Efflux of new lipids was expressed as counts in media per unit cell protein or
counts in media as a percentage of the total counts (media plus lysate) for that lipid.
14C-Oleate Incorporation.  The incorporation of [1-14C]-oleate into cholesteryl
esters and phospholipids were measured. Macrophages were cultured for 48 hours in
DMEM/2% FCS with 0 or 70 mg/ml acLDL. The incorporation period (3 h) was initiated
by the addition of oleate and 14C-oleate complexed with BSA (0.25 mCi/ml, 0.66% BSA,
molar ratio of 1:1 oleate/BSA, molar ratio of 1:20 14C-oleate/oleate) in DMEM (Brown et
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al., 1979; Kritharides et al., 1998). Cells were rinsed and scraped in PBS. Protein
concentration in cell lysates was determined by a modified Lowry assay (Lowry et al.,
1951). Lipids were extracted, separated by TLC, and counted as described in Chapter IV.
Incorporation of oleate into lipids was expressed as counts per unit cell protein.
Fatty Acid Profile of Phospholipids.  Macrophages were cultured for 48 hours in
DMEM/2% FCS with 0 or 70 mg/ml acLDL. Cells were rinsed and scraped in PBS.
Protein concentration in cell lysates was determined by a modified Lowry assay (Lowry
et al., 1951). To measure phospholipid fatty acids, sample extracts were transmethylated
and the total fatty acid composition was quantified using gas chromatography with flame
ionization detection (Fazio et al., 2001). The profile was separated into
saturated/monounsaturated (14:0, 16:0, 16:1, 18:0, and 18:1) and polyunsaturated fatty
acids (18:2, 20:4, 20:5, 22:4, 22:5, 22:6).
Results
Synthesis and Efflux of New Cholesterol and New Phospholipid
To determine whether ACAT1 deficiency causes changes in cholesterol synthesis,
3H-acetate incorporation was measured in untreated or oxLDL-treated macrophages. In
untreated macrophages, synthesis of 3H-cholesterol was increased by 33% (p<0.001) in
ACAT1(-/-) macrophages compared to wildtype (C57Bl/6) macrophages (Figure 13A).
After treatment with oxLDL, cholesterol synthesis was 134% higher (p<0.001) in
ACAT1(-/-) macrophages than in C57BL/6 wildtype macrophages. The down-regulation
of cholesterol synthesis that resulted from treatment with oxLDL was present in both
types of macrophages but was somewhat attenuated in the ACAT1(-/-) macrophages
(decreased 52%, p<0.001) compared to wildtype macrophages (decreased 73%,
p<0.001).
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Figure 13. ACAT1 Deficiency Increases the Synthesis and Efflux of New
Cholesterol but Does not Affect New Phospholipids in Macrophages.
 (A) The synthesis of 3H-Cholesterol, (B and C) the efflux of newly synthesized
3H-Cholesterol, (D) the synthesis of 3H-Phospholipid, and (E and F) the efflux of
newly synthesized 3H-Phospholipid were measured in ACAT1(+/+) or ACAT1(-/-
) macrophages. Macrophages were cultured with 0 or 50 mg/ml oxLDL during
incorporation of 3H-Acetate. Bars and error bars represent the mean (n=4) and
standard deviation of samples. Asterisks (*) denote a statistically significant
difference (p<0.05) between ACAT1(+/+) and ACAT1(-/-) groups as determined
by two-way ANOVA with Bonferroni post-test. Pounds (#) denote a statistically
significant difference (p<0.05) between untreated and oxLDL groups as
determined by two-way ANOVA with Bonferroni post-test.
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3H-cholesterol efflux was measured during 3H-acetate incorporation because the
efflux of newly synthesized cholesterol is a marker of the removal of internal cholesterol
pools (Johnson et al., 1995). In untreated macrophages, efflux of newly synthesized 3H-
cholesterol was increased by 73% (p<0.001) in ACAT1(-/-) macrophages compared to
wildtype macrophages (Figure 13B). In oxLDL-treated macrophages, efflux was
increased by 94% (p<0.001) in ACAT1(-/-) macrophages. However, when efflux was
expressed as a percentage of the 3H-cholesterol synthesized during the incorporation
period, there was no increase between wildtype and ACAT1(-/-) macrophages (Figure
13C), indicating that the proportional increase in efflux was linked with or possibly due
to increased synthesis.
To determine whether ACAT1 deficiency causes changes in phospholipid
synthesis, 3H-acetate incorporation was measured in untreated or oxLDL-treated
macrophages. In untreated macrophages, synthesis of 3H-phospholipid was not different
in ACAT1(-/-) macrophages compared to wildtype macrophages (Figure 13D). Similarly,
in oxLDL-treated macrophages, there were no differences in phospholipid synthesis.
Treatment with oxLDL down-regulated phospholipid synthesis in wildtype and ACAT1(-
/-) macrophages by 35% (p<0.001) and 29% (p<0.001), respectively. The absence of
ACAT1 did not affect the efflux of newly synthesized 3H-phospholipid in untreated or in
oxLDL-treated macrophages (Figure 13E and Figure 13F).
Esterification of New Cholesterol
To determine if newly synthesized cholesterol was available for esterification, 3H-
cholesteryl esters were measured after 3H-acetate incorporation. 3H-cholesteryl esters
represented a small percentage (<2%) of the 3H-cholesterol synthesized during the
incorporation period. It is likely that hydrolysis of new 3H-cholesteryl esters prevents
their accumulation. In wildtype macrophages, the amount of 3H-cholesteryl esters
increased 182% (p<0.001) when treated with oxLDL (Figure 14A). Unexpectedly,
ACAT1(-/-) macrophages had measurable amounts of 3H-cholesteryl esters. ACAT1(-/-)
macrophages had less than 8% (p<0.001) of the 3H-cholesteryl esters that were found in
wildtype macrophages (Figure 14B). The results were similar when macrophages were
treated with oxLDL.
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Figure 14. ACAT1 Deficiency Decreases but does not Eliminate the
Esterification of Newly Synthesized Cholesterol.
Esterification of newly synthesized 3H-Cholesteryl ester was measured in
ACAT1(+/+) or ACAT1(-/-) macrophages. Macrophages were cultured with 0 or
50 mg/ml oxLDL during incorporation of 3H-Acetate. The amount of esterified
cholesterol is expressed (A) as a percentage of all the cholesterol synthesized
during the incorporation period and (B) as counts normalized by cellular protein.
Bars and error bars represent the mean (n=4) and standard deviation of samples.
Asterisks (*) denote a statistically significant difference (p<0.05) between
ACAT1(+/+) and ACAT1(-/-) groups as determined by two-way ANOVA with
Bonferroni post-test. Pounds (#) denote a statistically significant difference
(p<0.05) between untreated and oxLDL groups as determined by two-way
ANOVA with Bonferroni post-test.
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Figure 15. ACAT1 Deficiency Increases the Polyunsaturated Fatty Acid
Content of Membrane Phospholipids.
The fatty acid content of phospholipids was measured in ACAT1(+/+) or
ACAT1(-/-) macrophages by gas chromatography. Macrophages were cultured
with 0 or 70 mg/ml acLDL. Synthesis of (A) cholesteryl esters and (B)
phospholipids was measured by the incorporation of 14C-oleate. (C) The fatty
acid masses are divided into unsaturated/monounsaturated fatty acids (solid bars)
and polyunsaturated fatty acids (empty bars) and were normalized by cellular
protein. Bars and error bars represent the mean (n=3) and standard deviation of
samples. Asterisks (*) denote a statistically significant difference (p<0.05)
between ACAT1(+/+) and ACAT1(-/-) groups as determined by two-way
ANOVA with Bonferroni post-test. Pounds (#) denote a statistically significant
difference (p<0.05) between untreated and acLDL groups as determined by two-
way ANOVA with Bonferroni post-test.
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Oleate Incorporation and the Fatty Acid Content of Membrane Phospholipids
Fatty acids modulate cholesterol synthesis and ACAT1 activity (Rumsey et al.,
1995; Seo et al., 2001; Worgall et al., 1998). Because fatty acids are hydrolyzed from
membrane phospholipids for utilization by ACAT1 (Akiba et al., 2003), the effects of
ACAT1 deficiency on the incorporation of 14C-oleate into cellular lipids and on the fatty
acid profile of phospholipids were studied. Similar to the residual esterification activity
observed with newly synthesized cholesterol, ACAT1(-/-) macrophages pulsed with 14C-
oleate had measurable amounts of cholesteryl 14C-oleate. Relative to wildtype
macrophages, the amount cholesteryl 14C-oleate for untreated and acLDL-treated
ACAT1(-/-) macrophages was 50% (not significant) and 22% (p<0.001), respectively
(Figure 15A). In wildtype macrophages, the amount of cholesteryl 14C-oleate increased
140% (p<0.001) when cells were treated with acLDL. In ACAT1(-/-) macrophages, the
amount of cholesteryl 14C-oleate was not changed (p=0.90) when cells were treated with
acLDL. In untreated macrophages pulsed with 14C-oleate, incorporation into
phospholipid was not different in ACAT1(-/-) macrophages compared to wildtype
macrophages (Figure 15B). Similarly, in acLDL-treated macrophages, there was no
difference in the incorporation of 14C-oleate into phospholipids. Treatment with acLDL
did not affect the incorporation of 14C-oleate into phospholipids.
In addition, there was no difference in the mass of unsaturated and
monounsaturated fatty acids in phospholipids of the two macrophage types. However,
polyunsaturated fatty acids increased 26% (p<0.05) in ACAT1(-/-) macrophages treated
with acLDL (Figure 15C) compared to wildtype macrophages.
Discussion
The purpose of this study was to determine the contributions of cholesterol and
phospholipid synthesis to the disrupted cholesterol homeostasis and the atherogenic
potential of ACAT1(-/-) macrophages. We measured lipid synthesis in peritoneal
macrophages and found that ACAT1 deficiency increases cholesterol synthesis without
affecting phospholipid synthesis. This change in cholesterol homeostasis in ACAT1(-/-)
macrophages may contribute to foam cell formation and atherosclerosis.
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ACAT1 Deficiency and Cholesterol Synthesis.  The down-regulation of
cholesterol synthesis by modified LDL was attenuated in ACAT1(-/-) macrophages
(Figure 13A). Although most cellular cholesterol is likely to be derived from lipoprotein
uptake, de novo cholesterol synthesis may contribute to internal cholesterol pools that
lead to foam cell formation (Johnson et al., 1995; Mendez et al., 1991). The increased
cholesterol synthesis in ACAT1(-/-) macrophages may play a role in the accelerated
progression of these cells to the stage of foam cell. Efflux of newly synthesized
cholesterol is a marker of the removal of internal cholesterol pools. Although efflux of
newly synthesized cholesterol was increased in ACAT1(-/-) macrophages (Figure 13B),
the increase was proportional to the increase in cholesterol synthesis (Figure 13C). This
indicates that the proportional increase in efflux was linked with or possibly due to
increased synthesis. In contrast, the efflux of cellular cholesterol was decreased whereas
the efflux of lipoprotein-derived cholesterol was increased in ACAT1(-/-) macrophages
(Chapter IV). Efflux of newly synthesized 3H-phospholipid in untreated or in oxLDL-
treated macrophages was not affected by the absence of ACAT1 (Figure 13E and Figure
13F). This indicates that the effects of ACAT are limited to cholesterol synthesis, and
suggests that phospholipid synthesis is not responsible for the accumulation of
membrane-bound intracellular vesicles in ACAT1(-/-) macrophages (Chapter IV).
Esterification Despite ACAT1 Deficiency.  ACAT1(-/-) macrophages had
measurable amounts of 3H-cholesteryl esters (Figure 14A and Figure 14B). The
physiologic importance of this residual esterification activity in ACAT1(-/-) macrophages
is unknown. This activity could represent physiologic redundancy (i.e. another ACAT
isozyme) or broad substrate specificity of other acyl-transferases (e.g. DGAT). Although
ACAT2 has not been detected in resident murine peritoneal macrophages, ACAT2
mRNA and protein is present in thioglycollate-elicited mouse peritoneal macrophages
and in atherosclerotic lesions from mice (Anderson et al., 1998; Cases et al., 1998a;
Meiner et al., 1996; Sakashita et al., 2003). Functional studies characterizing ACAT2
activity in macrophages have not been reported. Interestingly, the esterification of 3H-
cholesterol in ACAT1(-/-) macrophages was not totally eliminated by the ACAT inhibitor
cp113-818 (Appendix, Figure 30C). This ACAT inhibitor is non-selective (Lada et al.,
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2004), so these results suggest that ACAT2 activity is not responsible for the residual
esterification activity. The specificity of DGAT for fatty acids has been well
characterized, but cholesterol is not a substrate for DGAT (Cases et al., 1998b). Also,
there may be other uncharacterized ACAT isozymes and acyl-transferases contributing to
the residual cholesterol esterification activity in ACAT1(-/-)  macrophages. The reversible
reactions catalyzed by lipases could also contribute to esterification of newly synthesized
cholesterol with fatty acids (Bhat and Brockman, 1981).
ACAT1 Deficiency and Phospholipids.  There was no difference in the
incorporation of 14C-oleate into phospholipids in ACAT1(-/-) macrophages (Figure 15B).
While unsaturated and monounsaturated fatty acids were unchanged, polyunsaturated
fatty acids increased in ACAT1(-/-) macrophages (Figure 15C) compared to wildtype
macrophages. The increase of the polyunsaturated fatty acids in phospholipids may
represent an attempt to solubilize excess or aberrantly trafficked cholesterol resulting
from the disruption of the cholesterol esterification cycle (Spector and Yorek, 1985a;
Stubbs and Smith, 1984). Since polyunsaturated fatty acids have an inhibitory effect on
cholesterol synthesis (Worgall et al., 1998), sequestration of these fatty acids in
phospholipid membranes could explain the increased cholesterol synthesis in ACAT1(-/-)
macrophages treated with acLDL. However, untreated macrophages had increased
cholesterol synthesis without any changes in phospholipid fatty acids, suggesting that
these changes were not directly related. These changes in the fatty acid content of
membranes may be associated with the accumulation of intracellular membrane bound
vesicles and the accumulation of free cholesterol observed in other studies (Chapter IV).
Cholesterol Trafficking and Cholesterol Synthesis in ACAT1 Deficient
Macrophages.  Mechanistic insight into the cholesterol homeostasis phenotype of
ACAT1(-/-) macrophages can be gained by considering similarities with the Niemann-
Pick type C1 (NPC1) phenotype and similarities with cells treated with drugs like the
U18666A compound or progesterone. Increased cholesterol synthesis is an important part
of the phenotypic change in ACAT1(-/-) macrophages. Other changes in ACAT1(-/-)
macrophages include decreased cholesterol esterification, the accumulation of
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lipoprotein-derived cholesterol, disrupted cholesterol efflux, and increased lipoprotein
uptake (Chapter IV). The similarity of these changes with the NPC1 phenotype suggests
that cholesterol trafficking is disrupted. NPC1 protein plays a key role in cholesterol
trafficking between lysosomes, the plasma membrane, and the endoplasmic reticulum.
The phenotype of NPC1(-/-) cells includes increased cholesterol synthesis, decreased
cholesterol esterification, the accumulation of cholesterol in lysosomes, and decreased
cholesterol efflux (Ory, 2004). In contrast to ACAT1(-/-) macrophages, NPC1(-/-) cells
have decreased lipoprotein uptake. By mechanisms that are not entirely clear,
progesterone and U18666A disrupt cholesterol trafficking and result in the same
phenotype as NPC1(-/-) cells (Soccio and Breslow, 2004). Decreased delivery of
cholesterol to regulatory or signaling pools may result in this common phenotype. For
macrophages, the cholesterol esterification cycle may be an essential pathway in
cholesterol trafficking.
Summary.  In summary, these data show that the absence of ACAT1 in
macrophages has effects on lipid homeostasis that go beyond the decrease in cholesteryl
esters. ACAT1 deficiency in macrophages increases cholesterol synthesis without
affecting phospholipid synthesis. This increase may represent dysregulation of the
cholesterol sensing mechanisms in macrophages and suggests that de novo synthesis of
cholesterol may contribute to the atherogenic potential of ACAT1(-/-) macrophages.
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CHAPTER VI
THE EFFECTS OF ENDOGENOUSLY SYNTHESIZED APOLIPOPROTEIN E ON
CHOLESTEROL EFFLUX
Abstract
Objective.  Apolipoprotein (apo) E is a cholesterol acceptor that drives cholesterol
efflux from macrophages and prevents foam cell transformation. Our laboratory has
shown that secretion of apoE by macrophages decreases atherosclerotic lesion area in
hyperlipidemic mice. The ATP-Binding Cassette (ABC)-A1 transporter is another major
pathway for cholesterol efflux. Both of these pathways are under the transcriptional
regulation of oxysterols via the Liver X Receptor (LXR). The objective of the current
study was to measure the effects of endogenous apoE synthesis on ABCA1-mediated
cholesterol efflux.
Methods and Results.  Cholesterol efflux mediated by apoE or ABCA1 was
measured with peritoneal macrophages from apoE(+/+) and apoE(-/-) mice. As a
cholesterol acceptor, macrophage apoE increased cholesterol efflux by 164% (p<0.001)
in apoE(+/+) macrophages compared to apoE(-/-) macrophages. In addition to its role as
an acceptor, endogenous apoE had a modest stimulatory effect on ABCA1-mediated
cholesterol efflux, which was increased by 9% (p=0.003) in apoE(+/+) macrophages
compared to apoE(-/-) macrophages. Stimulation of apoE(+/+) macrophages with 22(R)-
hydroxycholesterol, an LXR agonist, increased ABCA1-mediated cholesterol efflux by
59% (p<0.001) and increased apoE-mediated cholesterol efflux by 108% (p<0.001). To
test for functional cooperation between ABCA1 and apoE, experiments were also
performed with apoE(+/+) and apoE(-/-) macrophages that were ABCA1(-/+) or
ABCA1(-/+). When stimulated with an LXR agonist, ABCA1 mediates efflux to apoAI
independently of endogenous apoE. However, a small fraction of apoE-mediated efflux
depends on ABCA1 (p=0.0311).
Conclusions.  Together, these data show that endogenous apoE is an important
mediator of cholesterol efflux. Under certain experimental conditions, macrophage apoE
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and macrophage ABCA1 can cooperate to stimulate both apoE-mediated and ABCA1-
mediated cholesterol efflux. Although statistically significant, the cooperation between
apoE and ABCA1 was very small, suggesting that apoE-mediated efflux and ABCA1-
mediated efflux are parallel pathways.
Introduction
Cholesterol efflux from macrophages and reverse cholesterol transport prevents
foam cell formation and atherosclerosis. The two primary mediators of cholesterol efflux
that are endogenously synthesized by macrophages are apolipoprotein (apo) E and ATP-
Binding Cassette (ABC)-A1. ApoE is secreted locally by macrophages in the walls of
vessels. Although apoE synthesized by the liver plays a major role in cholesterol
transport, previous studies from our laboratory have demonstrated that apoE synthesized
by macrophages has a greater role in the prevention of atherosclerosis (Fazio et al., 1997;
Linton et al., 1995). ApoE-mediated cholesterol efflux is thought to be the mechanism of
this protective effect (Kinoshita et al., 2000; Laffitte et al., 2001; Lin et al., 1999).
ABCA1 is a membrane protein that facilitates the movement of cholesterol and
phospholipids to cholesterol acceptors. While apoAI is the main acceptor for ABCA1,
apoE and other apolipoproteins interact with ABCA1 and accept lipids (Krimbou et al.,
2004; Remaley et al., 2001). Both apoE and ABCA1 are up-regulated by oxysterols
through the LXR/RXR system (Laffitte et al., 2001; Schwartz et al., 2000). It is not
known if the coordinated expression of apoE and ABCA1 promotes cooperation between
these two efflux pathways. The objective of the current study was to determine if apoE
synthesis can stimulate ABCA1-mediated cholesterol efflux. Peritoneal macrophages
from apoE(+/+), apoE(-/-), ABCA1(+/-) and apoE(-/-)ABCA1(+/-) mice were used in
cholesterol efflux studies. Under certain experimental conditions, endogenous apoE
synthesis stimulated ABCA1-mediated cholesterol efflux. Conversely, ABCA1
stimulated apoE-mediated cholesterol efflux. This study found that endogenous apoE
functions as an acceptor in a cholesterol efflux pathway but can also act as a stimulator of
a separate efflux pathway that is mediated by ABCA1 and apoAI.
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Methods
ApoE-Mediated and ABCA1-Mediated Cholesterol Efflux.  Murine peritoneal
macrophages were elicited with thioglycollate (3%) as described in Chapter IV and
cultured in 24-well or 96-well plates. Macrophages were treated as specified in the
Results. To cholesterol load cultured macrophages, culture media was replaced with
media containing 2-3 mCi/ml of 3H-cholesterol and 70-100 mg/ml acLDL for 24-48 hours.
Acetyl-LDL (acLDL) was prepared as described in Chapter IV. Monolayers were treated
with 1 mM 22(R)-hydroxycholesterol when specified in the Results. The efflux period
was initiated by the addition of efflux media with no acceptors or apoAI. To measure
apoE-mediated efflux, serum-free DMEM with 0-0.1% BSA was added to designated
wells. To measure ABCA1-mediated efflux, serum-free DMEM with 10-15 mg/ml human
apoAI was added to designated wells. Efflux media was sampled at multiple time points
and cell debris was removed by centrifugation. Remaining cellular 3H-cholesterol were
harvested by rinsing cells with PBS and then lysing cells with 1.0 ml of 0.1N sodium
hydroxide. Counts (cpm) in media and lysate were detected with a Beckman LS 6000IC
scintillation counter using EcoliteÔ scintillation fluid (ICN, Costa Mesa, CA).
Cholesterol efflux was calculated from the counts in the media as a percentage of the
total counts (media plus lysate).
ApoE and ABCA1 mRNA Expression.  For mRNA quantification, total RNA was
isolated from cultured peritoneal macrophages using TrizolÔ reagent (Invitrogen). The
relative quantities of apoE or ABCA1 message were measured by real time RT-PCR
according to the method described by Su et al. (Su et al., 2002). TaqManÔ one-step RT-
PCR master mix reagent kit (Applied Biosystems) was used for RT-PCR. Relative
quantification of apoE or ABCA1 was normalized with 18S ribosomal RNA.
Western Blot Analysis for ApoE or ABCA1 Protein.  For Western blot analysis of
apoE or ABCA1, proteins were separated on 3-8% NuPAGEÔ Tris-Acetate gels (Novex)
and transferred to nitrocellulose membranes. Murine apoE in growth media was measure
by Western analysis with rabbit anti-mouse apoE antiserum. Murine ABCA1 from cell
extracts was detected with a primary antibody (Novus Biological). Bands were visualized
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by a chemiluminescent ECL PlusÔ (Amersham Pharmacia Biotech) according to
Bortnick et al. (Bortnick et al., 2000). Bands were quantified by densitometric analysis.
Results
Endogenously Synthesized ApoE Mediates Cholesterol Efflux
In order to measure the effects of apoE on cholesterol efflux, peritoneal
macrophages were labeled with 3H-cholesterol and then incubated in serum-free efflux
media containing only BSA. ApoE-mediated cholesterol efflux after 6 hours was
increased by 164% (p<0.001) in apoE(+/+) macrophages compared to apoE(-/-)
macrophages (Figure 16).
Figure 16. Endogenous ApoE Synthesis Increases Cholesterol Efflux from
Macrophages.
Macrophages were treated for 36 hours with 2.0 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol. Cells were then cultured
in serum-free efflux media with bovine serum albumin (0.1%). Bars and error
bars represent the mean (n=6) and standard deviation of samples. Asterisks (*)
denote a statistically significant difference (p<0.05) compared to the apoE(-/-)
group as determined by Student’s t-test.
Endogenous ApoE Stimulates ABCA1-Mediated Cholesterol Efflux
To determine the effects of apoE on ABCA1-mediated cholesterol efflux,
macrophages labeled with 3H-cholesterol were incubated with serum-free efflux media
containing only apoAI. ABCA1-mediated cholesterol efflux was increased by 9%
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(p=0.003) in apoE(+/+) macrophages compared to apoE(-/-) macrophages (Figure 17A).
ABCA1 mRNA expression was not changed in apoE(+/+) macrophages (Figure 17B).
Figure 17. Endogenous ApoE Stimulates ABCA1-Mediated Cholesterol
Efflux from Macrophages.
ApoE(-/-) (empty bars) and apoE(+/+) (solid bars) macrophages were treated for
24 hours with 70 mg/ml acLDL and 1.5 mCi/ml 3H-cholesterol in serum-free
DMEM/RPMI (1:1) with 1% NutridomaÔ media supplement. (A) ABCA1-
mediated cholesterol efflux was measured from macrophages cultured in serum-
free efflux media with excess apoAI (15 mg/ml) for 4.5 hours. Bars and error bars
represent the mean (n=8) and standard deviation of samples. Asterisks (*) denote
a statistically significant difference (p<0.05) compared to the apoE(-/-) group as
determined by Student’s t-test. (B) The relative quantity of ABCA1 mRNA was
measured by real time RT-PCR. Each bar represents the measurement of a
pooled sample from two mice.
LXR Agonism Stimulates ABCA1 and ApoE Cholesterol Efflux Pathways
Because LXR up-regulates both apoE and ABCA1 expression, the effects of the
LXR agonist 22(R)-hydroxycholesterol on cholesterol efflux were measured. Stimulation
with 22(R)-hydroxycholesterol increased ABCA1 mRNA 248% in apoE(+/+)
macrophages and by 146% (p<0.001) in apoE(-/-) macrophages (Figure 18A).
Stimulation with 22(R)-hydroxycholesterol increased ABCA1-mediated cholesterol
efflux by 59% (p<0.001) in apoE(+/+) macrophages and by 60% (p<0.001) in apoE(-/-)
macrophages (Figure 18B). Stimulation with 22(R)-hydroxycholesterol increased apoE-
mediated cholesterol efflux to media with BSA by 108% (p<0.001) in apoE(+/+)
macrophages, but in apoE(-/-) macrophages efflux to media with BSA was only
increased by 72% (p<0.001) (Figure 18C).
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ABCA1 Stimulates Endogenous ApoE-Mediated Cholesterol Efflux
To determine the effects of ABCA1 on apoE-mediated cholesterol efflux,
experiments were performed with ABCA1(+/-) and ABCA1(+/+) macrophages that were
also either apoE(-/-) or apoE(+/+). These macrophages were stimulated with 22(R)-
hydroxycholesterol to stimulate both efflux pathways.
On the background of apoE(-/-) macrophages, homozygous ABCA1(+/+)
expression increased ABCA1-mediated cholesterol efflux by 54% (p<0.001) compared to
heterozygous ABCA1(+/-) expression (Figure 19A). On the background of apoE(+/+)
macrophages, homozygous ABCA1(+/+) expression increased ABCA1-mediated
cholesterol efflux by 48% (p<0.001) compared to heterozygous ABCA1(+/-) expression
(Figure 19A).
On the background of apoE(-/-) macrophages, homozygous ABCA1(+/+)
expression did not change apoE-mediated cholesterol efflux compared to heterozygous
ABCA1(+/-) expression (Figure 19B). On the background of apoE(+/+) macrophages,
homozygous ABCA1(+/+) expression increased apoE-mediated cholesterol efflux by
13% (p<0.001) compared to heterozygous ABCA1(+/-) expression (Figure 19B).
ABCA1 protein was drastically increased in apoE(+/+)ABCA1(+/+)
macrophages compared to apoE(+/+)ABCA1(+/-) macrophages (Figure 19C). This
increase was not associated with increased ABCA1 mRNA in these macrophages. ApoE
protein was similar in apoE(+/+)ABCA1(+/+) macrophages compared to
apoE(+/+)ABCA1(+/-) macrophages (Figure 19C). There was increased apoE mRNA in
apoE(+/+)ABCA1(+/-) macrophages (Figure 19D).
Two-way ANOVA with Bonferroni post-test was used to determine if apoE and
ABCA1 cooperate to mediate cholesterol efflux. For ABCA1-mediated cholesterol
efflux, ABCA1(+/+) homozygosity had a significant effect (p<0.0001) but endogenous
apoE expression did not (Table 4). There was no interaction between ABCA1 and
endogenous apoE for ABCA1-mediated cholesterol efflux. For apoE-mediated
cholesterol efflux, both ABCA1(+/+) homozygosity (p=0.0311) and endogenous apoE
(p<0.0001) had a significant effect (Table 4). There was a small but significant
interaction (p=0.0311) between ABCA1 and endogenous apoE for ABCA1-mediated
cholesterol efflux.
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Figure 18. LXR Agonism Increases ApoE-Mediated and ABCA1-Mediated
Cholesterol Efflux from Macrophages.
ApoE(-/-) (empty bars) and apoE(+/+) (solid bars) macrophages were treated for
48 hours with 3.0 mCi/ml of 3H-FC and 100 mg/ml acLDL in DMEM/1% FBS to
label cellular cholesterol. Macrophages were treated with 1 mM 22(R)-
hydroxycholesterol for 18 hours. (A) The relative quantity of ABCA1 mRNA
was measured by real time RT-PCR. Each bar represents the measurement of a
pooled sample. (B) ABCA1-mediated cholesterol efflux was measured from
macrophages cultured for 6 hours in serum-free efflux media with 10 mg/ml
apoAI and 1 mM 22(R)-hydroxycholesterol. Bars and error bars represent the
mean (n=8) and standard deviation of samples. Asterisks (*) denote a statistically
significant difference (p<0.05) compared to the apoE(-/-) group as determined by
Student’s t-test. (C) ApoE-mediated cholesterol efflux was measured from
macrophages cultured 6 hours in serum-free efflux media with bovine serum
albumin (0.1%) and 1 mM 22(R)-hydroxycholesterol. Bars and error bars
represent the mean (n=8) and standard deviation of samples. Asterisks (*) denote
a statistically significant difference (p<0.05) compared to the apoE(-/-) group as
determined by Student’s t-test.
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Figure 19. ABCA1 Stimulates Endogenous ApoE-Mediated Cholesterol
Efflux from Macrophages.
ABCA1(+/-) (empty bars) and ABCA1(+/+) (solid bars) macrophages were
treated for 48 hours with 3.0 mCi/ml of 3H-FC and 100 mg/ml acLDL in
DMEM/1% FBS to label cellular cholesterol. Macrophages were treated with 1
mM 22(R)-hydroxycholesterol for 18 hours. (A) ABCA1-mediated cholesterol
efflux was measured from macrophages cultured for 6 hours in serum-free efflux
media with 10 mg/ml apoAI and 1 mM 22(R)-hydroxycholesterol. Bars and error
bars represent the mean (n=8) and standard deviation of samples. Statistical
significance is determined by two-way ANOVA with Bonferroni post-test
(*p<0.05). (B) ApoE-mediated cholesterol efflux was measured from
macrophages cultured 6 hours in serum-free efflux media with 1 mM 22(R)-
hydroxycholesterol. Bars and error bars represent the mean (n=8) and standard
deviation of samples. Statistical significance is determined by two-way ANOVA
with Bonferroni post-test (*p<0.05). (C and E) The relative quantity of ABCA1
protein and ABCA1 mRNA. Each bar represents the measurement of a pooled
sample. (D and F) The relative quantity of apoE protein in media and apoE
mRNA. Each bar represents the measurement of a pooled sample.
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Table 4. Functional Cooperation between ApoE and ABCA1 Cholesterol Efflux Pathways.
ABCA1-Mediated Efflux
(Figure 19A)
ApoE-Mediated Efflux
(Figure 19B)
ABCA1 Effect? Yes p<0.0001 ABCA1 Effect? Yes p<0.0311
ApoE Effect? No ApoE Effect? Yes p<0.0001
Interaction? No Interaction? Yes p<0.0311
Statistical significance (p<0.05) was calculated by two-way ANOVA.
Discussion
To determine if endogenous apoE affects ABCA1-mediated cholesterol efflux, we
studied cholesterol efflux from apoE(+/+) and apoE(-/-) macrophages. We found that as
a cholesterol acceptor, endogenous apoE increased cholesterol efflux from macrophages.
Endogenous apoE also stimulated ABCA1-mediated cholesterol efflux to the cholesterol
acceptor apoAI. Conversely, ABCA1 stimulated apoE-mediated cholesterol efflux. The
cooperation between these two pathways of cholesterol efflux may be a mechanism by
which the synthesis of endogenous apoE by macrophages maintains cholesterol
homeostasis.
Interactions Between Cholesterol Efflux Pathways.  Endogenous apoE synthesis
caused an increase in ABCA1-mediated cholesterol efflux to apoAI (Figure 17). The
current study and previous reports from other laboratories show only very small increases
in cholesterol efflux from apoE(+/+) macrophages compared to apoE(-/-) controls when
apoAI, the acceptor for ABCA1-mediated cholesterol efflux, is the exogenous acceptor
(Langer et al., 2000). These data show the important role of endogenous apoE as a
mediator of cholesterol efflux to certain acceptors but also support the idea that apoE and
ABCA1-mediated cholesterol efflux are only minimally synergistic.
Both apoE and ABCA1 were able to mediate cholesterol efflux but there was a
small amount of cooperative interaction between the pathways. Under certain
experimental conditions, apoE stimulated the ABCA1-mediated cholesterol efflux
(Figure 17A) and ABCA1 stimulated apoE-mediated cholesterol efflux (Figure 19B). The
magnitude of these interactions were relatively small suggesting that these two pathways
of efflux are parallel. Previous studies that use high concentrations of exogenous apoE
show that apoE can bind and accept lipids from ABCA1 (Krimbou et al., 2004; Remaley
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et al., 2001). The current study focused on endogenously synthesized apoE because of the
physiologic delivery and concentrations achieved.
In the current study (Figure 18) and in previous reports from other laboratories,
there were large increases in cholesterol efflux when macrophages are treated with LXR
agonists (Chawla et al., 2001; Schwartz et al., 2000; Sparrow et al., 2002). However,
there have been no reports of the effects of LXR agonist on apoE deficient macrophages.
There was an increase in efflux to BSA even in the absence of apoE secretion (Figure
18C). This may be the result of LXR-induced changes in cholesterol trafficking within
the cell that allows for greater diffusion of cholesterol from the plasma membrane or the
secretion of other apolipoproteins (Mak et al., 2002). Alternatively, this increase may
actually represent ABCA1-mediated cholesterol efflux to apolipoprotein contaminants in
the BSA.
Cholesterol Acceptors and Atherosclerosis.  ApoE-mediated cholesterol efflux
was increased in apoE(+/+) macrophages compared to apoE(-/-) macrophages (Figure
16). These data are in agreement with previous reports that show that apoE secretion
increases cholesterol efflux in macrophage-like cells and in mouse macrophages (Langer
et al., 2000; Lin et al., 1999). The relationship between cholesterol efflux and protection
from atherosclerosis are upheld in studies of apoE, ABCA1, HDL, and other mediators of
the RCT system (Fazio et al., 1997; Ishiguro et al., 2001; Lin et al., 1999; Linton et al.,
1995; Major et al., 2001; Su et al., 2003; Zhang et al., 2003a).
Summary.  In summary, these data show that apoE is a mediator of cholesterol
efflux, both as a cholesterol acceptor in the apoE efflux pathway and as a mild stimulator
of the ABCA1 efflux pathway. In the apoE-mediated efflux pathway, ABCA1 has a
modest stimulatory effect on efflux to apoE. These data suggest that although there is
interaction and mutual stimulation of apoE-mediated and ABCA1-mediated cholesterol
efflux, these two efflux pathways are largely independent.
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CHAPTER VII
THE AUTOCRINE AND PARACRINE EFFECTS OF ENDOGENOUSLY
SYNTHESIZED APOLIPOPROTEIN E ON CHOLESTEROL EFFLUX
Abstract
Objective.  Macrophages in the vessel wall secrete high levels of apolipoprotein
(apo) E. Cholesterol efflux from macrophages to apoE has been shown to decrease foam
cell formation and prevent atherosclerosis. An apoE molecule can mediate cholesterol
efflux from the macrophage that originally secreted it (i.e. autocrine effect) or from
surrounding macrophages (i.e. paracrine effect). Traditional methodologies have not been
able to separate these serial effects. The novel methodology presented here was
developed to separate autocrine and paracrine effects by using a simple mathematical
model to interpret the effects of dilution on apoE-mediated cholesterol efflux.
Results.  Our results show that at very dilute concentrations, the paracrine effect
of apoE is not evident and that the autocrine effect becomes the dominant mediator of
efflux. However, at saturating concentrations, paracrine apoE causes 80 to 90% of the
apoE-mediated cholesterol efflux, while autocrine apoE is responsible for the remaining
10 to 20%.
Conclusions.  These results suggest that the relative importance of autocrine and
paracrine apoE depends on the size of the local distribution volume, a factor not
considered in previous in vitro studies regarding apoE function. Furthermore, autocrine
effects of apoE could be critical in the prevention of foam cell formation, in vivo. This
novel methodology may be applicable to other types of mixed autocrine/paracrine
systems, such as signal transduction systems (Dove et al., 2005a).
Introduction
An important challenge in atherosclerosis research is the characterization of the
effects of locally synthesized apolipoprotein (apo) E within the vessel wall. Endogenous
synthesis and secretion of apoE by macrophages in the vessel wall has been shown to
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protect against atherosclerosis (Linton et al., 1995). Arterial macrophages participate in
inflammation, tissue remodeling, and lipid metabolism. ApoE, which is synthesized by
hepatocytes, adipocytes and macrophages, mediates lipoprotein metabolism and affects
cellular cholesterol homeostasis. ApoE from macrophages accepts cholesterol from cells
in the vessel wall and transports it back to the liver where the cholesterol can be excreted
as bile (Basu et al., 1983; Dory, 1989). This pathway is called the reverse cholesterol
transport (RCT) system. The effect of apoE can be due to its cellular or extracellular
positioning, and therefore an apoE molecule can mediate cholesterol efflux from the
macrophage that originally secreted it (i.e. autocrine effect) or from surrounding
macrophages (i.e. paracrine effect) (Figure 20). The terms "autocrine" and "paracrine",
traditionally applied to signaling peptides and hormones, have also been used to describe
the actions of mediators with a broad range of functions besides signal transduction
(Balboa et al., 2003; Coussens et al., 2000; Moran et al., 2002). It can be assumed that for
the sake of cholesterol efflux an individual macrophage cannot distinguish the apoE that
it secretes from the apoE derived from neighboring cells. However, since the endogenous
synthesis of apoE causes high spatial proximity, autocrine apoE is at an advantage
compared to paracrine apoE. The spatial proximity advantage of endogenous apoE results
in a temporal sequence of autocrine effects occurring before paracrine effects and a
concentration gradient from an autocrine compartment (high concentration) to a paracrine
compartment (low concentration).
Making comparisons between the autocrine and paracrine effects of apoE
synthesized by macrophages has proven difficult. For in vitro experiments with cultured
macrophages, exogenously applied apoE has been used to approximate paracrine or
endocrine apoE (Ho et al., 2000; Lin et al., 1999). Endogenously synthesized apoE has
been used to approximate autocrine apoE (Huang et al., 2001; Lin et al., 1999; Lin et al.,
2001; Lin et al., 1998). These approximations do not consider that a single molecule of an
endogenously synthesized mediator can have a series of interactions that employ a
combination of autocrine and paracrine mechanisms (Batsilas et al., 2003).
The novel methodology discussed here was developed to separate autocrine and
paracrine mechanisms by using a simple mathematical model to interpret mediator-
induced biological effects. This study shows that while macrophage apoE has both
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autocrine and paracrine effects on cholesterol efflux, autocrine apoE has smaller but more
consistent effects than paracrine apoE (Dove et al., 2005a). Whereas macrophage apoE is
used to demonstrate this novel methodology, the concepts have applications for
separating the autocrine/paracrine effects of many other secreted biological mediators
including growth factors, cytokines, and carrier proteins.
Figure 20. Potential Mechanisms of ApoE-Mediated Cholesterol Efflux.
Within the walls of vessels, endogenously synthesized apoE can mediate
cholesterol efflux from the macrophage that originally secreted it (i.e. autocrine
effect) or from surrounding macrophages (i.e. paracrine effect). Regardless of
mechanism, apoE-mediated cholesterol efflux removes cholesterol and engages
the reverse cholesterol transport system.
Glossary
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EWT cholesterol efflux (% efflux) from apoE(+/+) macrophages
EKO cholesterol efflux (% efflux) from apoE(-/-) macrophages
DE apoE-mediated cholesterol efflux (% efflux)
V volume of the extracellular space (ml)
V -1 relative concentration (ml-1) of apoE in the extracellular space
m slope (% efflux / (ml-1)) of linear DE vs. V -1 curve
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b y-int. (% efflux) of the linear DE vs. V -1 curve
C effective concentration (ml-1) of apoE in the juxtacellular space
n slope (ml-1 / 24h) of the b/t vs. m curve
f y-int. (% efflux / 24h) of the b/t vs. m curve
kE coefficient (ml-1) for apoE-mediated cholesterol efflux
kI coefficient (ml-1) for apoE-mediated cholesterol influx
Methods
Primary Culture of Peritoneal Macrophages.  Murine peritoneal macrophages
were elicited by intraperitoneal injection of 3% thioglycollate as described in Chapter IV.
Macrophages were plated at 4 x 105 macrophages/well on 24-well plates. Macrophages
were treated with 100 mg/ml acLDL in DMEM/2% FBS for 48 hours to load with
cholesterol and to stimulate apoE secretion (Mazzone et al., 1987). Acetyl-LDL (acLDL)
was prepared as described in Chapter IV.
Efflux of Cellular Cholesterol.  Macrophages were labeled with 2 mCi/ml [1,2-
3H(N)]cholesterol (Perkin Elmer Life Sciences, Boston, MA) in DMEM for 12 hours (Lin
et al., 1999; Mukherjee et al., 1998). ApoE(+/+) and apoE(-/-) macrophages,
respectively, had 64.1 ± 5.0 and 98.0 ± 12.3 mg total cholesterol/mg cell protein.
ApoE(+/+) and apoE(-/-) macrophages, respectively, had 786.66 ± 133.36 versus 782.8 ±
98.93 mg cpm/mg cell protein. Labeled macrophages were rinsed three times with
DMEM/0.2% BSA. The efflux period is initiated by the addition of DMEM with no
acceptors (0.3, 0.5, 0.75, 1.0, 1.5, or 2.0 ml). Efflux media was removed following efflux
periods of 8, 24, 48, or 72 hours and cell debris was removed by centrifugation.
Remaining cellular 3H-cholesterol were harvested by rinsing cells with PBS and then
lysing cells with 1.0 ml of 0.1N sodium hydroxide. Counts (cpm) in media and lysate
were detected with a Beckman LS 6000IC scintillation counter using EcoliteÔ
scintillation fluid (ICN, Costa Mesa, CA). Cholesterol efflux was calculated from the
counts in the media as a percentage of the total counts (media plus lysate). The difference
in cholesterol efflux (E) between apoE(+/+) (WT) and apoE(-/-) (KO) macrophages is
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considered to be the cholesterol efflux that is specifically mediated by apoE. ApoE-
mediated efflux (DE) is calculated as
(1)
Western Blot Analysis of Secreted ApoE.  Macrophages were incubated in
DMEM with no acceptors (0.3, 0.5, 0.75, 1.0, 1.5, or 2.0 ml) for 18 hours and cell debris
was removed by centrifugation. After bringing the total culture volumes to 2.0 ml with
fresh DMEM, ApoE was extracted with LiposorbÔ gel (Calbiochem, San Diego, CA).
Western blot analysis of secreted apoE was performed as described in Chapter VI.
14C-Adenine Release Assay for Cellular Toxicity.  As described in Chapter IV,
cholesterol-induced toxicity in macrophages was assayed by measuring the leakage of
14C-adenine into media (Warner et al., 1995). After labeling, the release period was
initiated by the addition of DMEM. Media was removed after a release period of 24 hours
and counted by scintillation.
Volume-Dependence Theory.  In order to manipulate the extracellular
concentration of an endogenously synthesized biological mediator, this theory takes
advantage of the implicit relationship between concentration and distribution volume.
The concentration of a secreted mediator such as apoE is proportional to the reciprocal of
the extracellular distribution volume. Increasing the distribution volume (V) causes a
decrease in the relative concentration (V -1) of the secreted mediator. Varying the
extracellular volume of a given number of cells (Figure 21A) allows for the juxtacellular
and extracellular mechanisms of the synthesized mediator to be mathematically separated
and characterized. This theory can be illustrated graphically as follows. For a plot of the
biological effect (DE) versus extracellular volume (V), as the extracellular volume is
increased, the effect decreases asymptotically to a plateau that represents the portion of
the total effect that is independent of the extracellular volume (Figure 21B). The value of
this plateau is the y-intercept (b) of a plot of the biological effect (DE) versus reciprocal
volume (V -1) (Figure 21C). This dose-response curve is linear at low relative
concentrations (V -1) and fits the linear equation,
.KOWT EEE -=D
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(2)
Data Analysis.  Data were expressed as mean ± standard deviation. Means were
compared by Student's t-test. Curves were analyzed by linear regression.
Figure 21. Theoretical Basis for the Separation of Autocrine and Paracrine
Effects of ApoE on Cholesterol Efflux.
(A) The experimental design that changes the relative concentrations of apoE by
increasing the extracellular distribution volume. (B) Dependence of the effect of
apoE on the distribution volume. (C) Dependence of the effect of apoE on the
reciprocal volume. Effects of apoE that depend on the relative concentration in
the extracellular distribution volume are paracrine. Effects that occur solely in the
juxtacellular space are independent of the extracellular distribution volume and
are autocrine.
Results
Volume-Dependence of ApoE-Mediated Cholesterol Efflux
In apoE(+/+) macrophages, efflux decreased as the distribution volume increased
(Figure 22A). ApoE-mediated efflux appeared to be saturated at smaller distribution
volumes and then fell to a plateau (b) as the volume increased. At 48 hours, the
dependence of apoE-mediated efflux on reciprocal volume was initially linear (m = 2.95
± 0.63 % efflux / (ml-1), b = 0.85 ± 0.58 % efflux, R2 = 0.92) as determined by linear
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regression analysis (Figure 22B and Figure 22C). Similar trends were seen at 8, 24, and
72 hours. At least 10 to 20% (b expressed as a percentage of the maximum efflux) of the
apoE-mediated cholesterol efflux was independent of the reciprocal volume (Table 5).
The remaining 80 to 90% of the apoE-mediated cholesterol efflux was linearly dependent
on the reciprocal volume (Table 5). The volume-independent contributions to efflux
become dominant as extracellular apoE becomes more dilute. A descriptive equation for
apoE-mediated cholesterol efflux can be generated from these data.
Figure 22. Volume-Dependence of ApoE-Mediated Cholesterol Efflux.
The (A) volume-dependence and the (B) relative concentration-dependence of
cholesterol efflux from apoE(+/+) macrophages (squares) apoE(-/-)
macrophages (triangles) and the apoE-mediated efflux (filled circles). Values are
expressed as mean (4 samples) ± SD of efflux from apoE(+/+) and apoE(-/-)
macrophages with asterisks (*) denoting a statistically significant difference
(p<0.05) by Student’s t-test. (C) Linear fit of the apoE-mediated efflux versus
reciprocal volume for 8 h (diamonds), 24 h (triangles), 48 h (circles), and 72 h
(squares).
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Table 5. Autocrine and Paracrine ApoE Contributes to Cholesterol Efflux.
Volume-Independent: bTime
(h)
Maximum DE
(% efflux) (% efflux) (% of max. DE)
Volume-Dependent: mV -1
(% efflux)
72 ~10.74 1.98 ~18 8.61 V -1
48 ~5.41 0.85 ~16 2.95 V -1
24 ~3.87 0.38 ~10 1.61 V -1
8 ~0.99 0.10 ~11 0.32 V -1
ApoE-mediated efflux (DE ) data from experiments measuring dependence on distribution
volume (V) was fit to Equation 2 (DE = mV -1 + b) to determine y-intercepts (b) and slopes (m).
The maximum DE for each time-point was estimated from the highest DE value beyond the linear
portion of the curve. The volume-independent (autocrine) effects of apoE correspond to the y-
intercept (b). The volume-dependent (paracrine) effects of apoE correspond to the product of the
slope and the reciprocal volume (mV -1).
Volume-Dependence of ApoE Secretion
Western blot analysis was performed to determine if changes in apoE secretion
were related to trends in efflux. In order to determine if macrophages secreted equal
masses of apoE, the apoE was extracted from the culture media. By densitometric
analysis, macrophages cultured in higher media volumes (0.75, 1.0, 1.5, and 2.0 ml)
secreted similar amounts of apoE per cell culture suggesting that the size of the
distribution volume had no effect on apoE secretion (Figure 23A). However,
macrophages cultured in smaller volumes (0.3 and 0.5 ml) secreted more apoE per cell
culture.
Volume-Dependence of Cellular Viability
14C-adenine release studies were performed to determine if changes in viability
were related to trends in efflux or apoE secretion. Viability was increased in smaller
distribution volumes as indicated by higher amounts of 14C-adenine remaining (Figure
23B). Viability increased in a log-linear fashion (R2 = 0.99) with increasing reciprocal
volume (Figure 23C). This log-linear trend in viability is different from the linear trend in
efflux.
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Model for ApoE-Mediated Cholesterol Efflux
With a limited number of assumptions, a mathematical model can be generated
that suggests a physical model for the autocrine and paracrine effects of apoE on
cholesterol efflux. The calculation of apoE-mediated efflux (DE) in Equation 1 assumes
that any difference is a primary effect of apoE and not a secondary effect of changes in
cellular cholesterol homeostasis (i.e. changes in viability or changes in membrane
fluidity). The data in Figure 22, Table 5, and Figure 23 assume that evaporation of the
extracellular distribution volume is negligible. However evaporation was determined to
be ~0.03 ml/ 24 hours for this system. The evaporation rate affects the calculation of
apoE-mediated efflux (DE) and the calculation of reciprocal volume (V -1). Factoring in
the evaporation rate does not change the trends in the data. However, the evaporation
corrections are necessary to estimate the parameters in the mathematical model.
Figure 23. Volume-Dependence of ApoE Secretion and Macrophage
Viability.
The (A) secretion of apoE per cell culture and the (B and C) viability of
apoE(+/+) macrophages in varying reciprocal volumes. Values are expressed as
mean (4 samples) ± SD of adenine release from apoE(+/+) macrophages.
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From an extrapolation of the concentration-dependence lines, a common x-
intercept is observed and is assigned a value of negative C (-0.270 ± 0.047 ml-1) (Figure
24A). The common x-intercept (-C, 0) for all the lines that fit Equation 2 yields the
following equation:
(3)
This reveals that the concentration-dependence lines can be combined into one
equation that is a function of time rather than four unrelated equations. This would be
expected because the secretion of apoE is a function of time and, therefore, apoE-
mediated effects would also be a function of time. If the y-intercept represents an
autocrine effect that results from a constant rate of secretion of apoE then normalizing the
y-intercept for time would reveal a constant (f) where
 (4)
Normalized y-intercepts (b/t), however, are not constant for each time point: 0.66,
0.43, 0.39 and 0.33 % efflux/24h (Figure 24B). A plot of normalized y-intercepts (b/t)
versus the corresponding slope (m) reveals an unexpected relationship that is linear (n =
0.0411 ± 0.0009 ml-1/24h, f = 0.305 ± 0.004 % efflux/24h, R2 = 1.00) as determined by
linear regression analysis and can be expressed as
(5)
Equations 2, 3, and 5 are combined in order to generate a function that can
describe the effects of apoE on cholesterol efflux and that can be interpreted in a
mechanistically compartmentalized manner:
 (6)
Equation 6 fits the experimental data (Figure 24C and Figure 24D). In this form,
Equation 6 expresses apoE-mediated cholesterol efflux as the product of the capacity (ft)
of the system and the ratio of two coefficients: an efflux coefficient (kE = V -1 + C) and an
influx coefficient (kI = C - nt). Based on this mathematical model, a biological model is
proposed (Figure 25).
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Figure 24. Mathematical Trends in ApoE-Mediated Cholesterol Efflux Data.
(A) The common x-intercept (-C, 0) (arrow) of lines from apoE-mediated efflux
versus reciprocal volume plots. (B) The linear relationship between the
normalized y-intercept (b/t) and the slope (m) of lines from apoE-mediated efflux
versus reciprocal volume plots. (C) The kinetics of apoE-mediated efflux at
distribution volumes of 1.0 ml (triangles), 1.5 ml (squares), and 2.0 ml
(diamonds). The experimental data were fit to Equation 6 with experimentally
estimated values for the parameters C, n, and f. (D) Correlation of experimental
and theoretical values for the proposed model for apoE-mediated efflux
(Equation 6).
Discussion
To determine if the autocrine and paracrine actions of apolipoprotein E can be
separated and quantified we measured cholesterol efflux from macrophages cultured in
varying distribution volumes. We found that the volume-independent effects of apoE can
be identified by using a simple mathematical model (Equation 2). We theorize that these
volume-independent effects correspond to the autocrine actions of apoE. The basis of this
theory is that the range of autocrine signals approximates the width of the secretion layer,
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which separates the cell from the bulk media. Studies by Oehrtman et al. (Oehrtman et
al., 1998) and Shvartsman et al. (Shvartsman et al., 2001) suggest that two phenomena
occur when a mediator goes beyond the autocrine range: 1) the mediator is no longer
autocrine, and 2) the mediator becomes diluted in the bulk media. Our data suggests that
the relative importance of the autocrine and paracrine effects of apoE depends on the size
of the local distribution volume, with the autocrine effects remaining constant even when
the paracrine effects are diminished by apoE dilution. The descriptive equation generated
from these data (Equation 6) suggests that autocrine and paracrine apoE work in parallel
to mediate cholesterol efflux from macrophages.
Autocrine and Paracrine Effects of ApoE.  Our study suggests that autocrine apoE
has advantages that are biologically relevant. Even when the extracellular space is
saturated with apoE, at least 10 to 20% of the apoE-mediated cholesterol efflux is the
result of volume-independent interactions of endogenous apoE (Table 5). Lin et al. found
that with apoE deficient cells, the exogenous application of apoE at ten times the
concentration of normal endogenous apoE secretion did not increase cholesterol efflux as
much as normal endogenous apoE secretion by apoE-producing cells (Lin et al., 1999).
The fundamental importance of these media transfer studies are that they show that
exogenous apoE (paracrine) is not equivalent to endogenous apoE (autocrine and
paracrine). For a macrophage with endogenously synthesized apoE, the advantage of
autocrine apoE may become critical if homeostasis is challenged by cholesterol loading,
if the conditioned space is large (making apoE diluted), if the turnover of conditioned
space is high because of interstitial flow, or if a macrophage is isolated from other
macrophages. The interstitial concentration, distribution volume, and turnover of
macrophage apoE in the vessel wall are not known. These factors are critical for the
interpretation of data from in vitro cell culture systems and the generalization of these
data to the biology of macrophages in vivo. For example, the trend in viability may be
related to changes in apoE secretion observed at very low volumes (Figure 23A). The
log-linear trend in viability (Figure 23C) may be due to the relative concentrations of
confounding mediators like growth factors and culture gases (e.g. carbon dioxide) in
varying distribution volumes. Since apoE is not the only mediator being secreted in our
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system, it was necessary to subtract the effects of confounding mediators. This is why
apoE(+/+) macrophages were compared to apoE(-/-) macrophages and why the specific
apoE effect was calculated as apoE-mediated cholesterol efflux (DE). The effects of
confounding mediators on cholesterol efflux were minimal (Figure 22A and Figure 22B).
Although the major role of apoE is as an extracellular cholesterol acceptor, it is also
possible that a portion of the effect of apoE on cholesterol efflux is the consequence of
other actions of apoE, such as receptor or proteoglycan binding (Ji et al., 1998),
intracellular cholesterol routing (Deng et al., 1995), or even stabilization of the
cytoskeleton (Brecht et al., 2004). Irrespective of which ultimate mechanisms or
combination of effects may be responsible for the modulation of cholesterol efflux by
apoE, these can only occur through either autocrine or paracrine events, and are therefore
addressed as a whole in our study.
Although the volume-dependence of apoE secretion and viability could not
explain the volume-dependent trends of apoE-mediated efflux (Figure 22C), these data
definitely underscore the sensitivity of biological processes to in vitro culture volumes.
Some of the higher order characteristics of macrophage tissue could be overlooked by in
vitro studies with macrophages. For example, an aggregate of macrophages may become
a tissue that works with autocrine efficiency instead of being just the sum of its
autocrine/paracrine cellular units. The spatial range of autocrine effect (Shvartsman et al.,
2001) is very important because if another cell is within this range there is the possibility
of autocrine cooperation. This possibility could be explored by in vitro or in vivo studies
on the effects of the geometry and the density of cell aggregates on apoE-mediated
cholesterol efflux. Compared to exogenous lipoprotein-bound apoE of hepatic origin,
local secretion of lipid free apoE by macrophages results in decreased atherosclerosis due
to a small amount of apoE in a critical location (Fazio et al., 1997; Linton et al., 1995). In
the study by Fazio et al., wildtype mice were transplanted with apoE(-/-) bone marrow.
These chimeric mice had normal plasma apoE but no macrophage apoE production in the
vessel walls. Although immunocytochemical staining of lesions with wildtype
macrophages reveals high apoE levels, these chimeric mice with only plasma apoE had
little to no apoE in the lesions. The lack of staining for plasma-derived apoE within the
artery wall suggests that penetration into clusters of macrophages is limited. The
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macrophage, not plasma-derived apoE, is the primary source of apoE for reverse
cholesterol transport (Blum et al., 1980; Fazio et al., 1997; Linton et al., 1995). Along
these same lines, paracrine apoE may not be able to fulfill the critical actions of the small
amount autocrine apoE in the juxtacellular space or possibly even the intracellular space.
ApoE recycling, the internalization and re-secretion of apoE (Farkas et al., 2003; Heeren
et al., 2003; Swift et al., 2001), has been reported to mediate cholesterol efflux in
hepatocytes and in macrophages (Heeren et al., 2003). The methodology in this study is
unable to resolve the "internal autocrine" (Sporn and Roberts, 1992) or "intracrine" (Re,
1988; Re, 2002) mechanism that could be mediated by intracellular apoE (Figure 20).
Proposed Model for Autocrine/Paracrine ApoE.  We propose a model from
Equation 6 in which macrophages secrete apoE to create an extracellular sink for cellular
cholesterol. The capacity, concentration and compartmentalization of the sink affects
cholesterol efflux (Figure 25). The sink has a capacity (ft) that expands as apoE is
secreted. The sink can be separated into two compartments that are a consequence of the
location of apoE in juxtacellular or extracellular space, also described as the secretion
layer and bulk layer, respectively (Lauffenburger et al., 1998; Oehrtman et al., 1998). The
dilution of apoE as it moves to the extracellular space diminishes its efficacy. ApoE-
mediated efflux (DE) is a balance between the efflux and influx of cholesterol. Efflux
depends on the sink capacity (ft), the concentration of extracellular apoE (V -1), and the
functional concentration of juxtacellular apoE (C). Influx depends on the cholesterol in
the apoE sink (DE) and the functional concentration of juxtacellular apoE (kI). Decreases
in the functional concentration of apoE that contribute to influx (nt) may represent
changes in the capacitance of apoE due to accumulation of phospholipids that stabilize
cholesterol or due to proteolytic alteration of apoE. It is also possible that n is an artifact
of slight changes in viability or apoE secretion.
Mixed Autocrine/Paracrine Systems.  In many of the documents that are found by
a literature search for the term "autocrine", the phrase "autocrine and/or paracrine"
describes the proposed mechanism of action. It is difficult to quantitatively separate these
two mechanisms experimentally. Traditional approaches to this problem have limitations
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and rely on simple qualitative assessments. Traditional methodologies that have been
used to study macrophage apoE include characterizing the tissue distribution of apoE
(Fazio et al., 2002), measuring the effects of the endogenous synthesis of apoE versus its
complete absence (Fazio et al., 2002), and measuring the effects of the endogenous
synthesis versus exogenous application of apoE (Ho et al., 2001; Lin et al., 1999). These
methods are useful in comparative assessments but they are unable to simultaneously
quantify the serial effects mediated by apoE or other secreted biological mediators.
In the current study, we have performed experiments based on the theory that the
portion of the endogenous acceptor that mediates autocrine effects cannot be diluted. As
introduced in Chapter III, the protocol for these experiments relies on dilution of
extracellular mediators by increasing the distribution volumes in which cells are cultured.
Previous studies have utilized experimental strategies similar to the one used in our study.
Steck et al. have performed volume-dependence experiments to study whether efflux to
exogenous acceptors is proceeded by aqueous diffusion of cholesterol or by acceptor-
membrane collisions (Steck et al., 1988). They found that for certain types of acceptors,
efflux approached a "volume-insensitive plateau" and they proposed that these types of
acceptors may have "sites for efficient collisional transfer" (Steck et al., 1988). Our
studies with endogenously synthesized acceptors suggest that these sites may be a
combination of binding sites on the membrane and an enriched aqueous layer around the
membrane (i.e. the juxtacellular space). Oehrtman et al. used a theoretical model to study
the escape of autocrine signaling ligands into the extracellular space. They found in a
model of a ligand-receptor signaling system that "varying volume heights shows little
effect on ligand concentrations" (Oehrtman et al., 1998). It remains to be seen if the
dilution methodology discussed here can change mediator concentrations over the large
dynamic range (many orders of magnitude) of a log-linear dose-response curve such as
those seen for ligand-receptor signaling pathways.
Summary.  In summary, this study separates and quantifies the autocrine and
paracrine effects of apoE on cholesterol efflux from macrophages. These data suggest
that the relative importance of autocrine and paracrine apoE depends on the size of the
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local distribution volume, with the autocrine effects remaining constant even when the
paracrine effects are diminished by the dilution of apoE.
Figure 25. Proposed Model of ApoE-Mediated Cholesterol Efflux: Autocrine
and Paracrine Effects.
There are two compartments in which secreted apoE (·) is distributed: the
juxtacellular space and the extracellular space. All endogenously synthesized
apoE is initially distributed in the juxtacellular space where it accepts cholesterol
(o) in an autocrine fashion. ApoE is eventually distributed into the extracellular
space where it accepts cholesterol in a paracrine fashion that is sensitive to the
volume in which the cells are cultured. Determining the volume-independent
effects on cholesterol efflux can distinguish the autocrine actions of apoE from
the paracrine actions.
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CHAPTER VIII
THE EFFECTS OF ENDOGENOUSLY SYNTHESIZED HUMAN-
APOLIPOPROTEIN AI ON CHOLESTEROL EFFLUX
Abstract
Objective.  Apolipoprotein (apo) AI is a strong acceptor of cellular cholesterol
and is the major protein in HDL. The ability of apoAI to mediate cholesterol efflux from
macrophages makes apoAI a critical part of the reverse cholesterol transport system.
While apoE is synthesized locally in vessel walls by macrophages, apoAI is synthesized
in the liver. ATP-Binding Cassette (ABC)-A1 facilitates cholesterol efflux and has been
shown to use apoAI as an acceptor. The objectives of the current study were to measure
whether the endogenous production of transgenic apoAI by macrophages increases
cholesterol efflux and to compare the effects of endogenously synthesized apoAI with
exogenously applied apoAI.
Methods and Results.  Cholesterol efflux was measured from peritoneal
macrophages that express transgenic (tng) human-apoAI (h-apoAI). H-apoAI(tng)apoE(-
/-) macrophages showed about a 40% increase in efflux compared to apoE(-/-)
macrophages. Efflux was further increased when macrophages were treated with a low
concentration (<1 mM) of cyclodextrin in order to facilitate the exchange of cholesterol
between cells and extracellular acceptors. Furthermore, endogenous synthesis of apoAI
stimulated the efflux of cholesterol to exogenously applied apoAI by increasing the
expression of ABCA1.
Conclusions.  These results suggest that increased cholesterol efflux and increased
ABCA1 expression are the mechanisms by which h-apoAI is anti-atherogenic. The ability
of transgenic h-apoAI to substitute for the efflux functions of apoE emphasizes the
importance of endogenous cholesterol acceptors.
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Introduction
Apolipoprotein (apo) AI is the main protein component of HDL (Atmeh et al.,
1983). ApoAI and HDL plasma levels are inversely correlated with atherosclerosis risk
(Gordon and Rifkind, 1989). Like apoE, apoAI from plasma mediates an anti-atherogenic
effect by acting as an acceptor of cholesterol and inducing efflux from macrophages
(Moore et al., 2003; Zhang et al., 2003c). Unlike apoE, however, apoAI is not naturally
expressed by macrophages (Basu et al., 1981). ATP-binding cassette (ABC)-A1 is a
mediator of cholesterol and phospholipid efflux. Both apoAI and apoE have been shown
to interact with ABCA1 (Krimbou et al., 2004; Remaley et al., 2001). The exogenous
application of apoAI has been shown to stabilize and prevent the turnover of ABCA1
(Arakawa and Yokoyama, 2002). It remains unknown if endogenous apoAI has the
potential to perform the functions of endogenous apoE. Other studies from our laboratory
have shown that expression of h-apoAI by macrophages prevents atherosclerosis in
hyperlipidemic mice (Ishiguro et al., 2001; Major et al., 2001; Su et al., 2003). The
mechanism of this protection has not been determined. Many studies suggest that the
expression of apoE by macrophages prevents atherosclerosis by increasing cholesterol
efflux from macrophages in the vessel wall (Bellosta et al., 1995; Kinoshita et al., 2000;
Laffitte et al., 2001; Lin et al., 1999; Linton et al., 1995). The objective of the current
study was to determine whether apoAI production by macrophages can mediate
cholesterol efflux from macrophages. In vitro studies with peritoneal macrophages from
transgenic h-apoAI mice were performed. The expression of apoAI by h-
apoAI(tng)apoE(-/-) macrophages increased cholesterol efflux and ABCA1 expression
compared to apoE(-/-) macrophages. The substitution of the efflux functions of apoE by
transgenic h-apoAI emphasizes the importance of the endogenous synthesis of cholesterol
acceptors in order to maintain macrophage cholesterol homeostasis and prevent
atherosclerosis.
Methods
Human-ApoAI Transgenic Mice.  As described by Major et al., a transgenic
mouse model was generated from a construct with human apoAI driven by the scavenger
receptor A enhancer/promoter (Major et al., 2001). This promoter is macrophage-specific
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(Horvai et al., 1995). Briefly, a construct with the macrophage-specific scavenger
receptor A enhancer/promoter region 5` to the human apoAI cDNA and human growth
hormone splicing and polyadenylation sites on the 3` end were microinjected into
fertilized oocytes. A founder line was confirmed by southern blot. Expression and
secretion of h-apoAI by peritoneal macrophages was confirmed by immunocytochemistry
with an anti-h-apoAI monoclonal antibody.
Cholesterol Efflux to Endogenously Synthesized Acceptors.  Cholesterol efflux in
peritoneal macrophages was determined by a modified procedure from Lin et al. (Lin et
al., 1999). Peritoneal macrophages were elicited with thioglycollate (3%) as described in
Chapter IV and plated in 24-well plates. After 24 hours, media were removed and
replaced with loading media containing 2.0 µCi/ml of 3H-cholesterol (Perkin Elmer Life
Sciences) and 70 µg/ml acLDL. Acetyl-LDL (acLDL) was prepared as described in
Chapter IV. Cells were loaded for 48 hours, after which the monolayers were washed and
equilibrated for 2 hours in DMEM/0.5% BSA at 37°C and 5% CO2. Cells were incubated
in efflux media with DMEM/0.1% BSA at 37°C, 5% CO2, and 100 µL samples were
removed from each well at 0, 2, and 6 hours. Methyl-ß-cyclodextrin (MBCD) treatment
groups were incubated in efflux media with 0.2 mM MBCD (Sigma). Low concentrations
(<1 mM) of cyclodextrins like MBCD facilitates the exchange of cholesterol between
cells and extracellular acceptors (Atger et al., 1997). Cholesterol efflux was calculated
from the total counts in supernatant and is expressed as a percentage of the total counts
(media and lysate).
Effects on Endogenous and Exogenous ApoAI on ABCA1-Mediated Cholesterol
Efflux.  Elicited peritoneal macrophages were plated on 24-well plates in DMEM/10%
FBS. In order to wean cells from serum, cells were cultured in DMEM/RPMI (1/1) with
1% FBS and 1% NutridomaÔ (Roche) for 24 hours prior to experiments. In a loading
period, cells were incubated with 70 mg/ml acLDL and 1.5 mCi/ml 3H-cholesterol (Perkin
Elmer Life Sciences) in serum-free DMEM/RPMI (1/1) with 1% NutridomaÔ for 24
hours. During the loading period, macrophages were pre-treated with 0, 0.5, or 2 mg/ml
exogenous human apoAI (Calbiochem). After the loading/pre-treatment period, cells
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were rinsed and 15 mg/ml human apoAI was added exogenously to measure cholesterol
efflux mediated by the ABCA1 transporter. Media was collected after 4.5 h, centrifuged,
and counted by scintillation. Cells were lysed with 0.1 N sodium hydroxide and counted
by scintillation. Cholesterol efflux was calculated from the counts in media expressed as
a percentage of the total counts (medium and lysate).
Real-time quantitative RT-PCR for ABCA1.  Relative quantification of ABCA1
mRNA was performed as described in Chapter IV. ABCA1 mRNA expression levels in
different macrophage types were expressed relative to the expression in apoE(-/-)
macrophages.
Results
Endogenous h-ApoAI Increases Cholesterol Efflux
To determine if the expression of h-apoAI by macrophages affects cholesterol
efflux, peritoneal macrophages were labeled with 3H-cholesterol and then incubated in
serum-free efflux media containing only BSA. In time course experiments, cholesterol
efflux from h-apoAI(tng)apoE(-/-) macrophages was increased compared to apoE(-/-)
controls (Figure 26). At 6 hours, there was a 40% increase in cholesterol efflux from h-
apoAI(tng)apoE(-/-) macrophages compared to apoE(-/-) controls (Figure 27).
To facilitate cholesterol efflux to unsaturated acceptors in growth media,
macrophages were treated with MBCD. At low concentrations (<1 mM), MBCD acts as a
cholesterol shuttle between cells and high-capacity cholesterol acceptors such as apoAI
(Atger et al., 1997). In the presence of MBCD, we observed increased cholesterol efflux
from all groups of macrophages. Interestingly, cholesterol efflux in h-apoAI(tng)apoE(-/-
) macrophages increased to levels equal to that of apoE(+/+) macrophages (Figure 27).
The MBCD-facilitated increase in efflux (represented as D Efflux, Figure 27 inset) was
highest for the h-apoAI(tng)apoE(-/-) macrophages.
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Figure 26. Endogenous Transgenic h-ApoAI Synthesis Increases Cholesterol
Efflux from Macrophages.
Macrophages were treated for 36 hours with 2.0 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol. Cells were then cultured
in serum-free efflux media with bovine serum albumin (0.1%). Bars and error
bars represent the mean (n=6) and standard deviation of samples. Asterisks (*)
denote a statistically significant difference (p<0.05) compared to the apoE(-/-)
group as determined by Student’s t-test.
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Figure 27. Cholesterol Shuttles Facilitate Cholesterol Efflux to Transgenic h-
ApoAI.
Macrophages were treated for 36 hours with 2.0 mCi/ml of 3H-FC and 70 mg/ml
acLDL in DMEM/2% FBS to label cellular cholesterol. Macrophages were then
cultured in serum-free efflux media with bovine serum albumin (0.1%). During
the efflux period, macrophages were treated with 0 or 0.2 mM of the cholesterol
shuttle, MBCD. Bars and error bars represent the mean (n=6) and standard
deviation of samples from apoE(-/-) macrophages (open bars), h-
apoAI(tng)apoE(-/-) macrophages (solid bars), and apoE(+/+) macrophages
(hatched bars). The inset illustrates the change in cholesterol efflux that was
facilitated by MBCD (MBCD-treated minus control). Asterisks (*p<0.01 or
**p<0.05) denote a statistically significant difference compared to the apoE(-/-)
group as determined by Student’s t-test.
Endogenous h-ApoAI Stimulates ABCA1-Mediated Cholesterol Efflux and Up-regulates
ABCA1
To determine whether endogenous transgenic h-apoAI can stimulate cholesterol
transport to exogenous apoAI, we measured efflux to culture media with an excess of
exogenously applied apoAI. Efflux to exogenous apoAI was higher for h-
apoAI(tng)apoE(-/-) macrophages compared to apoE(-/-) macrophages (Figure 28A). For
comparison, we also pre-treated apoE(-/-) macrophages with low concentrations of
exogenous apoAI (0.5 to 2.0 mg/ml) which are comparable to the apoAI produced by the
transgenic h-apoAI-expressing macrophages. This pre-treatment with exogenous apoAI
resulted in a dose-dependent and significant increase in ABCA1-mediated cholesterol
efflux from apoE(-/-) cells.
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Figure 28. Endogenous h-ApoAI Stimulates ABCA1-Mediated Cholesterol
Efflux to Exogenous ApoAI.
ApoE(-/-) (empty bars) and h-apoAI(tng)apoE(-/-) (solid bars) macrophages were
treated for 24 hours with 70 mg/ml acLDL and 1.5 mCi/ml 3H-cholesterol in
serum-free DMEM/RPMI (1:1) with 1% NutridomaÔ media supplement. During
the loading period, cells were pre-treated with small amounts of exogenous
apoAI to compare the effects of endogenous and exogenous apoAI on ABCA1.
(A) ABCA1-mediated cholesterol efflux was measured from macrophages
cultured in serum-free efflux media with excess apoAI (15 mg/ml) for 4.5 hours.
Bars and error bars represent the mean (n=8) and standard deviation of samples.
Asterisks (*) denote a statistically significant difference (p<0.05) compared to
the apoE(-/-) group as determined by Student’s t-test. (B) The relative quantity of
ABCA1 mRNA was measured by real time RT-PCR. Each bar represents the
measurement of a pooled sample from two mice.
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Expression of ABCA1 mRNA was increased by the transgenic expression of
human apoAI in apoE(-/-) macrophages. The pre-treatment of apoE(-/-) macrophages
with low concentrations of exogenous apoAI also increased ABCA1 expression (Figure
28B). In similar experiments with apoE(-/-) macrophages, Su et al. found by Western
analysis that ABCA1 protein was increased by endogenous expression or exogenous
application of human apoAI (Su et al., 2003).
Discussion
To determine if endogenously synthesized human apoAI can act as a cholesterol
acceptor, we studied cholesterol efflux from h-apoAI(tng)apoE(-/-) and apoE(-/-)
macrophages. We found that the endogenous expression of h-apoAI increased cholesterol
efflux from cultured macrophages. Furthermore, endogenous h-apoAI stimulated
ABCA1-mediated cholesterol efflux and increased the expression of the ABCA1
transporter. The increase in efflux and increase in ABCA1 expression may be the
mechanism by which endogenous synthesis of apoAI protects against foam cell formation
and atherosclerosis.
Transgenic Macrophage ApoAI and Cholesterol Efflux.  The present studies
determine the functional equivalence of endogenous acceptors by genetically substituting
endogenous apoE with transgenic h-apoAI. Because lipid-free apoAI can enhance
cellular cholesterol efflux (Hara and Yokoyama, 1992), the possibility exists that the
beneficial effect of an activated reverse cholesterol transport system may be evident even
through more subtle modifications that do not affect plasma or serum HDL cholesterol
levels. When analyzed for the ability to efflux cholesterol, macrophages from h-
apoAI(tng)apoE(-/-) mice showed significant increases compared to apoE(-/-)
macrophages. In the absence of exogenously added extracellular acceptors (e.g. HDL,
apoAI, or apoE), the efflux of cholesterol was higher from macrophages expressing h-
apoAI than from controls (Figure 26).
Treatment with low concentrations of cyclodextrin facilitated a significantly
greater increase in efflux from h-apoAI(tng)apoE(-/-) macrophages than from apoE(-/-)
or wildtype apoE(+/+) macrophages (Figure 27). Low concentrations of cyclodextrins
100
have previously been shown to be catalysts of cholesterol efflux by acting as cholesterol
shuttles and allowing for a more rapid equilibration of cholesterol between cells and
extracellular acceptors (Atger et al., 1997). The greater cyclodextrin-facilitated increase
suggests that media conditioned by h-apoAI(tng)apoE(-/-) macrophages may have a
greater capacity for accepting cholesterol than unconditioned media. This suggests that
upon secretion from macrophages, apoAI is not saturated with cholesterol. These data
support a model in which the production of apoAI may confer an autocrine or paracrine
property to the macrophage, probably mediated by the accumulation of secreted apoAI
outside the plasma membrane, where it activates cholesterol efflux. Such an anti-
atherogenic property related to increased cellular cholesterol efflux has been described
for macrophage-derived apoE (Lin et al., 1999; Mazzone and Reardon, 1994). ApoE and
apoAI are thought to be anti-atherogenic by several mechanisms. Because enhancement
of cholesterol efflux is a shared function of apoAI and apoE, these findings emphasize
the protective effect of reverse cholesterol transport in the developing atherosclerotic
plaque.
Transgenic Macrophage ApoAI and ABCA1 Stimulation.  Synergy between
endogenous and exogenous acceptors was observed for ABCA1-mediated efflux from h-
apoAI(tng)apoE(-/-) macrophages (Figure 28A). The ability of apolipoproteins to
stabilize ABCA1 and stimulate ABCA1 expression are well characterized (Arakawa et
al., 2004; Natarajan et al., 2004). These data suggest that functionally, endogenous apoAI
is more effective than pre-treatment with exogenous apoAI (2 mg/ml). Based on the
secretion rate determined by Major et al., we estimate that the cells in the current study
conditioned the media with h-apoAI to a concentration of approximately 0.2 mg/ml. This
suggests that despite very low concentrations, endogenous apoAI was able to be more
effective than exogenous apoAI at stimulating ABCA1-mediated cholesterol efflux.
One potential mechanism for increased ABCA1 expression in cells treated with
apoAI is the ability of apoAI to induce cAMP signaling. The current study showed
increased ABCA1 expression upon treatment with endogenous or exogenous apoAI
(Figure 28B). ApoAI has been shown to trigger phosphorylation of ABCA1 and
subsequent rises in cellular cAMP (Haidar et al., 2004). Because cAMP is a known
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stimulator of ABCA1 expression (Oram et al., 2000), this potential signaling mechanism
warrants further investigation.
Macrophage ApoAI and Atherosclerosis.  These in vitro results in the current
study correlate with decreases in atherosclerosis shown by other studies from our
laboratory. We have previously shown that the lack of apoE expression by macrophages
results in a 10-fold increase in atherosclerosis without affecting serum lipids (Fazio et al.,
1997). Since macrophages do not naturally express apoAI, we hypothesized that apoAI
production by macrophages could substitute for the anti-atherogenic effects of apoE.
Macrophage expression of human apoAI reduces aortic lesions in mice susceptible to
spontaneous atherogenesis with no differences in serum lipid levels or lipoprotein
distribution (Major et al., 2001). In the bone marrow transplantation study by Major et
al., apoE deficient mice were the recipients of bone marrow. The donors were apoE(-/-),
h-apoAI(tng)apoE(-/-), and wildtype apoE(+/+) mice. The lesion area in the proximal
aorta of the h-apoAI(tng)apoE(-/-), bone marrow recipients was about 60% less than the
apoE(-/-) bone marrow recipients.
Experiments with h-apoAI(tng)apoE(-/-) macrophages showed that endogenous
human apoAI has an effect on cholesterol efflux that is similar to that of exogenous
apoAI on apoE(-/-) macrophages. These results suggest that the local effects of human
apoAI produced by macrophages can promote removal of excess cholesterol in the
plaque. In normolipidemic human plasma, lipid-free apoAI levels are around 5–10% of
the total plasma apoAI (Neary and Gowland, 1987). The lipid-free apoAI particles are
able to enter the subendothelial space and promote the removal of excess cholesterol
from peripheral cells. If the lipid-free human apoAI produced by macrophages in the
subendothelial space can effectively promote cholesterol efflux, high levels of apoAI in
plasma may not represent a necessary condition to obtain beneficial effects on the
vascular wall. Modulating atherogenesis by increasing the apoAI concentration locally in
the vascular wall may represent a viable therapeutic approach.
Summary.  In summary, macrophage-specific expression of human apoAI
increased cholesterol efflux from loaded apoE deficient macrophages and increased the
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expression of ABCA1. Similar effects were seen with endogenous apoE synthesis
(Chapter VI), suggesting that the endogenously synthesized cholesterol acceptors like
apoE or apoAI have overlapping functions in macrophages and may be interchangeable.
These results also suggest that cholesterol efflux is a mechanism by which the apoAI
produced by macrophages protects against atherosclerosis.
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CHAPTER IX
CONCLUSION:  CHOLESTEROL EFFLUX AFFECTS CHOLESTEROL
HOMEOSTASIS AND THE ATHEROGENIC POTENTIAL OF MACROPHAGES
Overview
Atherosclerosis and foam cell formation are the consequence of altered
cholesterol homeostasis in macrophages. Cholesterol efflux, the first step of the reverse
cholesterol transport system, is associated with protection from atherosclerosis. To
determine the role of cholesterol efflux in macrophage cholesterol homeostasis, we
developed protocols to measure cholesterol efflux, and performed studies to measure
cholesterol efflux from macrophages with cholesterol storage deficits and from
macrophages that secrete cholesterol acceptors. In previous in vivo studies with mice, our
laboratory has shown that cholesterol storage deficits in macrophages and cholesterol
acceptor secretion from macrophages affect foam cell transformation and atherosclerosis
(Fazio et al., 2001; Ishiguro et al., 2001; Linton et al., 1995; Major et al., 2001; Su et al.,
2003). The current studies examine cholesterol efflux from these macrophages, in vitro.
We show that ACAT1(-/-) macrophages, which lack the enzyme that stores cholesterol,
are characterized by disruptions in cholesterol efflux, altered cellular morphology,
increased lipoprotein uptake, and increased cholesterol synthesis. We show that the
secretion of cholesterol acceptors, like apolipoprotein (apo) E or transgenic human apoAI
increased cholesterol efflux by multiple mechanistic pathways. These studies show that
cholesterol efflux is an integral part of cholesterol balance in macrophages. In
combination with previous in vivo studies, these in vitro studies suggest that cholesterol
efflux is a mechanism that affects the atherogenic potential of macrophages.
General Discussion
Macrophage cholesterol homeostasis is a central focus in understanding the
biology of foam cell formation and atherosclerosis. Atherosclerosis is a complex disease
process that leads to complications such as coronary heart disease and stroke.
Macrophages are a critical part of the progression of this disease because macrophages
accumulate cholesterol and transform into foam cells. The uptake, storage, synthesis, and
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efflux of cholesterol are processes that maintain cholesterol homeostasis in macrophages.
Because cholesterol efflux is the initial step of the reverse cholesterol transport system, it
has a critical role in protecting macrophages from foam cell transformation. The aims of
our studies were to develop protocols to measure cholesterol efflux, to study the effects
of cholesterol storage deficits on cholesterol efflux, and to study the effects of cholesterol
acceptors on cholesterol efflux. These aims were addressed by experiments with
peritoneal mouse macrophages that were elicited from genetically engineered mice. We
show that cholesterol storage deficits disrupted cholesterol efflux while endogenous
synthesis of cholesterol acceptors stimulated cholesterol efflux. These findings will be
discussed by their relevance to cholesterol efflux, cholesterol homeostasis, technical
developments, potential therapeutics, and atherosclerosis.
Cholesterol Efflux
Cholesterol efflux from macrophages is associated with the reverse cholesterol
transport system and with protection from foam cell formation. In the current studies we
studied cholesterol efflux in the contexts of macrophages with a cholesterol storage
deficit and macrophages that secrete cholesterol acceptors. The findings from both of
these systems have helped to elucidate the role of cholesterol efflux in maintaining
cholesterol homeostasis in macrophages.
ACAT1 Deficiency and ABCA1-Mediated Cholesterol Efflux.  Acyl-coenzyme
A: cholesterol acyltransferase (ACAT) is the enzyme that esterifies cholesterol with fatty
acids. Esterified cholesterol is the storage form of cholesterol that is abundant in foam
cells. In Chapter IV, we showed that ACAT1(-/-) macrophages, which lack this enzyme,
had major alterations in cholesterol efflux mediated by the ATP-Binding Cassette (ABC)-
A1 transporter. ACAT1(-/-) macrophages have decreased efflux of cellular cholesterol
and increased efflux of lipoprotein-derived cholesterol. The net result, under relatively
mild cholesterol loading conditions, was the accumulation of lipoprotein-derived free
cholesterol and the accumulation of intracellular vesicles. These changes in cholesterol
homeostasis and cellular morphology were not the result of cholesterol-induced toxicity.
These changes show that cholesterol esterification is a crucial part of the cellular
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cholesterol cycle and suggest that the absence of cholesterol esterification makes
ACAT1(-/-) macrophages pro-atherogenic.
Cholesterol Acceptors and ACAT1 Deficient Macrophages.  The disruptions in
cholesterol efflux from ACAT1(-/-) macrophages were not limited to the ABCA1/apoAI
efflux pathway. In additional experiments, cholesterol efflux from ACAT1(-/-)
macrophages to other cholesterol acceptors was measured. ApoE-mediated cholesterol
efflux was decreased from ACAT1(-/-) macrophages compared to wildtype macrophages
(Appendix, Figure 31A). Cholesterol efflux mediated by HDL was also decreased from
ACAT1(-/-) macrophages (Appendix, Figure 31B). Together with the finding of decreased
ABCA1-mediated efflux, these data suggest that the disruptions in ACAT1(-/-)
macrophages may be due to a global change in cellular cholesterol homeostasis, like
cholesterol trafficking or vesicular trafficking.
General defects in protein secretory pathways could affect apoE secretion and
apoE-mediated cholesterol efflux from macrophages. The endogenous synthesis of apoE
by macrophages stimulated cholesterol efflux, as discussed in Chapter VI. For ACAT1(-/-
) macrophages, it is unclear if the morphological changes and the accumulation of
intracellular vesicles (Chapter IV) affect apoE secretion. In additional experiments, the
secretion of apoE from ACAT1(-/-) macrophages was measured by Western blot analysis.
Endogenous apoE secretion was not changed by ACAT1 deficiency (Appendix, Figure
32A). Despite normal apoE secretion, apoE-mediated cholesterol efflux was decreased in
ACAT1(-/-) macrophages (Figure 31A). To determine if the effects of ACAT1 deficiency
on ABCA1-mediated cholesterol efflux are affected by endogenous synthesis of apoE, we
measured cholesterol efflux from ACAT1(-/-)apoE(-/-) macrophages. Cholesterol efflux
to apoAI from ACAT1(-/-)apoE(-/-) macrophages was not different from ACAT1(-/-)
macrophages but was significantly reduced compared to either wildtype or apoE(-/-)
(Appendix, Figure 32B). These additional data suggest that the endogenous apoE
secretion from ACAT1(-/-) is not responsible for the decreases in apoE-mediated or
ABCA1-mediated efflux of cellular cholesterol.
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Interactions Between Cholesterol Efflux Pathways.  The presence of multiple
efflux pathways suggests that cholesterol efflux has a high physiological importance.
Cholesterol-loaded macrophages in the vascular wall benefit from the multiple effects
that apoAI, apoE, and HDL have on cholesterol homeostasis. In addition to their direct
effects as cholesterol acceptors, apoAI, apoE, and HDL affect cholesterol homeostasis by
other mechanisms. ApoAI is the major cholesterol acceptor for the ABCA1 efflux
pathway, a pathway that is disrupted in Tangier disease. ApoAI also has a stabilizing
effect on ABCA1 proteins, which further stimulates cholesterol efflux (Feng and Tabas,
2002). In Chapter VIII and in other studies from our laboratory, we showed that
transgenic expression of apoAI in macrophages stimulated cholesterol efflux by
stimulating the expression of ABCA1 (Su et al., 2003). Other laboratories have shown
that both apoAI and ABCA1 have a positive effect on the secretion of apoE, the acceptor
for a separate cholesterol efflux pathway (Kockx et al., 2004; Von Eckardstein et al.,
2001). As apoAI accepts cellular lipids it matures into HDL. ApoE can also be
constituents of HDL particles (Weisgraber et al., 1977). HDL accepts cholesterol by
interacting with the SR-BI receptor and by acting as an extracellular sink for cholesterol.
Studies have shown that cholesterol efflux to HDL is increased by endogenous synthesis
of apoE in macrophages (Lin et al., 1998). Together, apoAI, HDL, and apoE found
locally in the vascular wall can protect macrophages from foam cell transformation
through multiple mechanisms that increase cholesterol efflux and maintain cholesterol
homeostasis.
In Chapter VI, we showed that apoE increased cholesterol efflux by acting as a
cholesterol acceptor in the apoE efflux pathway and as a mild stimulator of the ABCA1
efflux pathway. In the apoE-mediated efflux pathway, ABCA1 had a modest stimulatory
effect on efflux to apoE. These data suggest that although there is interaction and mutual
stimulation of apoE-mediated and ABCA1-mediated cholesterol efflux, these two efflux
pathways are largely independent.
The ABCA1 transporter is a mediator of cholesterol efflux that can tie together
efflux pathways involving apoAI and apoE. One way that ABCA1 ties these pathways
together is its specificity for the class of apolipoproteins known as exchangeable
apolipoproteins (Bortnick et al., 2000; Krimbou et al., 2004; Remaley et al., 2001).
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Krimbou et al. found that apoE can bind ABCA1. However, when compared to apoAI,
the affinity of apoE for ABCA1 was not as specific and cholesterol efflux was not as
much. In these studies, Krimbou et al. applied relatively large amounts of exogenous
apoE to fibroblasts. In contrast, we were able to detect this interaction between apoE and
ABCA1 with the endogenously synthesized apoE that was secreted from macrophages
(Chapter VI). Our study used macrophages that were ABCA1(+/-) and ABCA1(+/+) to
explore interactions of ABCA1 and apoE at the functional level of cholesterol efflux. As
discussed in Chapter VIII, endogenous transgenic h-apoAI also had a functional
interaction with ABCA1. These studies highlight the ability for two different cholesterol
acceptors to interact with ABCA1 when synthesized endogenously by macrophages.
Transgenic Macrophage ApoAI and Cholesterol Efflux.  In Chapter VIII, we
showed that macrophage-specific expression of transgenic human apoAI increased
cholesterol efflux from loaded apoE deficient macrophages and increased the expression
of ABCA1. Similar effects were present with endogenous apoE synthesis (Chapter VI),
suggesting that the endogenously synthesized cholesterol acceptors like apoE or apoAI
have overlapping functions in macrophages and may be interchangeable. These results
also suggest that cholesterol efflux is a mechanism by which the transgenic apoAI
produced by macrophages could protect against atherosclerosis.
The ability of apolipoproteins to stabilize ABCA1 and stimulate ABCA1
expression are well characterized (Arakawa et al., 2004; Natarajan et al., 2004). In
Chapter VIII, we observed synergy between endogenous and exogenous acceptors for
ABCA1-mediated efflux. For stimulation the ABCA1 efflux pathway, endogenous apoAI
was more effective than treatment with ten times more exogenous apoAI. This suggests
that despite very low concentrations, endogenous apoAI has an advantage. Differences
between endogenous and exogenous cholesterol acceptors were reported in previous
studies. Lin et al. showed that endogenously synthesized apoE was able to increase
cholesterol efflux more than exogenously applied apoE that was ten times the
concentration (Lin et al., 1999). The advantages of endogenous cholesterol acceptors,
even at relatively low levels compared to exogenous cholesterol acceptors, may be
related to intracellular events or to the proximity of the acceptors to point of action (i.e.
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cellular membranes). As discussed in Chapter VII, the effects of endogenous apoE on
cholesterol efflux were separated into autocrine effects and paracrine effects.
Autocrine and Paracrine Effects of Cholesterol Acceptors.  In Chapter VII, we
separated and quantified the autocrine and paracrine effects of apolipoprotein E on
cholesterol efflux from macrophages. These data show that the relative importance of
autocrine and paracrine apoE depends on the size of the local distribution volume. The
autocrine effects of apoE remain constant even when the paracrine effects are diminished
by the dilution of apoE. This suggests that paracrine apoE may not be able to fulfill the
critical actions of a small amount of autocrine apoE in the juxtacellular space. Together,
these findings suggest that the apoE that is endogenously synthesized by macrophages
uses autocrine and paracrine mechanisms to protect against atherosclerosis.
The effect of apoE secretion rate on apoE-mediated cholesterol efflux is not
known. In additional experiments, apoE-mediated cholesterol efflux was measured using
heterozygous apoE(+/-) macrophages as a "low-secretor" cell model. Even though
apoE(+/-) macrophages were expected to have apoE expression levels of about 50% of
the apoE that is secreted by wildtype apoE(+/+) macrophages, they only secreted
approximately 10% of the apoE (Appendix, Figure 33). Although apoE was available in
the extracellular space, the heterozygous apoE(+/-) macrophages did not efficiently
engage it to mediate cholesterol efflux. This data suggests that a certain threshold level of
apoE secretion may be necessary for the autocrine action of apoE. "High-secretor" cell
models, with apoE over-expression and secretion that is higher than physiologic levels,
have not been examined. Future experiments will characterize the effects of different
levels of apoE over-expression on the autocrine and paracrine mechanisms of apoE-
mediated cholesterol efflux.
The autocrine and paracrine actions of endogenous acceptors were further
characterized in additional experiments with macrophage that secrete transgenic human
apoAI instead of apoE. As discussed in Chapter VIII, endogenous apoAI stimulated
cholesterol efflux by stimulating ABCA1-mediated cholesterol efflux. These studies
showed that endogenous apoAI, like endogenous apoE, increased cholesterol efflux
compared to macrophages that do not synthesize cholesterol acceptors (Appendix, Figure
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34). The positive effect on cholesterol efflux was diminished by increasing the
distribution volumes in which the cells were cultured. These results suggest that this
methodology may be applicable to other cholesterol acceptors.
Cholesterol Homeostasis
Cholesterol efflux works in concert with many other cellular processes to
maintain cholesterol homeostasis. The uptake, storage, synthesis, or trafficking of
cholesterol has the potential to affect cholesterol efflux. In the current studies, we
explored the association between cholesterol efflux and other aspects of cholesterol
homeostasis in the context of macrophages with a cholesterol storage deficit. The
findings from this system suggest that a specific disruption in a single process of
cholesterol homeostasis has global cellular consequences.
ACAT1 Deficiency and Cholesterol Synthesis.  In Chapter V, we showed that the
absence of ACAT1 in macrophages had effects on lipid homeostasis that go beyond
decreased cholesteryl esters. ACAT1 deficiency in macrophages increases cholesterol
synthesis without affecting phospholipid synthesis. This increase may represent
dysregulation of the cholesterol sensing mechanisms in macrophages and suggests that de
novo synthesis of cholesterol may contribute to the atherogenic potential of ACAT1(-/-)
macrophages.
Cholesterol Trafficking in ACAT1 Deficient Macrophages.  As discussed in
Chapter IV and Chapter V, the similarities between ACAT1 deficiency, Niemann-Pick
type C1 (NPC1) deficiency, U18666A treatment, and progesterone treatment suggests
that ACAT1(-/-) macrophages may suffer from aberrant cholesterol trafficking. Although
these treatments and genotypes have phenotypic similarities, they represent an array of
mechanisms. ACAT1 esterifies cholesterol. NPC1 traffics cholesterol from lysosomes to
the plasma membrane and endoplasmic reticulum. U18666A is an amphiphile that
inhibits intracellular cholesterol trafficking by sequestering cholesterol in vesicles
(Kellner-Weibel et al., 1998; Sparrow et al., 1999). Progesterone and imipramine, which
are also amphiphiles, have similar effects. It is interesting that NPC1 is necessary for the
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actions of amphiphile compounds on cholesterol trafficking and that the resulting
phenotype resembles NPC1 deficiency (Lange et al., 2000). In a study of these
amphiphiles, Lange et al. suggest that disruption of cholesterol trafficking results in the
accumulation of vesicles that are "modified for lipid storage" (Lange et al., 1998).
Vesicular accumulation in ACAT1(-/-) macrophages was described in Chapter IV. The
association of vesicular accumulation, disrupted cholesterol trafficking, and altered
cholesterol homeostasis supports the idea that ACAT1 deficiency disrupts normal
cholesterol trafficking. The cycle of cholesterol esterification and de-esterification may
be a critical part of cholesterol trafficking and cholesterol homeostasis.
Characterization of Vesicles in ACAT1(-/-) Macrophages.  ACAT1(-/-)
macrophages have increased surface activity, more cytoplasmic extensions, and increased
intracellular vesicles (Chapter IV). These vesicles were identified as endosomes and
lysosomes by the presence of specific protein markers. In future experiments, time-lapse
microscopy of these macrophages in vitro could identify differences in vesicle formation
and movement. This would provide important clues about potential changes in
cholesterol trafficking that result from ACAT1 deficiency.
Studies with ACAT inhibitors have described accumulations of intracellular
vesicles and extrusion of the vesicles into the extracellular space (Robenek and Schmitz,
1988). In future studies, we will explore the possibility that ACAT1(-/-) macrophages
extrude vesicles into the interstitial space of atherosclerotic lesions in vivo or into culture
media in vitro. Extrusion of vesicles into the extracellular space could be a pro-
atherogenic event, especially if they are enriched in cholesterol. Accumulation of these
types of vesicles, in both intracellular and extracellular spaces, is associated with the
progression of fatty streaks into more complicated plaques (Guyton and Klemp, 1989;
Guyton and Klemp, 1994).
Vesicles in ACAT1(-/-) macrophages appear to be heterogeneous. Identification of
vesicles as both endosomes and lysosomes explains some of the morphological
differences in vesicles. In future experiments, it would be interesting to correlate the
functional differences (i.e. endosome, lysosome, secretory vesicle, trafficking vesicles)
with structural differences in the vesicles (i.e. size, density, lipid composition). Cellular
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vesicles can be isolated by density gradient centrifugation (Galloway et al., 1983).
Protein markers and lipid constituents on isolated vesicles could also be characterized is
these experiments. Isolated vesicle fractions can be visualized by electron microscopy to
characterize size and structure. Density gradient separation would facilitate
characterization of the different types of vesicles and may suggest functional differences
in cholesterol trafficking between the wildtype and ACAT1(-/-) macrophages.
Technical Developments
Protocol Developments.  In Chapter III, we described protocols for assaying
cholesterol efflux from macrophages. These protocols were further modified to focus on
larger experimental capacity and greater experimental efficiency. Other developments
include software for data analysis (Appendix, Figure 29) and protocols to study the
autocrine and paracrine effects of cholesterol acceptors (Chapter VII).
Development of data analysis software for efflux experiments (Appendix, Figure
29) will continue with a strategy of making the current software user-friendly. The
strategy to improve this software will include automating many analysis steps (e.g. data
input, analysis decisions, and report output). Improvements will be achieved by
constructing user input forms, which will guide the user through data entry and analysis
decisions while protecting the user from interfacing the data at the level of the Microsoft
ExcelÔ spreadsheet. Input forms will be very simple interfaces with yes/no answer
boxes, brief explanations of available choices, and entry boxes for data input. Visual
BasicÔ for Applications, which is a Microsoft WindowsÔ-based programming
language, will be used along with the built-in capabilities of Microsoft ExcelÔ to achieve
a user-friendly analysis tool for cholesterol efflux data (Tack et al., 1995).
Targeted Cholesterol Labeling and ACAT1 Deficient Macrophages.  In Chapter
III, we described protocols for targeted labeling of cholesterol pools that were used to
study the effects of ACAT1 deficiency on cholesterol efflux. In Chapter IV, ACAT1(-/-)
macrophages treated with the “lipoprotein-derived” labeling methodology had greater
efflux of the labeled lipoprotein-derived cholesterol but less efflux of cholesterol mass
(Figure 1B). This does not represent a discrepancy, but rather demonstrates that the
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cholesterol pool targeted with 3H-cholesterol in this experiment is distinct from the bulk
of the cellular cholesterol. The 3H-cholesterol in the lipoprotein-derived pool does not
reach equilibrium with the rest of the cholesterol mass, and does not behave like the bulk
of cellular cholesterol. The efflux measurements from the labeled pool and the mass
measurements from the bulk cholesterol were performed on same set of cells in this
study. These data suggest that even though the ACAT1(-/-) macrophages efflux less of
their total cholesterol mass, they are selectively increasing the efflux of the labeled
cholesterol that comes from lipoproteins, possibly due to changes in trafficking.
96-Well Efflux System and ApoE/ABCA1 Interaction Studies.  In Chapter III, we
summarized the protocols for cholesterol efflux in 96-well cell culture plates. These
protocols were used in Chapter VI to study the effects of ABCA1 heterozygosity. The 96-
well protocol was useful in this set of experiments because of the large number of
experimental groups and the scarcity of experimental animals. In these experiments,
individual experimental groups included combinations of four different genotypes, two
agonist treatment conditions, and three cholesterol acceptors. This generates a total of 24
experimental groups. Experiments of this magnitude would be cumbersome in 24-well or
6-well culture systems because of the large number of mice needed to produce enough
peritoneal macrophages. The cost and availability of reagents such as radiolabeled
cholesterol and modified lipoproteins are another issue.
Future developments in this protocol will partially automate the washes by using a
TecanÔ Microplate Washer. This plate washer is equipped with an 8-channel manifold
that allows the simultaneous wash of an entire column of wells in a standard 96-well
plate. The plate washer has dispense, aspirate, and continuous wash functions. Sequences
of these functions can be stored as programmed protocols. This cell culture system has
great potential for more efficient studies of cholesterol homeostasis.
Modeling the Effects of Autocrine/Paracrine ApoE.  As discussed in Chapter VII,
by using a basic mathematical model, the effects of endogenous apoE on cholesterol
efflux were separated into autocrine effects and paracrine effects. Modeling of this type
has been used in previous studies of cholesterol efflux. Rothblat et al. found that
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cholesterol efflux increased linearly with cholesterol acceptor concentration in a saturable
manner (Rothblat and Phillips, 1986; Yancey et al., 1996). Yancey et al. found that efflux
to cyclodextrins, very strong acceptors of cholesterol, occurs from two kinetic pools of
cholesterol (Yancey et al., 1996). Yancey et al. describe these two pools with a bi-
exponential model of cholesterol efflux. More complex mathematical computer models
have been used to study autocrine and paracrine actions of endogenously synthesized
ligands (Oehrtman et al., 1998; Shvartsman et al., 2001). Together, these studies
demonstrate that mathematical modeling is a viable method for generating testable
hypothesis regarding cholesterol efflux and autocrine/paracrine mechanisms. In Chapter
VII, a simple model of the relationship between distribution volume and cholesterol
efflux generated data that contained more complex mathematical trends. From these
mathematical trends a biological model was proposed. However, it remains to be seen if
the proposed model correlates with actual biological mechanisms. Future studies will test
the proposed model for autocrine/paracrine apoE.
Effects of Lesion Geometry on Cholesterol Efflux from Macrophages.  As
discussed in Chapter VI and Chapter VIII, endogenous synthesis of cholesterol acceptors
increased cholesterol efflux. Of the two major cholesterol efflux pathway, one depends
on an endogenous cholesterol acceptor (i.e. macrophage apoE) and the other depends on
an exogenous cholesterol acceptor (i.e. hepatic apoAI). The relative physiological
relevance of these two pathways is not known. In the vessel wall, apoE of macrophage
origin may be more anti-atherogenic than apoAI of hepatic origin. Studies from our
laboratory have shown that macrophages that endogenously synthesize transgenic human
apoAI can protect against atherosclerosis, even when ample amounts of hepatic apoAI
are present in the plasma compartment (Ishiguro et al., 2001). Two factors that could
contribute to a higher efficacy of endogenous acceptors are the geometry of the lesion
and the proximity of acceptors to their point of action. While the macrophage monolayer
is both the most commonly used and the most simplistic in vitro model of macrophage
physiology, monolayers are a poor representation of the atherosclerotic lesion. For
example, this model cannot account for the effects of lesion geometry on the progression
of macrophages into foam cells. For certain cell types, three-dimensional culture
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techniques have been successful at revealing cell characteristics that cultured monolayers
do not demonstrate (Wang and Tarbell, 2000). Likewise, three-dimensional macrophage
aggregates may be a more effective model to study how lesion geometry affects the
functions of apoE and apoAI. Future directions in the development of cholesterol efflux
protocols will include macrophage aggregates and macrophage culture in three-
dimensional extracellular matrices.
Potential Therapeutics
The current studies establish a basis for potential therapeutic interventions that
could aid cholesterol efflux, block foam cell formation, and prevent atherosclerosis.
These potential therapeutics include bone marrow transplantation to deliver genetically
engineered macrophages and pharmacologic manipulation of individual processes of
cholesterol homeostasis. In the current studies we studied cholesterol efflux in the
contexts of macrophages with a cholesterol storage deficit and macrophages that secrete
cholesterol acceptors. Together, these systems suggest that cholesterol acceptors and
LXR agonist may have therapeutic value but that abolishing cholesterol esterification
may have undo consequences.
ACAT Inhibitors and Cholesterol Efflux.  ACAT inhibition has been reported to
increase the efflux of cholesterol to various cholesterol acceptors (Kellner-Weibel et al.,
1998; Mazzone and Reardon, 1994; Warner et al., 1995; Zhang et al., 1996). There are
methodological considerations that are important for the interpretation of previous studies
with ACAT inhibitors. A common experimental setup found in many studies is that cells
are cholesterol loaded until a large cholesteryl ester pool exists. Immediately following
the loading period, cells are treated with ACAT inhibitor. This acute blockage of the
esterification cycle in the presence of a large cholesteryl ester pool, increased cholesterol
efflux by liberating free cholesterol. A second experimental setup is that cells are loaded
with lipoproteins that contain radiolabeled cholesteryl esters. Cells are concurrently
treated with ACAT inhibitor. As lipoproteins are degraded and lipids are hydrolyzed in
lysosomes, the radiolabeled cholesterol is blocked from entering the esterified cholesterol
pool. Thus, turnover of the radiolabeled cholesterol occurs as the cholesterol is
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hydrolyzed and effluxed to acceptors in the media. A good example of this setup comes
from Rodriguez et al., who reported increased efflux of lipoprotein-derived cholesterol
during treatment with the ACAT inhibitor 58-035 in human monocyte-derived
macrophages (Rodriguez et al., 1999).
The experimental setup of the current studies differs from those of previous
studies in one fundamental way. In our experiments, it was necessary to compare genetic
ACAT1 deficiency with treatment with ACAT inhibitor. To mimic the conditions of
ACAT1 deficiency, ACAT inhibitors must be continuously applied. Instead of
establishing a cholesteryl ester pool before the application of the inhibitor, the cells were
continuously inhibited throughout the cholesterol loading and cholesterol efflux periods.
Like Rodriguez et al., our experimental setup was able to test the turnover of lipoprotein-
derived cholesterol during the loading period. Subsequently, ACAT inhibitor treatment
continued as ABCA1-mediated cholesterol efflux was measured. Our findings are similar
to previous studies with ACAT inhibitors. Our studies have an extra dimension because
we measure the effects of deficiency or inhibition independently of an established
cholesteryl ester pool. Chronic therapy with ACAT inhibitors to block the establishment
of atherosclerotic lesions is likely to mimic these experimental conditions.
Pharmacologic Inhibition of ACAT versus Genetic ACAT1 Deficiency.  In
additional experiments, both ACAT1 deficiency and ACAT inhibition increased the
turnover of lipoprotein-derived cholesterol and decreased the esterification of labeled
cholesterol (Appendix, Figure 30). A notable difference, however, was that ACAT1
deficiency increased FC accumulation while ACAT inhibition did not change
intracellular FC when compared to untreated wildtype macrophages. This may be due to
residual ACAT activity or to the abrupt onset of pharmacologic inhibition. ACAT1
deficiency may result in structurally and functionally abnormal macrophages due either
to chronic compensatory mechanisms or to direct effects of the absence of ACAT1.
ACAT1-Independent Effects of ACAT Inhibitors.  ACAT1-independent effects
from ACAT inhibitors have not been reported previously. The decrease in the efflux of
lipoprotein-derived cholesterol in ACAT1(-/-) macrophages with ACAT inhibitor
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compared to vehicle would suggest secondary effects of the inhibitor that may affect
cholesterol homeostasis (Appendix, Figure 30). The concentration of ACAT inhibitor
used did not induce toxicity in our studies or in previous ACAT inhibitor studies (Warner
et al., 1995) so it is unlikely that toxicity is responsible for the secondary effects seen in
ACAT1(-/-) macrophages.
The residual esterification activity in ACAT1(-/-) macrophages raises the question
of whether ACAT2 can compensate functionally for a loss of ACAT1. Cholesterol
esterification experiments showed that ACAT1(-/-) macrophages were able to esterify
cholesterol even when treated with an inhibitor of both ACAT1 and ACAT2 (Appendix,
Figure 30C). Since the cp113-818 ACAT inhibitor is non-selective (Lada et al., 2004),
the experiments suggest that ACAT2 activity is not responsible for the residual
esterification activity in ACAT1(-/-) macrophages.
Because of the apparent effects of a non-selective ACAT inhibitor on ACAT1(-/-)
macrophages, more detailed studies are warranted. Non-selective inhibitors for ACAT
include 58-035 (Sandoz), cp113-818 (Pfizer), PD-138142-15 (Parke-Davis), PD-156759
(Parke-Davis), XD-793-11 (DuPont), and DuP128 (DuPont) (Lada et al., 2004). Lada et
al., also found that derivatives of a Werner-Lambert compound are selective for ACAT1.
Pyripyropene A is selective for ACAT2. Different non-selective ACAT inhibitors, as
well as ACAT1-selective and ACAT2-selective inhibitors should be used in future
studies with ACAT1(-/-) macrophages. Also, the expression of ACAT2 will be measured
in future experiments to further exclude ACAT2 activity in ACAT1(-/-) macrophages.
Transgenic ApoAI and ABCA1 Deficiency.  In Chapter VI, we showed that
endogenous apoE and ABCA1 cooperated to mediate cholesterol efflux. We also showed
that endogenous transgenic h-apoAI stimulated cholesterol efflux (Chapter VIII). While
stimulation of ABCA1 was a mechanism of the increased cholesterol efflux, there may
also be ABCA1-independent mechanisms. In future studies, it will be essential to
determine if transgenic h-apoAI can still protect against atherosclerosis and stimulate
efflux even when ABCA1 is not expressed by macrophages (i.e. h-apoAI(tng)ABCA1(-/-)
macrophages).
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LXR Agonists and ACAT1 Deficient Macrophages.  The phenotype of ACAT1(-/-
) macrophages resembles the changes that occur in NPC1(-/-) cells. The similarities
include the accumulation of cholesterol in lysosomes, decreased cholesterol efflux,
decreased cholesterol esterification, increased cholesterol synthesis, and decreased
lipoprotein uptake (Ory, 2004). In NPC1(-/-) cells, this phenotype and cholesterol
trafficking problems can be corrected by treating cells with LXR agonists (Frolov et al.,
2003). ACAT1(-/-) macrophages also respond to LXR agonists by increasing cholesterol
efflux (Appendix, Figure 35). oxLDL contains oxysterols that stimulate LXR. ACAT1(-/-)
macrophages respond to oxLDL with decreased cholesterol synthesis (Figure 13A).
However, oxLDL-treated wildtype cells still have higher cholesterol synthesis than
oxLDL-treated ACAT1(-/-) macrophages. Together, these data suggest that LXR agonism
does not correct the underlying defect that causes disruptions in cholesterol efflux from
ACAT1(-/-) macrophages. Regardless, the positive effects of LXR agonism on cholesterol
efflux and cholesterol synthesis still have the potential to protect ACAT1(-/-)
macrophages from foam cell formation. In future studies, the effects of LXR agonists on
cholesterol uptake, cholesterol storage, and on the morphology of ACAT1(-/-)
macrophages should be determined.
Atherosclerosis and Other Diseases
The many functions of macrophages in the vascular wall can directly or indirectly
affect cellular cholesterol balance. The transformation from macrophage into foam cell
represents more than a shift in lipid metabolism. Foam cell transformation is associated
with changes in the inflammatory functions, immune functions, and scavenger functions
of macrophages (Table 1). With such complex pathogenesis, it is likely that lipid burden
can either lead to or result from these other changes in macrophage function. Because
macrophage cholesterol homeostasis is at the center of this complex disease, cholesterol
efflux has the potential to be protective or to promote atherogenesis.
Macrophage ApoE and Atherosclerosis.  ApoE is a lipoprotein structural protein,
a ligand for lipoprotein receptors, a cholesterol acceptor, has anti-inflammatory and anti-
oxidant properties, and can act as a growth factor (Bocksch et al., 2001). Each of these
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functions can modify atherogenesis. Atherosclerosis studies with macrophages that
secrete different isoforms of apoE allow for a direct comparison of how subtle changes in
cholesterol efflux and cholesterol homeostasis affect the development of atherosclerosis
(Table 1). Bone marrow replacement studies in mice have shown that mouse apoE from
macrophages protects while a lack of macrophage apoE promotes atherosclerosis (Fazio
et al., 1997; Linton et al., 1995). Studies with human apoE show that some isoforms are
protective and others are atherogenic. ApoE3 is the most common isoform. ApoE2 has
reduced LDLR binding compared to apoE3, but apoE4 binds LDLR with an affinity
similar to apoE3 (Weisgraber et al., 1982). The apoEcys142 mutant has reduced HSPG
binding (Ji et al., 1994). The differences in these isoforms are associated with differences
in cholesterol efflux and cholesterol loading. ApoE3 and apoE2 prevent macrophages
from becoming loaded with cholesterol by stimulating cholesterol efflux (Cullen et al.,
1998). However, apoE4 does not stimulate cholesterol efflux due to enhanced surface
binding and re-uptake. In atherosclerosis studies apoE3 significantly decreases lesions
size, while apoE2 does not have significant effects. Expression of apoEcys142 increases
atherosclerosis. This increase in atherosclerosis can be explained by the critical role of
HSPG binding in apoE-mediated cholesterol efflux (Lin et al., 2001). Interestingly, apoE
can bind and accept cholesterol from ABCA1 (Krimbou et al., 2004). ApoE2, apoE3, and
apoE4 isoforms are functionally equivalent in this regard. In Chapter VII, the effects of
endogenous apoE on cholesterol efflux were separated into autocrine effects and
paracrine effects that may depend on interactions of apoE with surface receptors. Because
the human apoE isoforms have different receptor binding affinities, macrophages that
express these human apoE proteins will be useful for determining the nature of
proteoglycans and LDLR in autocrine and paracrine cholesterol efflux mechanisms.
Endogenous interactions of these human apoE proteins with ABCA1 will also be tested
in future experiments.
Macrophage ApoAI and Atherosclerosis.  Plasma apoAI and HDL protect against
atherosclerosis (Gordon and Rifkind, 1989). ApoAI is synthesized by hepatocytes, but in
contrast to apoE, it is not synthesized by macrophages (Basu et al., 1981). Previous
studies from our laboratory express transgenic human apoAI (h-apoAI) regulated by a
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macrophage-specific promoter. Major et al. show that in the absence of macrophage apoE
expression, macrophage h-apoAI protects hyperlipidemic mice from atherosclerosis
without altering plasma lipid profiles (Major et al., 2001). Ishiguro et al. found that apoE
deficient macrophages expressing h-apoAI as a result of viral transduction, decrease
lesion size in hyperlipidemic mice (Ishiguro et al., 2001). Ishiguro et al. also found that
macrophage h-apoAI can protect against atherosclerosis, even in a model of hepatic over-
expression of transgenic apoAI, were ample amounts of hepatic apoAI are present in the
plasma compartment. Recently, Su et al. found increased expression of ABCA1 in
macrophages that express h-apoAI (Su et al., 2003). In chapter VIII, we showed that
endogenous macrophage h-apoAI stimulated ABCA1-mediated cholesterol efflux to
exogenous apoAI. Together these studies provide evidence supporting cholesterol efflux
as a mechanism of protection from atherosclerosis in hyperlipidemic mice.
Macrophage ACAT1 and Atherosclerosis.  While blocking the esterification of
cholesterol is a strategy for blocking foam cell formation, Fazio et al. found that
hyperlipidemic mice that were reconstituted with ACAT1(-/-) macrophages had increased
atherosclerosis and cellular death within lesions (Fazio et al., 2001). In Chapter IV and
Chapter V, we showed that ACAT1(-/-) macrophages had severe changes in cholesterol
homeostasis. While Fazio et al. reported that free cholesterol accumulates in the vascular
wall, the mechanism of this accumulation remains unclear. Because the availability of
free cholesterol to extracellular acceptors is thought to be protective, cholesterol toxicity
or decreased efflux to available acceptors may counteract any advantages that would
result from free cholesterol availability. The current in vitro studies show that even under
mild cholesterol-loading conditions macrophage cholesterol homeostasis assumes a
phenotype that is similar to that found with disruptions in cholesterol trafficking. Under
the severe conditions present in an atherosclerotic lesion in vivo, these macrophages with
compromised cholesterol homeostasis are likely to have a high susceptibility to free
cholesterol accumulation and toxicity.
Cholesterol Efflux in Atherosclerosis and Other Diseases. Inflammation,
oxidative stress, and cell death are common pathological elements in atherosclerosis,
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diabetes, inflammatory diseases, and neurodegenerative diseases. Inflammation and
oxidative stress occurs in each of these diseases (Aiello et al., 2003; Andersen, 2004;
Linton and Fazio, 2003; Schmitz et al., 1999). Cell death and tissue damage occurs in
each of these diseases, making phagocytic cells and the removal of cellular membrane
debris a common element. Whether the phagocytes involved in each disease are
macrophages or other cell types, intracellular lipid accumulation is a possibility.
While evidence for connections between cholesterol efflux and atherosclerosis are
substantial, the connections between cholesterol efflux and diseases like diabetes and
Alzheimer's disease require more investigation. The importance of HDL and apoE in
preventing atherosclerosis is partially due to their effects on cholesterol efflux. HDL and
apoE also have a protective role in other diseases including diabetes (Rohrer et al., 2004;
von Eckardstein et al., 2000) and Alzheimer's disease (Rebeck, 2004). Since HDL and
apoE have effects not directly related to choletserol efflux, it is necessary to study
cellular cholesterol homeostasis in the context of these other diseases. Other mediators of
lipid homeostasis such as peroxisome proliferator-activated receptors (PPAR) (Moore et
al., 2001; Torra et al., 2001), scavenger receptors (Miyazaki et al., 2002), and unsaturated
fatty acids (Wang and Oram, 2002) provide additional links between cholesterol efflux,
atherosclerosis, and other diseases, especially diabetes.
Changes that accompany any disease process may also affect the function of
mediators of cholesterol efflux. For example, glycosylation of cholesterol acceptors or
lipid transporters could affect cholesterol efflux in diabetes. Sequestration of apoE in
amyloid plaques could affect choletserol efflux in Alzheimer's disease. Membrane
function and surface receptors are critical aspects of cellular viability. The importance of
cholesterol for membrane fluidity and the presence of cholesterol in specific membrane
domains suggests mechanisms by which cholesterol efflux could affect the progression of
diseases (Incardona and Eaton, 2000; Spector and Yorek, 1985b). Because cholesterol
homeostasis is important in all cells, there is a potential role for cholesterol efflux in the
pathogenesis of atherosclerosis and many other important diseases.
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General Conclusion
With the current studies, we have focused on the role of cholesterol efflux in
macrophage cholesterol homeostasis. We have approached this problem from two angles.
We have studied macrophages with cholesterol storage deficits and macrophages that
secrete cholesterol acceptors. Studying cholesterol efflux by each of these approaches has
provided mechanistic detail about cholesterol homeostasis in macrophages. The degree of
overlap between these two approaches highlights the connections between the
mechanisms of macrophage cholesterol homeostasis. In macrophages, a cholesterol
storage deficiency precipitated disruptions in cholesterol efflux and was associated with a
constellation of cellular changes including altered morphology, aberrant cholesterol
trafficking, and apparent changes in cholesterol sensing. There were connections between
different pathways of cholesterol efflux in macrophages that secrete cholesterol
acceptors. The presence of multiple efflux pathways and the degree to which these
pathways interact suggests a high biological importance for macrophage cholesterol
efflux. As an addition to previous in vivo studies of atherosclerosis, the current in vitro
studies converge on the idea that cholesterol efflux helps to maintain cholesterol
homeostasis in macrophages. These studies suggest that cholesterol efflux is a
mechanism used by macrophages to protect against foam cell formation and
atherosclerosis.
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APPENDIX:  FIGURES 29 - 35
Figure 29. Sample Screens from the Efflux 4.4 Data Analysis Spreadsheet.
As discussed in Chapter III, Efflux 4.4 is a data analysis spreadsheet that (A)
describes experiments, (B) analyzes data, (C) executes automated routines, (D)
displays graphics, and (E) summarizes and statistically compares data.
A.
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B.
C.
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D.
E.
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Figure 30. Effects of ACAT1 Deficiency or Inhibition on Lipoprotein-
derived Cholesterol in Macrophages.
As described in Chapter IV, ACAT1(+/+) (WT) or ACAT1(-/-) (KO)
macrophages were treated with 70 mg/ml 3H-CE/acLDL in DMEM/2% FBS for
36 hours to label lipoprotein-derived cholesterol pools. Macrophages where
treated with vehicle or 2 mg/ml cp113-818 ACAT inhibitor. Bars and error bars
represent the mean (n=4) and standard deviation of samples from ACAT1(+/+) or
ACAT1(-/-) macrophages treated with vehicle or 2 mg/ml cp113-818 ACAT
inhibitor. Asterisks (*) denote a statistically significant difference (p<0.05)
compared to the ACAT1(+/+)/Vehicle group and pound signs (#) denote a
statistically significant difference (p<0.05) compared to the
ACAT1(+/+)/Inhibitor group as determined by ANOVA with Bonferroni post-
test. (A) The uptake of 3H-CE/acLDL by macrophages was calculated by adding
the counts from the 3H-FC and 3H-CE stored within the cell and the 3H-FC that
appeared in the culture media during loading. The sum of these counts was
normalized for cellular protein and then converted to mass by dividing by the
counts of 3H-CE per mass acLDL. (B) The turnover of 3H-CE by macrophages
was measured by the appearance of 3H-FC in the culture media over 36 hours and
was normalized for cellular protein. (C) Cholesterol storage as 3H-FC (solid bars)
and 3H-CE (empty bars) was measured in cellular lysate and was normalized for
cellular protein. (D) Cholesterol efflux was measured from macrophages to
media with 10 mg/ml human apoAI for 6 hours.
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Figure 31. ApoE-Mediated and HDL-Mediated Cholesterol Efflux from
ACAT1 Deficient Macrophages.
Macrophages were treated for 24 hours with 2 mCi/ml of 3H-cholesterol and 50
mg/ml acLDL in DMEM/4% FBS. Cholesterol efflux was then measured for 24
hours. Bars and error bars represent the mean (n=6) and standard deviation of
samples from ACAT1(+/+) (WT) or ACAT1(-/-) macrophages. Asterisks (*)
denote a statistically significant difference (p<0.05) compared to the ACAT1(-/-)
group as determined by Student’s t-test. (A) To measure apoE-mediated
cholesterol efflux, cells were cultured in efflux media with 0.1% BSA. (B) To
measure HDL-mediated cholesterol efflux, cells were cultured in efflux media
with 25 mg/ml HDL3 (density = 1.125 to 1.210 mg/ml).
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Figure 32. ABCA1-Mediated Cholesterol Efflux from ACAT1/ApoE
Deficient Macrophages.
Macrophages were treated for 24 hours with 2 mCi/ml of 3H-cholesterol and 50
mg/ml acLDL in DMEM/4% FBS. (A) ApoE secretion was measured for 18
hours from ACAT1(+/+) or ACAT1(-/-) macrophages by Western analysis as
described in Chapter VI. (B) ABCA1-mediated cholesterol efflux was measured
to media with 10 mg/ml human apoAI for 18 hours. Bars and error bars represent
the mean (n=6) and standard deviation of samples from ACAT1(+/+) (WT),
apoE(-/-), ACAT1(-/-), or apoE(-/-)ACAT1(-/-) (DKO) macrophages.
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Figure 33. ApoE-Mediated Cholesterol Efflux from ApoE Heterozygous
Macrophages.
ApoE(+/+), apoE(+/-), and apoE(-/-) macrophages in 24-well plates were
stimulated with modified LDL, labeled with 3H-cholesterol, and then cultured in
1.0 ml of media with no acceptors for 48 h. (A) Efflux was measured by counts
in the culture media. Bars and error bars represent the mean (n=4) and standard
deviation of samples. Asterisks (*) denote a statistically significant difference
(p<0.05) compared to the apoE(-/-) group as determined by Student’s t-test. (B)
ApoE secretion was measured by Western analysis as described in Chapter VI.
Cholesterol efflux from heterozygous apoE(+/-) macrophages was significantly
less (p<0.001) compared to efflux from wildtype apoE(+/+) macrophages (Appendix,
Figure 33A). However, there was no significant increase in cholesterol efflux from
heterozygous apoE(+/-) macrophages when compared to knockout apoE(-/-)
macrophages. Even though these cells were expected to have apoE expression levels of
about 50% of normal, they only secreted approximately 10% of the apoE compared to
wildtype apoE(+/+) macrophages (Appendix, Figure 33B).
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Figure 34. Volume-Dependence of h-ApoAI-Mediated Cholesterol Efflux.
The (A) volume-dependence and the (B) relative concentration-dependence of
cholesterol efflux from h-apoAI(tng)apoE(-/-) macrophages (diamonds) apoE(-/-)
macrophages (triangles) and the h-apoAI-mediated efflux (filled circles). Values
are expressed as mean (4 samples) ± SD of efflux from h-apoAI(tng)apoE(-/-)
and apoE(-/-) macrophages with asterisks (*) denoting a statistically significant
difference (p<0.05) by Student’s t-test. Methodology is described in Chapter VII.
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Figure 35. LXR Agonism Increases ABCA1-Mediated Cholesterol Efflux
from ACAT1 Deficient Macrophages.
ACAT1(+/+) (WT) and ACAT1(-/-) (KO) macrophages were treated for 48 hours
with 3.0 mCi/ml of 3H-FC and 100 mg/ml acLDL in DMEM/1% FBS to label
cellular cholesterol. Macrophages were treated with 1 mM 22(R)-
hydroxycholesterol for 18 hours. Methods are described in Chapter VI. ABCA1-
mediated cholesterol efflux was measured from macrophages cultured for 6 hours
in serum-free efflux media with 10 mg/ml apoAI and 1 mM 22(R)-
hydroxycholesterol. Bars and error bars represent the mean (n=8) and standard
deviation of samples. Asterix (*) denote a statistically significant difference
(p<0.05) compared to the vehicle group as determined by two-way ANOVA with
Bonferroni post-test. Pounds (#) denote a statistically significant difference
(p<0.05) compared to the ACAT1(+/+) (WT) group as determined by two-way
ANOVA with Bonferroni post-test.
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